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I. INTRODUCTION 
A· The problem 
This investigation involves an examination in rats, of the effects on the 
duration of drug-induced sleep or hypnosis ~esulting from the pretreatment 
with pharmacological agents that affect one or more neuroamine systems. The 
primary index of the duration of sleep used is the loss and recovery of the 
righting reflex. The excitatory and depressant activity of monoamines in the 
CNS have been revealed by studies involving their direct application, systemic 
injection and pharmacological alteration or, inferentially, from studies 
demonstrating diurnal or circadian fluctuations (~infra). In as much as 
Friedman and Walker (1969), among others, have shown that the duration of pento-
barbital hypnosis varies with the time of day, and that levels of monoamines 
in several CNS areas also follow a circadian pattern (~infra), it was of 
interest to extend these studies and examine the effects that pretreatment 
with drugs influencing the monoamine systems might have on CNS monoamine levels 
and sleep duration. Such an approach seeks to determine a possible interrela-
tionship between central amines and drug-induced sleep. Because the exact 
mechanism of sleep produced by hypnotics is unclear, experiments were designed 
to examine the nature of the involvement of monoamines in the phenomenom. 
Furthermore, the efficacy of the modulating drugs used for these pretreatments 
has not heretofore been examined on a 24-hour basis. 
The circadian pattern for hypnotic sleep duration is inversely related 
to metabolizing enzyme activity(~~). Nair and Casper (1969) sug-
1 
2 
gested that there might be a central component for the control of the enzyme 
activity, and in turn, the duration of hypnosis. By utilizing appropriate 
dosages of the pretreatment drugs that significantly alter amine levels (ac-
cording to published reports), the effect of changes in the levels of CNS 
monoamines on the duration of action of hypnotics might be demonstrated. The 
presence or absence of specific monoamines, as well as their relative levels 
might serve to augment or limit the hypnotic effect. Daily fluctuations of 
these amines could change the sensitivity of the CNS and its possible regula-
tion of drug metabolizing systems, thereby resulting in an altered effect of 
the hypnotic. 
B. Terminology. 
The present study examines periodic alterations in 1) the duration of 
drug-induced sleep and 2) central monoamine le~els, and possible interrela-
tionships. The review of the literature sunnnarizes studies on states of normal 
sleep and the effects of drugs on normal sleep. Furthermore, it examines the 
nature of the formation of specific monoamines, their effects on sleep and the 
pharmacology of drugs utilized to induce sleep. The stages of normal sleep 
and drugs which affect these stages are discussed. It is understood that 
drug-induced sleep differs markedly from normal sleep. Briefly, the stages 
of sleep can be classified as paradoxical sleep (PS or REM, rapid eye movement) 
or slow wave sleep (SWS or non-REM, NREM). The monoamines to be considered in 
these phenomena include; norepinephrine (NE), dopamine(DA), epinephrine (Epi), 
serotonin (SH'l'), histamine (H) and acetylcholine (ACh). 
3 
The term "circadian", coined by Halberg, is derived from the Latin, 
circa diem, which means "about one day". It refers to rhythms that have a 
--
frequency of about one cycle per day, or a period of 20-28 hours. The term 
"diurnal" has been used by some workers to describe rhythms that have been 
measured on a 24-hour basis, although it also has a secondary meaning of 
"daily", as opposed to nocturnal, or nightly. Wurtman (1967) criticized the 
ambiguous use of the term "circadian", which he suggested should be restricted 
to free-running rhythms. The problem arises in studies in which the animal must 
be sacrificed to determine the aspect under study and can only be measured 
once (eg. toxicity, brain amines, etc.) as opposed to rhythms which can be 
continuously measured (eg. temperature, urine or blood contents, etc.). In 
this study the terms circadian, 24-hour, diurnal or daily rhythms are used 
interchangeably. To establish whether or not rhythms are free-running requires 
examination for several cycles, as well as their insensitivity to exogenous 
cues. 
Halberg also proposed terms to refer to non-circadian rhythms. Ultradian 
rhythms have a frequency greater than one cycle per day, or a period between 
one and 19. 9 hours. Infradian refers to a rhythm with a frequency of less than 
one cycle per day, or a period greater than 28.5 hours. Exogenous rhythms are 
those which can be altered by changes in environmental parameters, while 
endogenous rhythms (free-running) appear to be under internal control, as they 
persist under an unchanging environment, such as constant light or constant 
darkness. 
C. Practical considerations 
The present study concerns itself only with the effects on drug-induced 
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sleep and not with the effects of drugs on normal sleep. Effects of these 
drugs on normal sleep and drug-induced sleep are cited with regard to possible 
relationships to the results of this study. 
In studies of circadian rhythms of physiological and pharmacological 
phenomena, an investigator concerns himself with the problem of frequency of 
sampling. Some investigators are content to show differences between the 
and dark periods, while others take measurements every hour. As in previous 
studies from this laboratory, data is obtained every six hours (0600, 1200, 
1800 and 2400 hours), giving two points in the light and two in the dark. 
Ordinarily this is sufficient to show differences between light and dark 
phases and demonstrate the basic 24-hour pattern. Pretreatment and sacrifice 
times are bracketed around these test times, so that the average time occurs 
at the six-intervals. 
II. REVIEW OF THE LITERATURE 
A. Parameters affecting biological rhythms. 
The importance of biological rhythms in physiological and pharmaco-
logical phenomena is becoming better appreciated. Biological rhythms (growth, 
motor activity, feeding, etc.) of plants and submammalian species (protozoa, 
coelenterates, mollusks, insects and birds) have been demonstrated (cf. 
Bunning, 1967; van Mayersbach, 1967; Walker, 1969). This review however, will 
be confined to studies of rhythms in mannnals, primarily mice and rats. It 
will consider parameters affecting biological rhythms and studies demonstrating 
physiological and pharmacological rhythms. 
1. Sex 
Sex hormones (vide infra) alter the ongoing biorhythms and result in 
differences in male and female rhythms. Slonaker (1912) demonstrated that 
motor activity increases progressively and is maximal at the peak of estrus. 
Colvin~ al. (1968) attributed variations in the sleep-wakefulness (S-W) 
cycle to the superimposition of the estrous cycle. EEG monitoring of chroni-
cally-implanted female rats revealed that the pre-estrus rat has PS in the 
afternoon, followed by an alert pattern in the evening. The day of vaginal 
cornification is marked by a higher percentage of PS, after a night in which 
the animal is alert and PS is absent. The hormonal changes of proestrus 
appears to increase alertness, which is compensated for on the following 
night. 
Dray et al. (1965) reported a diurnal rhythm of testosterone levels 
in man, which peaked at 0800-0900 hours and reached a trough at midnight. 
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This variation appeared to be due to a decrease in its production, rather than 
an alteration in metabolism. (Women had too little testosterone to detect a 
circadian rhythm.) Baird and Guevera (1969) found no differences in the mean 
plasmas~crone or estridiol content of six non-pregnant women and five men, 
sampled at 0800 or 1700 hours. However, Tulchinsky and Korenman (1970) re-
ported that plasma estrone levels in women and men were three times as high 
at 0800-0900 hours than at 2400 or 0400 hours. The differences between cir-
culating sex hormones in male and female influence the basic biorhythm, as 
well as the response to drugs (vide infra). 
2. Species 
The differences between species has been examined most extensively in 
rodents, which are nocturnal. The ability to adapt to altered photoperiods 
differs among species. Phase-shifting leads to a resynchronization of the 
biorhythm in two days in spiders (Aschoff, 1963), while about three weeks are 
needed for mice and rats to readapt (Hanin et al., 1970). 
3. Age 
Differences in physiological and pharmacological response of the 
irmnature and adult animal have been reported. These include the development 
of liver metabolizing enzymes, brain biogenic amines (vide infra) and the S-W 
cycle. The newborn of most higher species start with very short S-W cycles 
which merge, then prolong into the 24-hour adult pattern (cf. Ellington, 1972). 
Enzyme development influences metabolism of drugs and/or endogenous sub-
stances. The changes in sleep cycle and brain amines are probably inter-
related, both reflecting the maturation of the CNS. Shaywitz ~al. (1971) 
were unable to correlate growth hormone and sleep state in newborns, although 
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levels were elevated for the first 2-3 days after birth and became normal by 
day 4 (cf. Mills, 1966). In the adult, growth hormone release is related to 
sws (vide infra). 
4. Population 
Quay~ al. (1969) examined the effect of isolation on the anatomy of 
the CNS. Isolated rats have greater body and pineal weights and a higher 
ratio of pineal to brain weight, than do grouped animals. Grouped animals 
exhibited higher mean cerebral cortical weight than isolated rats. The ratio 
of cortical acetylcholinesterase to cholinesterase decreased in grouped rats, 
when more than two rats were maintained per cage. There were no differences 
in pineal SHT levels or pineal HIOMT activity between grouped and isolated 
rats. Amphetamine toxicity in aggregated mice has been shown by several in-
vestigators to be greater than for isolated mice. Walker (1972) reported that 
amphetamine was most toxic during the dark (active) phase for isolated or 
aggregated mice. 
5. Illumination 
The influence of light on biorhythms can be considered with regard to 
photoperiod (relative duration of light-dark periods), intensity and spectrum 
of the light source. This includes not only circadian periods, but longer 
periods, such as monthly (lunar) and seasonal (solar). The physiological 
transducer for these effects involves the eye-pineal axis (cf. pineal gland, 
under SHT section) and possible extraretinal receptors, which respond to 
• 
direct penetration of light through the skull (Lisk and Kannwischer, 1964). 
Biorhythms are most easily synchronized by light-dark photoperiods, 
usually of a 12:12 or 14:10 hours relationship (cf. Aschoff, 1969). The exact 
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ratio requirement of light and dark is probably species specific. A number of 
studies have examined the time required for animals to adapt to 1) a specific 
photoperiod, 2) reversal of the photoperiod and 3) constant light, constant 
darkness or a new photoperiod. Some rhythms are resistant to photoperiod 
changes and require days or weeks to readapt fully. Others do not readapt, 
i.e. free run, and are not controlled by light, but by some other environ-
mental factor or the rhythm might fade out. Von Mayersbach (1967) points to 
difficulties involved in such experiments. He was never able to duplicate 
values 24 hours apart, indicating that certain cycles might be greater or 
lesser than 24 hours or that in the process of removing animals those to be 
used subsequently are disturbed. 
Reiter (1969) reported that the levels of light found in most artifi-
cially-lit animal rooms (10-150 footcandles) are sufficient to have an inhi-
bitory action on the pineal, and probably affect other systems. Harker (1964) 
stated that light intensity has relatively little effect on period length, but 
changes in light intensity determine phase setting. 
Marshall and Bowden (1936) demonstrated the effects of wavelength of 
light on the timing of the sexual cycle of the ferret. Estrus begins earlier 
0 
in animals exposed to ultraviolet light (3650 A). Infrared light has no effecL 
Luce-Clausen and Brown (1939) showed a delayed onset of estrus in rats main-
tained in darkness but a normal onset for animals exposed to visible or 
infrared illumination. Spaulding et al. (1969) studied the effects of spec-
tral components of light on motor activity in mice. The lowest activity 
occurred in mice exposed to blue or green light, or daylight; intermediate 
activity occurred under yellow, while the highest activity was in red light 
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or darkness. Wurtman and Weisel (1969) found that rats maintained under Vita-
Lite, which closely (93%) approximate the daylight spectrum, have larger 
gonads and smaller spleens than those under conventional cool-white fluor-
escent lights. Cool-white lights are deficient in the near-UV wavelengths 
and have greater amounts of the yellow and orange wavelengths. 
6. Temperature 
The effects of ambient temperature on biorhythms appear to be minimal 
within a 2-6°C. range from normal environmental temperature, to which the 
mannnalian thennoregulatory system can adjust. Body temperature is a balance 
between heat production and heat loss. Heat production is high during the 
day in man, due to muscular activity, but even subjects at rest and fasting 
exhibit a diurnal temperature rhythm. Halberg (1959) found that artificial 
alterations of body temperature have no effect on the activity rhythm (cf. 
Sweeney and Hastings, 1960). 
7. Barometric eressure 
Harker (1958) described barometric pressure as a weak synchronizer, 
i.e. although it is incapable of controlling a biorhythm, it might have an 
. 
influence on an existing rhythm. Hayden and Lindberg (1969) entrained body 
temperature rhythm in mice by fluctuations in ambient barometric pressure, 
under constant ambient temperature and darkness. 
8. Feeding habits 
Feeding may be involved as a phasing factor of other biorhythms but 
it is difficult to devise methods of testing its role. If food is present 
only at one time during the day, animals will feed then, but if present con-
tinually rodents will eat during the dark phase. Honova et al. (1968) showed 
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a rhythm ·of rat liver tyrosine transaminase, which they stated might be con-
trolled by the feeding pattern in rats and man. Studies of diurnal fluctua-
tions of plasma amino acids (Wurtman et al., 1967b, 1968b), of course, must 
-- ~ 
consider the effect of dietary intake and its amino acid content. 
9. Miscellany 
Other factors which might subtly influence ongoing circadian rhythms 
include sound, odors, lunar or seasonal variations, magnetism and electrical 
fields. Sound can interrupt sleep and activity rhythms, depending upon in-
tensity and duration. Halberg et al. (1954) reported that the activity of 
normal mice affected blind mice. After exposure of rats to the pungent odor 
of isonitrile for six hours, Miline et al. (1963) noted atrophic alterations 
of pineal parenchymal cells (which might also be due to a direct effect). 
Taste, smell and hearing rhythms in man (Henkin et al., 1963; Henkin, 1968), 
are influenced by adrenal hormones. 
The influence of the moon and sun on living things is an old observa-
tion that is coming under scientific scrutiny. Rhythms related to the lunar 
cycle have been demonstrated for lower aquatic species (cf. Harker, 1964: 
Bunning, 1967). Brown~ al. (1970) have demonstrated that living systems are 
able to distinguish among strengths and directions of magnetic, electrostatic 
and ganuna radiation. Radiation is probably involved in the seasonal varia-
tions (well-appreciated for plants) and cycles of long duration such as the 
eleven-year sunspot cycles (Brown~ al., 1958). Wever (1971) showed that a 
10.0 Hz alternating electrical field can affect human circadian rhythms 
(activity and rectal temperature). 
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B· Physiological parameters 
1. Motor activity 
Circadian rhythms in motor activity with a peak in the dark have 
been demonstrated in the mouse (Saelens~ al., 1968) and the rat (Quay, 
1970). Holmquest~ al. (1966) studied the relationship between motor 
activity and body weight and the adrenals, in rats. After 40 days of random 
illumination, the activity rhythms were lost without affecting the steady rise 
of body weight or endocrine organ weight. Quay (1970) reported that normal 
and pinealectomized rats could reverse their activity rhythms after photo-
period reversal. Curtis (1937) demonstrated diurnal activity rhythms for 
sheep and pigs, which was maximal during the day. Lindsley et al. (1964) 
initiated a circadian activity rhythm in young monkeys that had been main-
tained in darkness for three years. This rhythm required 3-5 weeks to 
stabilize after the initiation of the standard photoperiod. Winget et al. 
(1969) found a correlation between diurnal motor activity and body temperature 
in the monkey. RUther et al. (1967) reported that rats under constant light 
were less active and rats under constant dark were more active, than rats 
maintained under a normal light-dark photoperiod. 
2. Body temperature 
Many studies have shown that the diurnal pattern of body tempera-
ture fluctuates in phase with the activity rhythm (Brahmachary, 1967; 
Friedman and Walker, 1968; cf. Kleitman, 1963). Julku et al. (1970) showed 
that mice exposed to a cold environment had better thermoregulatory ability 
at 1600 hours than at 0500 hours. Smith (1969) studied human rectal •_ciur(~r'.1-
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ture and thermoregulation (as measured by core-periphery heat conductance) and 
found that they generally peaked in the light phase. 
3. Blood composition 
Halberg et al. (1954) reported circadian variation of eosinophils 
in rats. Even blind mice exhibit a circadian rhythm in eosinophils, lympho-
cytes and other white cells, as well as adrenal cortical hormones (Haus et al., 
1967). After adrenalectomy or under constant light, the rhythms disappeared. 
pauly and Scheving (1965) showed similar rhythms for neutorphils, eosinophils 
and lymphocytes, with peaks at the onset of inactivity, when the light period 
began. Under continuous darkness, the rhythms persisted but became dissociated 
with continuous light. In pregnant women, total counts of leukocytes, seg-
mented neutrophils and stab neutorphils was maximum during the day and fell to 
a minimum in the early morning, while eosinophils and lymphocytes showed a 
reverse pattern (Luce, 1970). Diurnal rhythms for circulating eosinophils 
have also been demonstrated for the monkey (Migeon et al., 1955) and man 
(Donato and Strumia, 1952; Halberg~~., 1951). Scheving and Pauly (1967) 
demonstrated that the diurnal rhythm for blood clotting time in rats was 
longest at 0130 hours. Scheving ~al. (1968c) also found diurnal rhythm in 
.the levels of several rat blood proteins, such as mucoproteins, albumin and 
several globulins (including gamma-globulin), which peak at the end of the 
phase. Buckell and Elliott (1959) reported a diurnal pattern of plasma fibri-
nolytic activity. In humans, blood pH rises over the day, then decreases 
during the night, with the onset of sleep (Cullen and Earle, 1929). 
Bonilla and Stringham (1968) were unable to demonstrate a diurnal rhythm 
for serum ca+I- in mice, but this might be due to stress or interruption of the 
, 
rhythm, since each animal was sampled four times during the day by orbital 
venous plexus puncture. Bahorsky and Bernardis (1967) observed that normal 
rats had a diurnal rhythm in serum Na+ and K+ levels, peaking in the early 
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dark phase, but found no rhythm in serum phosphorus or urea nitrogen. Fasted 
rats maintained the serum Na+ rhythm, but lost the serum K+ rhythm. 
4. Urinary excretion 
Norn (1929) demonstrated a circadian rhythm for urinary Na+, K+ 
and Cl in man, which peaked during the day and troughed at night. Min et al. 
(1966) examined electrolyte excretion in normal and fasted subjects. In 
normal subjects, with an evenly spaced diet and minimum activity, a diurnal 
rhythm for Mg+I- and ca+I- excretion was observed, which peaked in the early 
morning. The pattern for phosphorus excretion was reversed. Na+ and K+ ex-
cretion peaked in the late morning. The electrolyte patterns observed in 
fasting, obese patients were almost identical to those of normals, except the 
+ K and phosphorus rhythms were absent. Fiorica~ al. (1968) found similar 
patterns for human urinary Mg+I- and Ca+!- excretion. During and following 
exercise their excretion was decreased, suggesting that the activity cycle 
might cause their rhythm. Cohn~ al. (1970) reported that rats fed ad 
libitum exhibit diurnal rhythms in the rates of food consumption and urinary 
excretion of Na+, K+, c1-, inorganic phosphorus and creatinine, with peak 
values during the dark. If the rats are fed 1/24 of their daily food allotment 
hourly, the excretion rhythms are either extinguished or markedly decreased, 
suggesting that the food or feeding might be a synchronizer. Acid and annnonium 
excretion is high at night and decreases in the morning, and is not dependent 
on whether the subject is fed or fasting or the night is spent awake and 
recumbent, or active (cf. Mills, 1966). 
5, Hormones in blood and urine 
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The rate of urine flow is the result of several potentially in-
dependent influences , of which the rate of liberation of posterior pituitary 
antidiuretic hormone (ADH) and the total solute excretion are probably the 
most important. Zsoter and Sebok (1955) reported a diurnal pattern for human 
serum ADH levels, which peaks during the night, and helps to explain the de-
creased urinary output while asleep. 
Venning et al. (1956) reported that human urinary aldosterone excre-
tion was greater during the day than the night. The phenomena was not affected 
by changes in sodium intake but was abolished if subjects remained horizontal 
(Muller et al., 1958). However, plasma aldosterone has a circadian pattern, 
even in subjects continuously horizontal (Michelakis and Horton, 1970). An 
identical pattern for human plasma renin has been shown (Gordon et al., 1966), 
suggesting that the aldosterone rhythm might be driven by renin secretion. 
Circadian variation in the urine and plasma levels of 17-hydroxy-
corticosteroids (170HCS) have been demonstrated in humans and many animal 
species (cf. Nichols and Tyler, 1967; Krieger, 1970). In humans, plasma 
170HCS levels peak in the early morning, just prior to awakening, while in 
the rat, the peak occurs in the early evening. Plasma adrenocorticotrophic 
hormone (ACTH) exhibits a similar rhythm. Urinary 170HCS excretion follows a 
similar circadian pattern, but the cycle lags about two hours behind plasma 
170HCS. 170HCS rhythms, in man and rodents, can be reversed within eight days 
by reversal of the photoperiod. A child has no diurnal 170HCS cycle but 
develops one between 3-13 years of age. The infant monkey, however, exhibits 
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a circadian 170HCS pattern in the first week of life (Bowman~ al., 1970). 
The plasma 170HCS rhythm is absent in Cushing's disease (Doe et al., 1960), in 
which pituitary ACTH formation is increased. The response of humans to ACTH 
administration is decreased at night, suggesting a rhythm for adrenal sensi-
tivity (Perkoff et al., 1959). The control of the 170HCS rhythm might be due 
to changes in corticotrophin-releasing factor (CRF) or the sensitivity of 
anterior pituitary neurosecretory cells to CRF-induced ACTH release (Clayton 
~al., 1963). Krieger~ al. (1968) demonstrated that pretreatment of c~ts 
with atropine and thiamylal just prior to the normal rise of plasma 170HCS, 
blocks the rise. Krieger and Rizzo (1969) found that any alteration of CNS 
SHT levels blocked the daily rise of plasma 170HCS, but alteration of central 
NE with depletors or blockers had no effect on the rhythm. 
Hellman~ al. (1969) reported that human cortisol content exhibited a 
diurnal pattern. It was not smooth, but exhibited a series of steep peaks, 
due to about eight episodic bursts of cortisol per day. A circadian rhythm 
for mouse serum and adrenal gland corticosterone peaked at 1600 hours and 
troughed at 0400 hours (Reinberg and Halberg, 1971). In serum and in the 
adrenal, the greatest corticosterone response to saline occurred 4-8 hours 
before the normal circadian corticosterone peak, while the greatest response 
to ACTH was found eight hours after the peak. Ungar and Halberg (1962) and 
Andrews (1971) reported an in vitro circadian response of mouse and hamster 
adrenals to ACTH. Hodges and Mitchley (1970) found that circadian and stress-
induced changes in plasma corticosterone levels in rats were abolished by 
betamethasone in the drinking water. Adrenal sensitivity to ACTH was unim-
paired. The normal plasma corticosterone rhythm returned within one day of 
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drug withdrawal, but the stress response was normal only after three days. 
suprachiasmatic nuclear lesions and a caudal frontal cut abolished the adrenal 
corticosterone rhythm, while blinding shifted the rhythm (Moore and Eichler, 
1972). 
DeGroot (1967) found that the ovaries of prolactin-treated (pseudo-
pregnant) rats contained the lowest ascorbate levels and highest progesterone 
concentrations at 1600 hours. The latter response is thought to be due to 
luteotropic hormone (LR) release, since hypophysectomy prevented the proges-
terone rise. Serum prolactin of lactating cows exhibits a circadian fluctua-
tion, although individual patterns show sporadic release (Koprowski et al., 
1972). Clark and Zarrow (1967) found a diurnal rhythm in ovarian cholesterol 
content in the mature, cycling rat, which appears to be under the control of a 
daily release of LR. Rats maintained in constant light showed an earlier onset 
of this diurnal ovarian cholesterol pattern, while the pattern was absent in 
androgenized (sterilized) animals (Zarrow ~al., 1969). Pronounced rhythms 
of plasma immunoreactive FSH in both sexes have been reported (cf. Curtis, 
1972). They peak at 0400-0900 hours. 
Auerbach (1963) found a diurnal pattern in plasma protein bound iodine 
(PBI) in humans, which was maximum at 1230 hours and minimum at 0730 hours. 
Bushler ~al. (1968) reported similar results and also found PBI in phase with 
plasma thyroxine (T4), hematocrit, plasma proteins and plasma thyroid binding 
globulin (TBG). The patterns were reversed by reversing the sleep schedule, 
but not by dexamethasone treatment or rescheduling meals. The rate of dis-
appearance of thyroid hormone from blood is cyclic in humans, calves and rats, 
being maximum at the time of their greatest activity (cf. Curtis, 1972). 
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Diurnal variation has been reported in plasma PBI of rabbits, of thyroid 1311 
content in cats and monkeys after tracer doses of 131r, plasma thyroid stimu-
lating hormone (TSH) in humans and rats and rat pituitary TSH (cf. Curtis, 
1972). 
Von Euler~ al. (1955) reported a diurnal variation for free and con-
jugated urinary catecholamines in humans. Minumum excretion rates of free Epi 
and NE were at night, while the maximlllll rates, about three times the minimum, 
occurred at 0800-1100 hours. Catecholamine excretion is affected by emotion, 
exertion, and posture, but its rhytl:un persists, with reduced amplitude, during 
bed rest, sleep deprivation or constant darkness (cf. Curtis, 1972). Scheving 
~al. (1968b) reported that rat adrenal epinephrine fluctuates daily, with 
maximum concentrations occurring during the light phase. 
Fasting diabetics have a diurnal pattern for blood sugar, which peaks 
at about 0800 hours. Since a diurnal pattern of inununoreactive insulin (IR!) 
has not been demonstrated in fasting diabetics, the blood glucose pattern 
might be due to insulin resistance, which leaves the glucose-mobilizing 
effects of the ACTH-cortisol cycle unopposed (Faiman and Moorhouse; 1967). 
In normal subjects, plasma IR.I exhibits peaks associated with meals and falls 
during the night, so it is uncertain if there is a circadian pattern. 
Plasma growth hormone peaks at almost any time of day, but the largest 
and most consistent peaks occur at the onset of the first period of SWS 
(vide infra) • 
6. Rhythms in constituents of carbohydrate, lipid and protein 
metabolism. 
Circadian variations in blood glucose have been demonstrated in 
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the rat (Pauly and Scheving, 1967; Friedman and Walker, 1969), mouse (Dziekan-
ouska and Andrzej, 1961), chicken (Twiest and Smith, 1970) and cow (Allcroft, 
1933). Maximum levels occur during the period of maximum activity. Friedman 
and Walker (1969 ) found a biphasic pattern for blood glucose, with peaks at 
the end of the light and dark periods. Bahorsky and Bernardis (1967) obtained 
similar results in rats, and that were abolished by fasting. Normal subjects 
exhibit diurnal variation in the glucose tolerance test, while hyperglycemic 
patients do not (Jarrett and Keen, 1969). 
Agren !:.!, al. (1931) reported a circadian pattern for liver glycogen in 
the rat and rabbit. These rhythms were abolished by adrenalectomy. Halberg 
~al. (1960) found a similar liver glycogen rhythm in the mouse, which 
persisted after food deprivation, even to the point of death of the animal. 
Sollberger (1964) reported circadian variations in liver glycogen levels in 
several species, which generally peaked during the period of greatest motor 
activity. Fuller and Diller (1970) found that the hepatic liver glycogen 
rhythm in rats fed ad libitum peaks at 0500-0800 hours. In rats fed a single 
meal from 0800-1200 hours, hepatic glycogen levels exhibited a prolonged peak 
from 1200-2000 hours. They also found that the circadian pattern for plasma 
free fatty acids was inversely related to liver glycogen content. 
Feigen et al. (1968) demonstrated in humans, that blood amino acids 
levels (except citrulline) exhibit a diurnal rhythm, which peak between 1200-
2000 hours and trough between 0400-0800 hours. Increases and decreases in 
total protein content of an isocaloric diet or exercise had no effect on the 
pattern. Reversal of the S-W cycle resulted in a rapid reversal in the amino 
acid pattern. Wurtman et al. (1968b)obtained similar results. Coburn et al. 
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(1968) reported a circadian rhythm for plasma tyrosine in rats, but not for 
plasma phenylalanine, which was controlled by food intake. A circadian 
rhythm for plasma tyrosine occurred in human phenylketonuric subjects (who 
lack phenylalanine hydroxylase), suggesting that dietary absorption or liver 
metabolism might be controlling the rhythm. Tewksbury and Lohrenz (1970) 
found that urinary amino acid levels exhibit a rhythm similar to those of 
whole blood, suggesting that the basic amino acid rhythm is normally present 
and is augmented by food intake. 
7. Enzyme systems 
Wurtman and Axelrod (1967) reported that liver tyrosine trans-
aminase (TT; EC 2.6.1.5) in rats peaked shortly after the onset of darkness 
and was low during the day. Adrenalectomy, hypophysectomy, thyroidectomy, 
pancreatectomy, constant darkness or fasting did not alter the pattern. 
Transection of the spinal cord suppressed the rhythm at peak levels, while 
constant light decreased levels. Black and Axelrod (1968) showed that the 
enzyme activity was reduced by increasing NE, in vitro and in vivo, while 
depleting NE increased enzyme activity. Honova et al. (1968) reported that 
in the rat, the enzyme rhythm appeared within 48 hours after birth, but was 
180° out of phase with the adult pattern, which develops 21-23 days after 
birth. Brain TT activity does not fluctuate, indicating that separate control 
mechanisms exist for central and peripheral TT activity (cf. Fuller, 1970). 
Radzialowski and Bousquet (1968) demonstrated a circadian pattern in 
rats, for hexobarbital oxidase (HBO), aminopyrine N-demethylase, £-nitro-
anisole O-demethylase, 4-dimethylaminoazobenzene reductase (4DAB) activities, 
all peaking at 0200 hours. Adrenalectomy abolished all but the 4DAB pattern. 
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The peak of diurnal rat plasma corticosterone levels occurs at the time of 
minimal enzyme activities (1400 hours). Exogenous corticosterone abolished 
the diurnal aminopyrine and £-nitroanisol enzyme activities, suggesting that 
the adrenal might be involved in regulation of hepatic drug-metabolizing 
enzymes. Jori~ al. (1971) found a similar circadian pattern for the liver 
enzymes metabolizing hexobarbital, imipramine, £-nitroanisol and aminopyrine, 
which could be reversed by photoperiod reversal. Nair and Casper (1969) 
found a circadian rhythm for HBO and 0-demethylase activities in the rat 
liver, which were maximal midway through the dark phase. The daily pattern 
for HBO activity correlated inversely with the circadian pattern of RB 
sleeping time; ie., sleep was longest when HBO activity was minimal. Con-
tinuous light or darkness abolished the enzyme rhythm, although the activity 
was significantly higher in animals subjected to constant dark. Chedid and 
Nair (1972) demonstrated electron microscopically a circadian pattern for 
the relative amounts of hepatic endoplasmic reticulum in the rat. Roberts et 
al. (1970) reported a circadian variation for HBO activity, but not for PB 
sleep duration or brain, liver and serum concentration of.PB and its meta-
bolites. 
Diurnal fluctuations occur in the activities of hepatic steroid hydro-
xylases (Colas et al., 1969) and tryptophan pyrrolase (Rapport et al., 1966) 
-- -- . 
Phillips and Berry (1970) noted a circadian pattern in mouse liver phospho-
enolpyruvate from pyruvate). Gielen et al (1970) found a circadian pattern 
for cholesterol-7-alpha hydroxylase activity (involved in the biosynthesis of 
bile acids), which is controlled by the adrenocortical system. 
p 
1964). 
• 
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Mouse kidney transamidase activity is circadian (Van Pilsum and Halberg, 
8. CNS amines 
a. Serotonin (5HT) 
Scheving ~ .!!.· (1968a), who measured 5HT levels every hour, found 
a circadian rhythm for whole rat brain, which peaked during the light phase. 
Dixit and Buckley (1967) reported a similar pattern for rat brain 5HT, during 
normal and reversed photoperiods. Peak 5HT occurs at the time of lowest 
corticosterone (2300 hours, mid-light phase) and 6 hours before the corticos-
terone peak. Scapagnini ~al. (1971) noted that 5HT levels in the rat hippo-
campus and arnygdala followed a circadian pattern peaking at 2000 hours and 
troughing at 0400 hours. The plasma corticosterone pattern is similar, with 
a peak at 2000 hours and a trough at 0800 hours. Friedman and Walker (1968, 
1969) found that rat caudate nucleus (CN) and rnidbrain (MB) 5HT followed a 
circadian pattern, with a peak at 1800 hours and a minimum between 2400-0600 
hours. They related the 5HT levels to the sleep-wakefulness cycle. Reis 
~al., (1968) indicated that 5HT in the inferior colliculus and the red 
nucleus-medial tegmenturn of the cat was greater at 1900 hours than 0700 hours. 
Hery et al. (1972) obtained similar results for rat cortex, hypothalamus and 
brain stern 5HT. 5HT synthesis decreased significantly in the brain stern in 
the dark (2100 hours) as compared with the light phase (1500 hours) and was 
dependant on the initial tryptophan (TP) levels, not the rate of conversion 
of TP to 5HT. They further indicated that although 5HT synthesis was maximal 
during the light period(fo~ation of 5HT from TP), its release was maximal 
during the dark (formation of 5-hydroxyindole acetic acid from 5HT). Okada 
(1971) studied the maturation of the circadian rhythm of rat whole brain SHT. 
• 
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The pattern appeared at days 35-37, preceding the onset of the adult S-W 
pattern, which matures on days 49-52. Asano (1971) obtained similar results. 
R~ther et al. (1967) reported that whole brain 5HT levels of rats maintained 
under constant light or constant dark were elevated over that of rats under a 
normal light-dark photoperiod. 
b. Norepinephrine (NE) 
Scheving ~al. (1968a) found an ultradian pattern for NE levels 
in the whole brain of the rat while Friedman and Walker (1968, 1969) reported 
a circadian pattern for rat CN and MB NE, which was maximal at the end of the 
dark phase. Reis~ al. (1968) demonstrated a diurnal cycle in NE levels of 
the cat cervical cord, pons, substantia nigralateral tegmentum, anterior 
hypothalamus, tuber cinereum and the pineal. Generally, NE content was maxi-
mal at the middle or end of the light period. The pattern for the anterior 
hypothalamus and pineal peaked in the dark phase. Constant light abolished 
the pattern in the pineal but not in the cervical cord or anterior hypotha-
lamus. Reis and Wurtman (1968) demonstrated a circadian alteration in the 
NE concentrations in parts of the cat hypothalamus and cervical spinal cord. 
They did not find diurnal fluctuations in other brain areas, but they measured 
levels only at the onset of the light and dark periods. Reis and Gutnick 
(1970) demonstrated a circadian pattern for cat cervical and sacral-coccygeal 
spinal cord NE concentrations, peaking at 1900 hours, while that of the 
thoracic cord exhibited a biphasic pattern. Manshardt and Wurtman (1968) 
reported a circadian rhythm (peaking during the dark period) for hypothalamic 
NE, but not for striatum or midbrain. Walker et al. (1971) found that NE 
levels in the hypothalamus and caudate nucleus were greater at 0300 hours than 
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at 1500 hours. Asano (1971) indicated that the adult circadian pattern for 
whole brain NE does not appear until days 35-37, after birth. The NE levels 
peaked in the dark, similar to the pattern for brain parts (vide supra). 
A.ncill ~al. (1970) examined whole rat brain NE, DA and 5HT concentrations 
but found a circadian pattern only for 5HT levels, which was maximal at 1200 
hours (mid-light period) and minimal at 2400 hours. 
c. Dopamine (DA) 
Scheving et al. (1968a) reported an ultradian pattern for whole 
brain DA of rats. Piepho and Friedman (1968) found a ctrcad:im pattern for rat 
CN DA, and inverse pattern for caudate homovanillic acid, a degradative pro-
duct of DA. 
d. Achetylcholine (ACh) 
Friedman and Walker (1972) reported circadian patterns for rat 
CN and MB, and mouse whole brain ACh. Peak ACh levels occurred at 2400 
hours in the rat, 0600 hours in the mouse while the trough was at 1200 hours 
in the rat MB and 1800 hours in the rat CN and mouse brain. Hanin et al. 
(1970) also found a circadian pattern for whole rat brain ACh, which peaked 
at 1400 hours. The pattern was found in grouped rats only and emerged after 
18 days in controlled environmental conditions. 
e. Miscellany 
Friedman and Walker (1968, 1969) demonstrated a circadian rhythm 
for CN and MB histamine, which peaked at 0600 hours in the normal and in the 
caudate nucleus of the adrenalectomized rat. Piepho and Friedman (1971) 
found circadian patterns for hindbrain and s~inal cord glycine, which were 
significantly higher during the dark phase. 
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c. Circadian rhythms in drug response 
1. CNS depressants 
Davis (1962) demonstrated in mice that sleep duration (loss of the 
righting reflex) produced by a constant dose of PB (60 mg/kg) varied over the 
day, peaking during the light period and troughing during the dark period. 
Grouped mice showed a longer sleeping time during the day than did isolated 
mice. Pauly and Scheving (1964) found that the maximum toxicity of PB 
(75-90 mg/kg, IP) in rats occurred during the dark phase, while the doses 
were least toxic toward the end of the light period. Emlen and Kem (1963) 
reported that the rate of recovery from PB anesthesia was more rapid during 
the active (dark) than the inactive (light) phase. Lindsay and Kullman (1966) 
demonstrated in mice that PB toxicity was least during the dark period. 
Scheving ~al. (1968d) found a circadian pattern in rats for PB sleep 
duration, which was longest at 2000 hours and shortest at 0900 hours. Fried-
man and Walker (1969) also reported that sleep duration in rats due to PB 
(50 mg/kg, IP) exhibited a circadian pattern. The duration was longest during 
the light phase (1800 hours), and shortest during the dark period (0600-2400 
hours). 
Nair and Casper (1969) found in rats that hexobarbital (RB; 150 mg/kg, 
IP) sleeping time was significantly greater at 1400 hours than at 0200 hours. 
Haus and Halberg (1959) noted that the percentage of deaths due to ethanol 
was greater at 1600-2000 hours, than for the rest of the day. Marte and 
Halberg (1961) found that the maximum toxicity of chlordiazepoxide in mice 
occurred at 2400 hours. 
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2. CNS stimulants 
Scheving !:.!:. al. (1968e) showed that amphetamine toxicity in rats was 
greater in the dark than in the light phase. The pattern was relatively un-
altered by blinding but abolished by constant light. Walker (1972) found 
similar results in toxicity for isolated or aggregated mice, although the 
latter were more sensitive to the lethal effects. Ancill et al. (1970) found 
that amphetamine (10 mg/kg, IP) produced no alteration in the circadian loco-
motor cycle of the rat, while lower doses (1.25 and 2.5 mg/kg, IP) signifi-
cantly altered the pattern, in a dose-dependant fashion. The increases in 
activity were much greater between 0800-2000 hours. While control locomotor 
a:tntity doos not increase until the dark period, the low doses of amphetamine 
increased motor activity prior to the onset of the dark period. 
Pauly and Scheving (1964) reported that the onset time for rats to 
undergo continuous tremors from tremorine (100 and 64 mg/kg, SC) depended on 
the time of administration. The maximal latency to tremor occurred during the 
light phase (0200 hours) and the minimum occurred during the dark (2100 hours), 
for the two doses tested. Webb and Russell (1966) found that seizure component 
times due to the convulsant, hexafluorodiethyl ether, followed a circadian 
pattern. Seizure times and the percentage of animals affected were greater at 
1000 hours (light) than at 2100 hours (dark). Lutsch and Morris (1967) 
demonstrated that in mice, lidocaine produced convulsions in a significantly 
higher percentage of animals at 2100 hours (dark) than at 1500 hours (light). 
Halberg et al. (1955) reported a circadian periodicity in the inci-
dence of mortality and audiogenic seizures in mice, which were maximum at 2000 
hours (early dark period). Schreiber and Schlesinger (1971) showed that 
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audiogenic seizure susceptibility in mice was greater during the night than 
the day. Day-night differences in susceptibility appear at 22 days of age and 
persist until 30 days of age, reaching a maximum difference at 26 days of age. 
several species of mice tested on day 27, exhibited a circadian pattern in 
audiogenic seizure severity scores. Schreiber and Schlesinger (1972) found 
that reversing the photoperiod reversed the seizure susceptibility pattern. 
Increased susceptibility to audiogenic seizures was directly related to lower 
levels of NE and SHT in the brain. Piepho (1972) demonstrated in vehicle-
treated mice that the extensor latency time of minimal electroshock seizure 
(MES) is shorter during the dark phase, while there were no circadian dif-
ferences in the MES threshold. Peak toxicity of the convulsants, allylglycine 
and strychnine in mice occurred during the light phase, corresponding to mini-
mal brain GABA and glycine concentrations. The anti-convulsant activities of 
acetazolamide, diphenylhydantoin and phenobarbital do not differ in effective-
ness from day to night. However, meprobamate was more effective in protecting 
mice from seizures during the light phase. 
3. Allergic response 
Reinberg and Sidi (1966) demonstrated a circadian pattern in the 
allergic response of humans on a standardized routine, in terms of the area of 
erythema and wheal after intradermal histamine. The maximum response occurred 
at the onset of the sleeping (dark) period. The protective response of the 
antihistamine, periactine, was more rapid and of shorter duration when ad-
ministered at 1900 hours than at 0700 hours. Reinberg (1967) described 
several related studies testing the intradermal allergic response to histamine 
and compound 48/80 and urinary 17 OHCS and 17-ketosteroids. The peak response 
...---~ ~ ~ ~ 
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occurred at about 2300 hours, at the time of minimum urinary corticosteroid 
excretion. 
DeVries ~al. (1962) reported a circadian pattern in the hyper-
activity of the bronchial tree to histamine in patients with asthma and 
bronchitis, which was most sensitive during the night. Reinberg (1967) in-
dicated that asthma attacks correlated with times when adrenal steroid release 
(urinary 170HCS and 17-ketosteroids) and potassium excretion were low. 
4. Drugs altering monoamine levels 
Saelens et al. (1968) reported that in mice pargyline increased motor 
activity in the dark phase, while alpha-methyl-~-tryosine had an opposite 
effect. Black et al. (1969) found that reserpine produced a dose-dependant 
depletion of whole rat brain NE, which was maximal during the dark period. 
Walker et al. (1971) demonstrated that reserpine depleted hypothalamic and 
caudate NE to the same extent in the day or night, although NE concentrations 
in controls was greater during the dark. DL-DOPA with pargyline increased NE 
concentrations in these areas, which were greater during the day than the 
night. Scapagnini et al. (1971) found that although the SHT levels in the 
hippocampus, amygdala and hypothalamus were greater in the dark than the light 
period, £-chlorophenylalanine depleted their SHT content to about the same ex-
tent in the light and dark periods. Zigmond and Wurtman (1970) showed that 
the accumrnulation of rat brain 3H-catecholamines after JR-tyrosine adminis-
tration was significantly higher in the light period than the dark period. 
Reis et al. (1969) studied the NE-depleting action of morphine in several 
brain regions of the cat. They found a significant correlation between NE 
depletion of an area and the presence of a daily NE rhythm in the area. 
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Friedman and Walker (1972) described the circadian fluctuations in 
the toxicity of several cholinomimetics. ACh (IV and IP), neostigmine, 
pilocarpine and oxotremorine are most toxic during the dark period. The 
atropine (IP) pattern is inverted. IV scopolamine and atropine methyl nitrate 
also show maximum toxicity during the light period. 
Wurtman ~al. (1970) determined that rat brain S-adenosylmethionine 
concentrations were maximal in the dark and minimal during the light period. 
5. Analgetics 
Reinberg et al. (1967) found that human urinary salicylate excretion 
was circadian. The duration of salicylate excretion was longest when the drug 
was given at 1900 hours. Lutsch and Morris (1971) reported a circadian 
pattern for analgesia in mice exposed to a constant dose of morphine. It was 
maximum at 0300 hours. Reversal of the photoperiod reversed the analgesia 
response pattern. 
6. Miscellany 
Scheving ~al. (1972) measured SHT in rat spleen over a 24-hour 
period. A circadian pattern for SHT concentration was maximum at 2400-0700 
hours, in several experiments. Carlstrom and Laurel! (1968) studied the 
effect of nicotinic acid on the diurnal variation of plasma FFA. Mean plasma 
FFA concentration was elevated, in an ultradian pattern; plasma triglycerides 
and cholesterol were reduced. 
p 
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D. CNS Amines 
1. Serotonin (5HT) 
a. Metabolism 
Serotonin or 5-hydroxytryptamine (5HT), an indolealkylamine, was 
first isolated by Page (1954) from blood platelets and from intestinal mucos.a 
by Erspamer (1954). Rapport et al. (1948) isolated a vasoconstrictor from 
serum which they named serotonin and which had identical properties to syn-
thetic 5HT. 5HT is found in animals (eg. mammals to coelentrates) and plants 
(eg. bananas, nuts, etc.) (cf. Garattini and Valzelli, 1965; Erspamer, 1966). 
Large amounts are found in the gastrointestinal tract associated with the 
enterochromaffin cell system and blood platelets. 
The presence of 5HT in the CNS was demonstrated by Twarog and Page 
(1953) and Page (1954). Distribution in the manunalian brain is uneven: in 
the hypothalamus, septal area and midbrain concentrations are relatively high, 
while in the cortex, cerebellum and white matter they are low (Bogdanski et al. 
1957). Giarman and Day (1959) found the bovine pineal is rich in 5HT. Sub-
sequent studies in such species as the rat, monkey, etc. demonstrated that 
5HT is higher in the pineal gland than in any other mammalian organ examined 
(eg. in rat 57-73 µgm/gm;owman, 1963). 
5HT is synthesized from an essential amino acid, tryptophan (TP) in 
two steps (cf. Figure 1 ). The first step is the hydroxylation of TP to 
5-hydroxytryptophan (5HTP) and the second is the decarboxylation of 5HTP to 5HT. 
The first reaction, catalyzed by the enzyme, tryptophan-5-hydroxylase (TPH; 
EC 1.99.1.4), is the rate-limiting step in 5HT synthesis. Following its 
synthesis, 5HTP is almost immediately decarboxylated to 5HT by the enzyme 
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5HTP decarboxylase (5HTPD;EC 4.1.1.18). This intermediate is not normally 
detectable in the brain or plasma. The enzyme is not specific, since it is 
capable of decarboxylating other L-aromatic amino acids, including the NE 
precursor DOPA. Therefore, the designation L-aromatic amino acid decarboxy-
lase (AAAiDC) is a better term for the enzyme. Both enzymes are found in the 
brain and periphery. Brain 5HT can be synthesized from plasma TP taken into 
the brain by an active process. 
The cellular distribution of SHT in the CNS was determined by histo-
chemical fluorescence techniques, which delineate intraneuronal SHT (Falck 
et al., 1962). With this technique serotonergic pathways in the CNS, which 
are especially prominent in the raphe nuclei of the brain stem were traced 
(Hillarp et al., 1966). Ascending SHT-containing fibers go to the dience-
phalon and telencephalon from the rostral raph~ nuclei, while pathways from 
the caudal portion descend to the lumbar and sacral cord. Pujol et al. 
/ . (1971) demonstrated in cats, that lesions of the raphe system decrease dience-
phalon and telencephalon SHT and produce insomnia proportional to the extent 
of destruction of SHT-containing cell bodies in the raphe system. 
SHT is stored in the CNS in free (active, mobile) and bound (inactive, 
reserve) forms. The bound form is stored as a complex with ATP in synaptic 
vesicles in nerve endings. Such nerve endings and vesicles can be isolated 
by ultra-centrifugation techniques and visualized by transmission electron 
microscopy and electron microscopic autoradiographic methods. 
Degradation of SHT is primarily via oxidative deamination by monoa-
mine oxidase (MAO;EC 1.4.3.4), an enzyme found in the brain and most tissues. 
MAO is widely distributed and localized intracellularly within the mito-
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chondrial membrane. It is present in nerve cells, but not glia, and located 
in the mitochondria around the storage granules found in nerve endings. It 
deaminates a number of amines to unstable aldehydes which are subsequently 
transformed to corresponding alcohols or acids by reduction or oxidation, 
respectively. MAO deaminates compounds in which the amine group is attached 
to the terminal carbon. MAO forms the unstable 5-hydroxyindoleacetaldehyde 
(SHIAc) from SHT, which is oxidized primarily to 5-hydroxyindoleacetic acid 
(SHIAA), although a small amount is reduced to the alcohol, 5-Hydroxytrypto-
phol (SHTPL). MAO inhibitors increase 5HT tissue levels by blocking its 
destruction. Several metabolites of 5HT, such as melatonin, 5HTPL, and 5-
methoxytryptamine (SMT) are physiologically active (vide infra for further 
discussion). 
b. Physiological Effects 
1) Serotonin 
There is little doubt that 5HT is a neurotransmitter in the 
CNS, if the traditional criteria used to establish putative transmitters are 
applied to SHT. These include CNS localization of 5HT itself, its synthetic 
and degradative enzymes, release of 5HT after electrical stimulation and 
effects of microiontophoretic 5HT similar to normal physiological responses 
(Werman, 1966). 
The neurophysiological effects of SHT on the CNS have been extensively 
studied. Marrazzi and Hart (1956) found that 5HT depressed transcallosal 
responses. Krnjevic and Phillis (1963) found that SHT depressed cortical 
activity induced by both glutamate and peripheral stimulation. Intracarotid 
administration of 5HT in cats produced an initial arousal pattern, followed 
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by a prolonged hypersynchrony (sleep-like) (Koella and Czicman, 1966). 
After midpontine transection of the brain stem, cauterization of the area 
postrema or application of 5HT-blocking agents to the fourth ventricle, 5HT 
produced only arousal. They concluded that 5HT acts upon receptor sites in 
the area postrema and this stimulating effect is transmitted to cell bodies 
in the solitary tract nucleus (Moruzzi, 1960). Bronzino !:.!:. al. (1972) 
demonstrated a similar EEG synchronization effect of 5HT applied to the area 
postrema. Bradley and Wolstencraft (1965) found that application of SHT to 
single neurons of the pons and medulla had variable effects: 40% of the 
neurons examined were excited by 5HT, while 49% were inhibited. When stimu-
lation is induced via the optic tract, 5HT depresses the lateral geniculate 
body (LGB), but is without effect with antidromic stimulation or after 
application of excitant amino acids (Curtis and Davis, 1962; 1963). 5HT 
also has depressant actions on the hypothalamus (Bloom et al., 1963), 
olfactory bulb (Bloom et al., 1964), hippocampus (Biscoe and Straughan, 1965) 
and spinal cord (Phillis et al., 1968). 
2) Metabolites 
The actions of metabolites of 5HT and other indoleamines 
(IA) must be considered. Part of the interest generated in these substances 
is derived from a number of IA compounds which have psycho-pharmacological 
activity, such as LSD, DMT (N,N-dimethyltryptamine), DET (N,N-diethyltrypta-
mine), bufotenine (5-hydroxy-N,N-dimethyltryptamine) and psilocybine (4-
phosphoryloxy-N,N-dimethyltryptamine). Attempts have been made to relate 
schizophrenia and other psychiatric disorders to aberrant metabolism of IA 
which might cause the synthesis of these compounds in humans. Woolley and 
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shaw (1954) hypothesized that the hallucinogenic effect of LSD was based on 
5HT antagonism but this theory has since been refuted by demonstrating that 
bromo-LSD, which is a potent 5HT antagonist, has no hallucinogenic activity. 
A number of active hallucinogens (vide supra) are formed by the methylation 
of 5HT and tryptamine on the terminal amino position (N-methylation). 
Axelrod (1962) isolated a N-methylating enzyme system in rabbit and human 
lungs and found it absent in mice, rats and cats. Morgan and Mandell (1969) 
reported the presence of this enzyme in brains of chicks and rats. 
Melatonin (M, 5-methoxy-N-acetyltryptamine), is formed from 5HT 
(for a detailed discussion, vide infra). Mcisaac (1961) postulated (under 
unspecified conditions) a disorder of M metabolism, whereby the M side chain 
closes, forming 10-rnethoxyharmalan, which has hallucinogenic properties. 
Szara (1961) reported that 6-hydroxy derivatives of DMr and DET are the active 
forms of these compounds and hallucinogenic activity is correlated with 
urinary 6-hydroxy derivatives (Szara and Hearst, 1962). An enzyme is found 
in the liver (Jepson et al., 1962) which degrades M by 6-hydroxylation. 
Hydroxy indole O-methyl transferase (HIOMr), the enzyme which rnethylates the 
5-hydroxy group of N-acetyl 5HT to form M, is also able to methylate other IA 
such as 5HT, 5HIAA and 5HTPL, to form 5-methoxytryptarnine (SMT), 5-methoxy-
indoleacetic acid and 5-methoxytryptophol (SMTPL), respectively. Arutyunyan 
et al. (1964) reported sleep induction and other central actions of 5Mr 
(mexarnine). Taborsky (1971) found 5HT, 5HTPL and SMTPL produced sleep in 
young chicks. The action of 5HTPL was greatly potentiated by pyrazole but 
not by iproniazid or disulfiram. Iproniazid decreased 5HT sleep. Other 
investigators have demonstrated sleep-inducing properties for 5HTPL 
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(Feldstein, 1971), and 5-hydroxyindolacetaldehyde (5HIAc; Sabelli and 
Giardina, 1970), the immediate oxidative product of 5HT by MAO (see Fig. 1 ). 
Ethanol alters the metabolism of 5HIAc by shifting product formation away from 
SHIAA towards 5HTPL (Feldstein et al., 1967). 
Hoffer and Osmond (1967) have advanced a theory for schizophrenia 
which involves the transformation of Epi (adrenaline) to adrenochrome by an 
oxidative ring closure, to form an indole-like compound. 
3) Effect of Precursors 
The role of 5HT in the CNS has been studied by using depletors, 
inhibitors of synthesis and precursors. The innnediate precursor of 5HT, 5HTP, 
has been used to increase central 5HT, since 5HT does not cross the blood 
brain barrier (BBB). 5HTP injections in cats, dogs and rabbits (Bogdanski 
~al., 1958; Monnier and Tissot, 1958; Costa et al., 1960; Tabushi and 
Himwich, 1970) produce a high voltage, slow wave EEG and sedation. After a 
latency of 15-20 minutes, doses of 30-50 mg/kg (IP or IV) of DL-5HTP (or 15-
25 mg/kg of L-5HTP) induce a state resembling SWS, which lasts for 5-6 hours, 
without PS. In rats, small doses of 5HTP reduce spontaneous activity (Joyce 
and Mrosovsky, 1964) and can cause tremor and agitation (Udenfriend ~ ~., 
1957) although 5HT itself has a sedative effect (Pierre and Cahn, 1955). 
Similar effects are seen in mice. In rabbits, small doses of 5HT and 5HTP 
induce sedation, while large doses result in excitation. Ledebur and Tissot 
(1965) injected 5HTP directly into the mediolateral part of the caudal brain 
stem, inducing SWS, while injections in the dorsolateral pontine tegmentum 
induced cortical desynchronization. Tabushi and Himwich (1970) found that a 
low dose of 5HTP (50 mg/kg, IV) delayed the onset of PS, while higher doses 
p 
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(100-200 mg/kg) markedly increased SWS. The anti-SHT agent, methysergide 
(1 mg/kg), increased the alert stage and decreased both SWS and PS. Wyatt 
et al. (197la) have shown different effects of SHTP in htnnans. PS increased 
--
while SWS decreased slightly, apparently compensating for the increased PS. 
These results differ from those obtained in cats (Jouvet, 1967b)in which SHT 
was implicated in SWS. 
Increasing the dietary intake of TP increases the level of brain SHT 
(Green~ al., 1962), while animals on a TP-deficient diet have reduced SHT 
levels (Gal and Drewes, 1962). Brain SHT is derived by hydroxylation of TP, 
occurring mainly, if not wholly in the brain. Weber and Horita (1965) demon-
strated that the increase in cerebral SHT in rats after IP TP was unaffected 
by evisceration and that perfusion of cerebral hemispheres with a TP solution 
resulted in elevated SHT levels on the perfused side only. Moir and Eccleston 
(1968) studied changes in concentrations of 5-hydroxyindoles (SHI) in whole 
rat brain and various regions of dog brain after TP and 5HTP injections and 
concluded that intracerebral TP hydroxylation is the primary factor con-
trolling cerebral SHT formation. These and other investigators (Garattini 
and Valzelli, 1965) questioned the use of SHTP to increase central 5HT because 
it is also decarboxylated in parts of the brain where SHT is not normally 
present. 
TP levels in human plasma (Wurtman et al., 1968b) and certain rat 
tissues (Wurtman et al., 1968c) undergo diurnal variation. Although SHT con-
centrations in the rat brain and pineal gland also vary with time of day 
(vide supra), a relationship between these and the rhythms of plasma or tissue 
TP content is still conjectural. 
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In normal humans TP reduces sleep latency and slightly increases sleep 
length and increases total sleep time. In insomniacs it reduces sleep latency 
and the number of awakenings (Hartman, 1967; Hartman~ al., 197lb). Oswald 
et al. (1966) found an increased onset of PS sleep with TP in humans. 
--
4) Blockade of Synthesis or Storage of SHT. 
a) ~-Chlorophenylalanine (pCPA) 
Koe and Weissman (1966) reported that pCPA depletes SHT in 
brain, peripheral tissues and blood, in rats and dogs. Brain SHT and SHIAA 
content are reduced to very low levels, while brain NE and DA decreased only 
slightly. pCPA reduces the normal increase in SHI compounds after TP loading, 
inhibits liver TP hydroxylase and suppresses the TP- and phenylalanine-hydroxy-
lating activity of livers from animals treated with it. They concluded and 
others have since substantiated (Jequier ~al., 1967) that pCPA acts by in-
hibiting TPH, the rate limiting step in SHT synthesis. Bloom and Giarman 
(1970) observed that pCPA (316 mg/kg, IP) decreases rat pineal SHT content 
more than 90% within a day without affecting NE content. Pineal SHT concen-
trations return to normal levels 4-6 days after treatment. Granular vesicle 
opacity of pineal nerve endings observed by the electron microscope is also 
lost one day after pCPA treatment and recovers with a time-course similar to 
tissue SHT recovery. 
Tenen (1967) found that depleting doses of pCPA in rats had no effect 
on circular activity cage locomotion but depressed jiggle cage activity. 
Volicer (1969) examined the effects of pCPA in mice and rats and found 
spontaneous activity decreased only in rats. 
,.------------------------
. 
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The involvement of SIIT in SWS prompted Delorme et ~- (1966a) to study 
the effects of pCPA on sleep in cats. They observed it produced a state of 
insomnia or permanent wakefulness, with inhibition of PS and SWS. This pattern 
of disruption of sleep by pCPA in cats resembles the time-course of SIIT deple-
tion seen in rats (latency of 16 hours and duration of about 3 days). 
Mouret~ al. (1967, 1968) obtained similar results in chronically-implanted 
rats and cats with doses of pCPA which almost completely deplete central SIIT. 
The loss and recovery of sleep correlated with the time-course of central SIIT 
change in rats similarly treated. The loss of sleep in pCPA-treated cats 
(440 mg/kg) was inunediately suppressed by 5IITP (40 mg/kg) and restored to 
normal for 10-12 hours. Koella ~al. (1968) obtained equivalent results with 
pCPA and 5IITP treatment in chronically-implanted cats. Torda (1967) reported 
substantially the same results with chronically-recorded, pCPA-treated rats, 
and in sleep-deprived rats in which she measured SIIT content (75 hours after 
injection). Whole brain SIIT from animals deprived of sleep (for 15 hours) 
was slightly elevated from controls, indicating that pCPA reduction of brain 
5IIT is a direct and not a secondary effect produced by sleep-deprivation. 
Pujol et al. (1971) extensively examined the metabolism of 5HT with 
respect to the insomnia produced by pCPA and lesions of the raphe system, in 
chronically-recorded cats. After a 12-hour latency, a single dose of pCPA 
(500 mg/kg) eliminated PS and SWS, which was maximal 36-40 hours after injection 
and which recovered after 4 or 5 days without any sleep rebound. Lesions of 
the raphe system produced permanent arousal, with no PS and very little SWS, 
which correlated with the completeness of the lesion. Cortical 5IIT and 
• 
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SHIAA were greatly decreased; formation of 3H-51IT from 3H-TP decreased, but 
3 3n-TP uptake and synthesis of H-51ITP were unaffected. 5HTP injections in 
cats with raphe lesions did not abolish the arousal pattern. 
Cremeta and Koe (1966) found that no complaints of insomnia were 
reported by normal humans given up to 3 gm/day (about 40 mg/kg) of pCPA. 
b) Reserpine (R) 
R depletes tissue 51IT (and other amines) from their 
storage sites, probably by interfering with the intracellular binding 
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(Pletscher et al., 1956). R causes almost complete depletion of amine sotres, 
which, depending on the dose used, recover to normal levels in about a week. 
There are some differences in the mechanism of depletion of the amines since 
maintaining R-treated animals at 4°C. depletes CAs but not 51IT. The animals 
are not sedated but become so after returning to room temperature, when 
central 5IIT decreases (Garattini and Valzelli, 1958; Sulser and Brodie, 1960). 
In addition to the actions of R on binding, it also blocks uptake of endo-
genous and exogenous amines into nerve endings (Brodie~ al., 1960) in vivo 
and in vitro. The sedative effects of R last only several days compared to 
the longer time-course of brain amine depletion (Haggendahl and Lindquist, 
1964). Reserpinized animals have been given the amine precursors SIITP and 
DOPA, in an attempt to ascertain whether SHT or NE depletion accounts for the 
sedation. 5HT increases the sedation, although large doses cause excitation. 
On the other hand, when DOPA was injected the R signs were reversed, sug-
gesting that the depletion of CAs was responsible for the depression (Monnier 
" 
and Tissot, 1958; Jouvet, 1968). 
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In the cat, a single dose of R (0.5 mg/kg) suppressed SWS for 12-14 
hours and PS for 22-24 hours, the latter returning to control only 5-6 days 
later. A selective and prolonged period of PGO (ponto-geniculate-occipital) 
spiking (30-50/minute) appears within several hours of injection and lasts 
for 50-60 hours (Matsumoto and Jouvet, 1964; Jouvet, 1967a). This PGO 
activity is identical to PGO activity during PS. Recordings were made at 
the same level of the pons, mesencephalon, lateral geniculate and occipital 
cortex and accompanied by lateral eye movements and twitches of the eyes and 
ears. However, the appearance of the cat is quite different from sleep and 
there is no decrease of the neck muscle tone. Hoffman and Domino (1969) 
compared the effects of R on the sleep cycle in cats and humans. Low doses 
(0.01-0.16 mg/kg, IM) decreases SWS in cat and man. In the cat PS decreases 
for 48 hours without any rebound, while in man a fall in PS occurred on the 
first night with a rebound increase on the subsequent 2-3 nights. Coulter 
et al. (1971) examined the EEG sleep patterns of 20 subjects following 
single and repeated oral doses (1.0 mg) of R. Both treatments produced an 
increase in PS and a decrease in SWS. 
5HTP (30-50 mg/kg, IV) injected 2-3 hours after R inunediately 
suppresses the PGO activity and induces EEG and behavioral sleep for 4-6 
hours, after which the characteristic fast cortical activity and PGO spiking 
of R reappear. Similar dosages of DOPA increase the PGO activity 50-80/ 
minute for 4-6 hours. After a 20-30 minute latency, brief periods of SWS 
occur which are always followed by behavioral and EEG PS, demonstrating an 
almost normal pattern, which returns to the R pattern after 5-6 hours 
• 
(Jouvet, 1968). 
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c) MAO Inhibition 
MAO inhibitors (MAOis) which act upon both IAs and CAs 
by inhibiting their catabolism and thereby increasing their central con-
centration have actions on the sleep-wakefulness cycle. Inhibitors such as 
iproniazid, pargyline and nialamide have a specific and selective suppressive 
effect on PS, while increasing SWS, probably as a secondary response. After 
a single injection of nialamide (10 mg/kg), PS is suppressed for 90-100 
hours; it recovers after one week. PS suppression occurs even in animals 
deprived of PS (Jouvet, 1968). Recovery of PS after MAOis occurs without 
the rebound of PS seen after PS deprivation. Chronic administration of 
phenylisopropylhydrazine (1-4 mg/kg), which inhibits brain MAO without im-
pairing liver MAO, can produce PS suppression for several weeks (Delorme, 
1966). These studies also demonstrated a correlation between t~ loss of PS 
by nialamide and the disappearance of the histochemical MAO stain in the 
pontine tegmentum at the level of the locus coeruleus, where lesions 
selectively suppress PS. 
Wyatt ~al. (1969) administered MAOis to humans and found marked 
PS suppression. Akindele ~al. (1970) studied the actions of the MAOI, 
phenelzine and nialamide on human sleep. After 5-22 days of phenelzine 
(60-90 mg daily) PS was abolished, coinciding with the time of mood improve-
ment. No effect of nialamide (75 mg/day for 17 days or 500 mg once, IM) 
on PS were noted. 
c. The Pineal Gland 
• As a result of recent, extensive study, the mannnalian pineal can 
no longer be considered a vestigal organ (Wurtman et al., 1968a). The gland 
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(weighing 1.0 mg or less in rodents) is unusually rich in such biogenic 
amines as NE, H, 5HT and other IAs, as well as the enzymes which metabolize 
these compounds. Although the pineal gland develops embryologically from the 
roof of the diencephalon (Kelly, 1962), it maintains no direct neural con-
nections with the brain. It is on the "peripheral" side of the BBB and 
possesses peripheral innervation (vide infra). The pineal is of interest 
for several reasons. The 5HT synthesis and content is higher than any other 
organ. Two enzymes, which acetylate, then methylate SHT are unique to the 
pineal and form melatonin, which has marked physiological and pharmacologi-
cal effects. The concentrations of these compounds and enzymes are subject 
to alterations by environmental stimuli such as light, and physiological 
factors. Some pineal biochemical reactions can be regulated by the auto-
nomic nervous system. 
1) Melatonin (M) 
a) Localization 
Probably the most important biochemical discovery made 
in recent decades concerning the pineal gland was the isolation and identifi-
cation of its characteristic indole, M. McCord and Allen (1917) demon-
strated that bovine pineal extracts contained a substance which lightens 
amphibian skin. Beginning in 1947, Lerner and coworkers set out to isolate 
and characterize the active principle of the extracts, using over 250,000 
bovine pineal glands. Through a series of elegant experiments (Lerner~~., 
1959, 1960) the active substance was found to be 5-methoxy-N-acetyltrypta-
mine or M (see Figure 1) . 
.. 
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M is synthesized only in the pineal, although small amounts have been 
found in peripheral nerves. It is formed in a two-step process in which SHT 
is N-acetylated (Weissbach et al., 1960) and then is methoxylated on CS-
hydroxy group (Axelrod and Weissbach, 1961). Acetyl SHT methyl transferase 
(EC 2.1.1.4), the enzyme catalyzing the first reaction is widely distributed 
in mammalian tissues, however, the second enzyme, which transfers a methyl 
group from S-adenosylmethionine to N-acetyl-SHT (HIOMT) is found in the 
pineal and thus determines the selective localization of M synthesis (Axelrod 
et al., 1961). Spectral characteristics for pineal gland, retinal and 
Harderian gland HIOMT have been described recently (Cardinali et al., 1972). 
Although N-acetyl-SHT is the best substrate for HIOMT, it is not the only 
one. The enzyme can also methylate other indolamines such as SHT, SHIAA and 
SHTPL, forming small amounts of SMT, SMIAA and SMTPL, respectively (Axelrod 
and Weissbach, 1961; Mcisaac et~., 1965). 
M is degraded mainly in the liver, by hydroxylation at the sixth 
carbon (about 80/0 of M) and excreted in the urine in the conjugated forms 
as the 0-sulfate and 0-glucuronide. This enzyme is specific in forming a 
6-hydroxy indole. Thus it plays no role in SHT synthesis (Jepson~ al., 
1962). In addition, traces of injected M appear in the urine unchanged and 
as SMIAA (Kopin et al., 1960; Wurtman et al., 1964c). 
The disappearance of injected M (acetyl-3H) from blood and its tissue 
distribution have been studied in mice and rats (Kopin et al., 1960) and 
cats (Wurtman et~., 1964c). 3H-M appears to be taken up by all tissues, 
including the brain, indicating that unlike SHT, its access to the CNS is 
not hindered by the BBB. In the cat, one hour after injection it is 
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concentrated in the pineal, parts of the eye and ovaries (Wurtman ~al. , 
1968). Other endocrine tissues and peripheral nerves selectively take up 
3a-M to a small degree, while adipose tissue has the smallest uptake, indi-
cating that the uptake in such organs as ovary, pineal and adrenal gland is 
unrelated to their relatively high lipid contents. Anton-Tay and Wurtman 
(1969) have shown that 3H-M injected into the blood or the lateral cerebral 
ventricles is selectively concentrated in the hypothalamus and midbrain. 
M has been shown by several investigators to have pronounced effects 
on the reproductive system of rodents and birds (Wurtman ~al., 1968a;Tait 
~al., 1969; Reiter and Franchini, 1969). Relatively low doses decrease rat 
ovarian weight, retard vaginal opening, increase pituitary LR content and 
depress the proportion of daily vaginal smears showing estrus phases (Chu et 
al., 1964; Mcisaac et al., 1964). Male gonadal growth is similarly reduced. 
Baschieri et al. (196~) found that daily injections of M (l.O mg/kg) de-
creased thyroid cell height and 1311 uptake 
b) Pharmacological Effects 
Marczynski et al. (1964) examined the effects of M im-
plants on the EEG of unrestrained cats. Small amounts of crystalline M 
(15-30 µgm) were administered by cannulae directly into the preoptic region 
of the hypothalamus, nucleus centralis or brain stem reticular formation 
(RF) and the animals observed for behavioral and EEG effects. Implants in 
the preoptic region had the most pronounced actions, which appeared after 
15-30 minutes and lasted 2-3 hours. The EEG exhibited cortical synchroni-
zation with an increase in amplitude and slowing of subcortical activity, 
while at the same time the animals went to sleep. Implants in the nucleus 
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centralis medialis led to qualitatively similar EEG activity and behavior, 
however brain stem implants produced no consistent changes. Administration 
of pineal extracts or M decreases the spontaneous motor activity in the rat 
(Reiss~ al., 1963b; Wong and Whiteside, 1968). 
Arutyunyan et al. (1964) examined the pharmacological properties of 
M. Subcutaneous injection of M (25 mg/kg) produced a slight behavioral 
depression in cats lasting 1-1.5 hours. Similar doses (25-50 mg/kg, IV) in 
mice were without effect. Doses of M (10-20 mg/kg, IV) in cats and rabbits 
resulted in slow, high-amplitude waves in the EEG of cortical and subcortical 
structures 5-10 minutes after injection, which lasted 1-2 hours. M (20 mg/kg, 
SC) significantly prolonged the hypnotic effects of HB (60 mg/kg, IP) and 
chloral hydrate (200 mg/kg, IP) in mice. This effect might be due, in part, 
to the ability of M (50-100 mg/kg, SC) to reduce body temperature 2-3°C. In 
the rabbit, M (25 mg/kg) had no hypothermic action (Barchas ~al., 1967). 
In similar experiments, Barchas ~ ~· (1967) found M (25 mg/kg, IP) in-
creased HB (100 mg/kg, IP) sleeping time in mice 50 per cent. Fraschini and 
Martini (1970) examined the effect of M on PB sleep. They injected M into 
the lateral cerebral ventricles of rats immediately after PB (30 mg/kg, IP). 
M (30-120 µgm) potentiated PB sleep in a dose-dependent fashion (about a 14-
45% increase). These results seem specific for M, since comparable intra-
ventricular doses of SHT with PB produced small decreases in sleeping time. 
M (2.S mg/kg, IV or IP) in 4-day old chicks (which have an incomplete BBB) 
immediately caused the animals to assume a roosting posture for about 45 
minutes (Barchas ~al., 1967). A dose of M (10 mg/kg) did not alter blood 
pressure in cats or the contractile force of the heart or the EEG in dogs. 
,. 
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Hishikawa et al. (1969) found in young chickens that M (10-60 mg/kg, IP) 
had a powerful sedative and hypnotic effect which appeared within 1-2 minutes 
and lasted for 30-60 minutes. M-induced sleep was characterized by a slow, 
high voltage EEG, similar to normal SWS. Pinealectomized rats show increased 
motor activity and an activated EEG (Reiss et al., 1963a; Nir ~al., 1969a). 
Recently Anton-Tay~ al. (1971) gave human volunteers IV doses of M (0.25-
1.25 mg/kg in ethanol). Initially the EEG was "deactivated", followed in 
15-20 minutes by sleep lasting about 45 minutes. Similar results occurred 
in several epileptics but not in Parkinson patients who experienced minimal 
sleep effects but did improve in their condition. 
Anton-Tay~ al. (1968) administered M (about 1.0 mg/kg, IP) to 
female rats and measured 5HT and NE in the MB, hypothalamus and cerebral 
cortex over a 3 hour period. Cortical 5HT decreased 14% 20 minutes after M 
and was still depressed after 60 minutes, while its concentration in the MB 
and hypothalamus increased significantly. After 3 hours the cortical and 
hypothalamic 5HT concentration had returned to normal, but that in the MB 
continued to increase. A weakness in experimental design is the use of "zero-
time" controls instead of vehicle-treated animals (diluted ethanol) sacri-
ficed at specific times after injection, thereby obscuring possible (and 
probably) amine changes due to ethanol (Feldstein, 1971) and effects due to 
circadian rhythms. In preliminary experiments with rats sacrificed one hour 
after 0.5 mg of M (total dose), whole brain 5HT was elevated significantly 
while NE content was unchanged. In mice, M (30 mg/kg, IP) given every 3 
hours for 18 hours caused no change in gross behavior or NE content of the 
brain or heart. 
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Klein et al. (1970) and Berg and Klein (1971) have studied several 
aspects of M synthesis using cultured rat pineals. Treatment of cultures 
with NE or dibutyryl adenosine 3', 5 1 -monophosphate (DAMP) caused a 6-10-
fold increase of N-acetyltransferase activity and subsequent M formation. 
They concluded that N-acetyltransferase, which forms N-acetyl 5HT, is ele-
vated by NE through a cyclic AMP mechanism dependent on protein synthesis, 
since cycloheximide and actinomycin D block the augmented formation of 
labeled M from labeled TP. Wurtman et al. (1971) examined these effects of 
NE and found they could be blocked by the ~-adrenergic blocking drug propran-
olol but not the a-adrenergic blocker, phenoxybenzamine. Neither altered 
the response to DAMP. 
2) Anatomy 
The work of Rowan (1925) which demonstrated that gonadal 
function in the junco finch involved regulation by environmental lighting 
gave the first hint of the importance of light on physiological systems. 
His observations indicated that the endocrine system was not closed, but 
could be influenced greatly by environmental stimuli. Fiske et al. (1960, 
1962) showed that pineal weight and synthetic activity in rats kept in con-
stant light decreased 25%, while constant darkness had no effect (compared 
with animals maintained under diurnal lighting conditions). Axelrod et al. 
(1965) has shown that pineal weight varies over a 24-hour period, and is 
lowest at the end of th!light period. Pineal extracts depress gonadal weight 
and function (Wurtman et al., 1959), while pinealectomy or constant light 
increase ovarian weight (Wurtman et al., 1961). Injections of M reduced 
gonadal weight and function in animals maintained in normal lighting. These 
, 
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results suggested that the pineal contained a factor which inhibited gonadal 
function in the rat, whose synthesis or release was probably related to en-
vironmental lighting. 
The rat pineal gland is rich in such biogenic amines as SH.T (Quay, 
1963), histamine (Machado et al., 1965), DA and NE(Pellergrino de Iraldi and 
Zieber, 1966). Quay (1963) has shown that the concentration of pineal SH.T 
is not constant but exhibits a characteristic diurnal variation when animals 
are maintained under diurnal lighting conditions (usually 12 or 14 hours 
light, 12 or 10 hours dark). It is highest during the day and falls during 
the night, in these nocturnal animals. Quay (1965) demonstrated the same 
pattern for pineal 5HIAA. Rats placed in continuous darkness for one week 
retained their pineal 5HT rhythm (Snyder et al., 1964, 1965), although this 
might not have been sufficient time to abolish the 5HT rhythm. Blinded 
animals retain a similar pattern of pineal 5HT under normal illumination, 
constant light or constant dark. This rhythm is extinguished in 5 days when 
normal animals are placed in constant light. 
M, synthesized from pineal 5HT and in vitro M-forming activity have 
similar diurnal patterns although peaks and troughs do not correspond to that 
of pineal 5HT (Quay, 1965). Wurtman et al. (1963b) reported that continuous 
light decreased HIOMT activity relative to that of animals kept in darkness. 
If the nerves entering or leaving the superior cervical ganglion (SCG) were 
cut, pineal HIOMT activity was no longer alterable by continuous light or 
darkness (Wurtman et al., 1964a,b). Axelrod et al. (1965) observed in rats 
kept under diurnal lighting, a diurnal pattern of pineal HIOMT activity, 
which was greatest at midnight. Animals kept in darkness showed a marked 
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rise in HIOMT activity, which could be prevented by puromycin and partially 
blocked by actinomycin D, agents which interfere with DNA-directed protein 
synthesis. 
Kappers (1960) demonstrated that the pineal is richly innervated by 
post-ganglionic sympathetic axons, which have their cell bodies in the SCG. 
In the rat, these provide the only innervation to the pineal. Axons origi-
nating in the retinal ganglion cells travel via the optic nerve to the optic 
chiasm, where they separate into several components (Hayhow ~al., 1960). 
The largest and most important nerve bundle contributes crossed and uncrossed 
fibers to the primary optic tract (POT) which transmit to the occipital cor-
tex where images are perceived. The superior and inferior fasciculi of the 
accessory optic system leave the optic chiasm. The superior fasciculus 
terminates in three nuclei within the MB tegmemtum, while the inferior fasci-
culus enters the lateral hypothalamus, running with fibers of the median 
forebrain bundle (MFB) before terminating in the nucleus of Bochenek in the 
rostral midbrain tegmentum. Retinohypothalamic fibers have been described 
which leave the chiasm dorsally and terminate in the adjacent medial hypo-
thalamus in some species (Krieg, 1932), although other studies have questioned 
their existence (Hayhow et al., 1960). 
Studies by Moore and Axelrod and coworkers have elegantly determined 
the pathways by which light influences pineal function, with regard to M and 
HIOMT activity. Rats with bilateral lesions of the MFB (where it passes 
through the lateral hypothalamus) or sham-operated animals were placed in 
continual light or darkness for 30 days (Axelrod~ al., 1966). HIOMT 
activity and pineal weight in sham-operated animals kept in darkness was five 
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times greater than in animals kept in light, while animals with lesions 
showed no differences between the light and dark-treated animals. Four pro-
cedures were performed in rats: 1) both eyes were enucleated; 2) one eye was 
enucleated and the MFB on the ipsilateral side transected (interrupting the 
photic input to both inferior accessory optic tracts, IAOT); 3) bilateral 
lesions were placed in the optic tract at the LGB (producing a functionally 
blind rat with an input to IAOT intact); 4) both IADT and primary optic tracts 
were severed (only retinohypothalamic fibers maintained intact in order to 
determine if they mediate pineal function), (Moore et al., 1967). Animals 
prepared as outlined above were kept under continual light or dark for 30 days, 
then their pineals were assayed for HIOMT activity. In enucleated rats or 
animals in which the IAOT had been interrupted, light and dark had no effect 
on M synthesis but the characteristic changes in HIOMT activity did occur in 
animals with only POT lesions, implicating the IAOT in these effects. Wartman 
et al. (1969) demonstrated that although cholinergic innervation is not im-
portant in the pineal response to light, the facilitation of HIOMT activity 
in darkness is mediated by the parasympathetic system. The results of these 
experiments indicate that impulses produced in the eye by light travel in the 
optic nerve, are transmitted through the IAOT., reaching the nucleus of 
Bochenek in the MB. From there they descend through the spinal cord, where, 
at the upper thoracic cord, preganglionic sympathetic fibers enter the SCG. 
Postganglionic sympathetic fibers (nervi conarii) transmit the impulse to 
their termination in the pineal gland. 
A possible mechanism by which pineal IAs might exert their actions 
centrally has been suggested by several workers (Koella, 1969a; Fraschini and 
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Martini, 1970). Since Mis not found in the general circulation, it and other 
IAS may exert their effects by being transported through the cerebral spinal 
fluid (CSF), in a direct, internal circulation of the brain (Sheridan et al., 
1969). They have demonstrated such transport in the hamster. In the experi-
ments of Fraschini and Martini (1970) intraventricular injections of M poten-
tiated PB sleep. Koella (1969b) hypothesized that because of the high con-
centration in the pineal of SHT, M and some other active IAs, these substances 
could 11 leak" via the recessus pinealis, into the posterior part of the third 
ventricle, then flowing with the CSF into the fourth ventricle where they can 
exert a hypersynchronizing action on the area postrema, nucleus tractus 
solitarii and upper brain stem, areas which have been shown to be sensitive 
to such hypersynchronizing actions of IAs. 
3) Other Pineal Amines 
Pineal NE is present in relatively high concentrations in the 
rat (Pellegrino de Iraldi and Zieher, 1966; Wurtman and Axelrod, 1966). At 
the end of the light (sleep) period NE was three times that at the end of the 
dark (awake) period. The increase in pineal NE at the onset of the dark 
period is in phase with the rapid increase in M formation (Quay, 1965) and 
occurs when pineal 5HT is falling sharply (Quay, 1963). Thus the work of 
Klein and coworkers suggest that the stimulation of N-acetyltransferase and 
subsequent M production, by NE might occur physiologically. The NE rhythm 
is abolished by blinding or maintaining rats in constant light or constant 
darkness after as little as one day (Wurtman ~~., 1967a). This further 
suggests that the NE rhythm, like the HIOMT but not the 5HT rhythm is exo-
genous and dependent on environmental light input to the pineal. Sectioning 
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the preganglionic fibers to the SCG (Pellegrino de Iraldi and Zieher, 1966) 
or unilateral MFB transection and contralateral enucleation (Wurtman et al., 
1967a) also abolish the pineal NE rhythm, to a constant, intermediate level. 
Other rhythms in the pineal include greater incorporation of circula-
ting 32p during the dark than light (Roth, 1965) and increase content of 
ethanol soluble lipids during the day than the night (Quay, 1961). 
r 
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2. Cathecholamines 
a. Metabolism 
The CAs NE, Epi and DA are 3,4-dihydroxy derivatives of phenyle-
thylamine (see Figure 2 ). Elliot (1905) first postulated that an Epi-like 
substance might be released from sympathetic nerves and thus be responsible 
for chemical transmission at synapses. The presence of an adrenergic "sym-
pathin" in extracts of manunalian brain was first described by von Euler (1946). 
Von Euler (1948) finally established that NE is the sympathetic transmitter 
by chemically isolating NE in splenic nerves. Holtz (1950) confirmed this 
finding in brain and spinal cord and demonstrated that NE content was much 
greater than that of Epi. Until 1954 it was generally suspected that brain 
NE was located mainly in blood vessels. Vogt (1954) measured CAs by bioassay 
and first demonstrated their relatively high concentration in specific ana-
tomical areas, in cat and dog brain. The distribution pattern is generally 
similar in other species. In man, rat, cat and monkey, the highest con-
centrations are in the hypothalamus and range from 1-3 µgm/gm. The con-
centrations in other areas can be ranked as follows: MB and pons, medulla 
oblongata and striatum followed by a group of structures with very low con-
centrations, such as the hippocampus, cerebral cortex, cerebellum and spinal 
cord. In the corpus striatum, particularly the CN, where the NE concentration 
is relatively low, DA is found in very high concentrations (3-8 µgm/gm). 
Since 1962, the highly specific and sensitive histochemical fluores-
cence microscopy technique has permitted the direct visualization of the 
biogenic amines, NE, DA, Epi and SHT, at the cellular level. The use of 
these methods confirmed that NE present in peripheral manunalian tissues and 
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specific CNS areas is localized almost exclusively in sympathetic or adrener-
gic nerves (Carlsson.!:,£ al., 1962). In the presence of formaldehyde gas the 
amines are converted to fluorescent isoquinoline derivatives which are green 
in the case of the NE and DA products and yellow for the 5HT derivative. In 
many areas of the brain fine nerve fibers with extensive terminal arboriza-
tions or variscosities containing CAs or 5HT have been demonstrated. Using 
these techniques and selective stereotaxic placement of lesions in the CNS, 
Heller and Moore (1965) and Ungerstedt (1971) described NE, DA or 5HT pathways 
in the brain. More recently, the use of density-gradient centrifugation and 
autoradiographic localization of 3H-NE and electron microscopy have combined 
to reveal that NE is localized largely within specific storage particles or 
synaptic vesicles contained in adrenergic nerve endings. 
Gross mesencephalic and specific hypothalmic lesions produce a fall in 
CA and 5HT concentrations and fluorescence in the brain. After it was shown 
that thoracic cord section decreases spinal cord NE (Magnusson and Rosengren, 
1963), several NE-containing bulbospinal systems were described (Dahlstrom 
and Fuxe, 1965). They are localized in the medulla and send axon processes 
into the spinal cord. Ascending systems containing NE neurons originate in 
the lower brain stem (medulla, pons and MB) and extend to the hypothalamic, 
preoptic area, limbic system and cortex. Lesions in the MFB of the lateral 
hypothalamus and in the dorsomedial brain stem tegmentum significantly de-
creased whole brain NE and 5HT, while lesions in the ventrolateral tegmer_tum 
decreased NE only (Heller and Moore, 1965). 
Lesions have been used to demonstrate a nigro-striatal system of DA-
containing neurons which originate within the substantia nigra and project 
l 
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to the striatum. Other DA neurons are located in the MB and project rostrally, 
primarily to the olfactory tubercle. The only monoaminergic cell bodies 
located above the MB, with the exception of a DA cell group in the retina, is 
small set of neurons localized near the median eminence, which is thought to 
be of importance in neuroendocrine regulation. Areas where there is the 
greatest number of nerve endings (not cell bodies) contain the highest NE 
concentration. 
b. Biosynthesis 
As first suggested by Blaschko in 1939, the synthesis of CAs 
begins with tyrosine. Tyrosine is transported into the brain and central 
adrenergic neurons by specific active transport mechanisms. Once within the 
neuron it is hydroxylated by the cytoplasmic enzyme, tyrosine hydroxylase 
(TH; EC 1.14.3.a) to dihydroxyphenylalanine (DOPA; see Figure 2 ). Direct 
demonstration of enzymatic hydroxylation of tyrosine was only achieved 
recently (Nagatsu et al., 1964). They found that TH is easily saturated by 
substrate and is therefore the rate limiting step in the biosynthesis of CAs. 
Several CAs also inhibit TH, suggesting that this inhibition is involved in 
the regulation of CAs synthesis. (TH does not hydroxylate tyramine, D-£-
tyrosine or DL~-tyrosine to DA.) Alpha methyl-£-tyrosine (AMPT), a com-
petitive inhibitor of TH is converted to a-methyl DOPA, depleting tissue CAs 
but not SHT (Spector et al., 1965; Anden ~al., 1966). 
DOPA is decarboxylated within the cytoplasm to form DA which is taken 
up into storage granules by an active process. The decarboxylating enzyme 
is sometimes known as DOPA decarboxylase although it is the same non-specific 
L-aromatic amino acid decarboxylase (AAADC) that forms SHT from SHTP. The 
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wide distribution and high activity of this enzyme in many tissues has made 
it difficult to achieve sufficient enzyme inhibition to decrease CA levels. 
In DA-neurons there is no further synthesis, while in NE-neurons the DA is 
hydrozylated, within storage granules by dopamine~-hydroxylase (DH; E C 1. 
14.2.1). The enzyme also catalyzes the conversion of several other phenyle-
thylamines other than DA, to their ~-hydroxylated products (Kaufman and 
Friedman, 1965), as long as they contain an aromatic ring with a 2- or 3-
carbon side chain terminating in an amino group. The potent inhibitor of DH, 
disulfiram, decreases brain and heart NE content, probably by complexing with 
copper ions of the enzyme. 
In chromaffin tissue, such as the adrenal medulla and certain areas of 
the brain, the cytoplasmic enzyme, phenylethanolamine-N-methyltransferase 
(PNMT; EC 2.1.1) methylates NE to form Epi (Wurtman and Axelrod, 1966). 
Presumably the NE passes from the storage granules for .this step and newly 
formed Epi is taken back into storage granules. PNMT is strongly inhibited 
by its substrate NE and product Epi at concentrations (of Epi) normally 
present in the adrenal medulla. 
c. Degradation 
Armstrong et al. (1957) first reported that a 3-0-methylated 
4-hydroxylated catechol acid, 3-methoxy-4-hydroxymandelic acid ("vanillilman-
delic acid, VMA") is a urinary metabolite of both NE and Epi (see Figure 2 ) . 
Subsequently the 0-methylated amines normetanephrine (NM) and metanephrine 
(MET) were also found in the urine. Metabolic degradation of CAs primarily 
involved two enzymes: monoamine oxidase (MAO) and catechol-0-methyltrans-
ferase (COMT). Since both act on a wide variety of amine substrates and each 
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is active on the products of the other, a spectrum of CA metabolites can be 
identified in urine. 
N-methylation and ~-hydroxylation decrease the susceptibility of pheny-
lethylamines to MAO. The relative proportion of oxidized to reduced products 
in the deaminating steps varies among species and under different conditions. 
DA is a better substrate for MAO than Epi or NE, so large amounts of the 
deaminated metabolites of DA (dihydroxyphenylacetic acid, DOPAC and homo-
vanillic acid, HVA) are excreted in the urine. 
d. MAO Inhibition 
Inhibition of MAO elevates tissue levels of biogenic amines such 
as NE, DA and SHT (Spector, 1963) and decreases the excretion of deaminated 
metabolites of amines, such as VMA, 3-methoxy-4-hydroxyphenylglycol and HVA, 
while the excretion of NM, octopamine and tyramine increases (Sjoerdsma, 
1966). Although MAO inhibition does not prolong the physiological effects 
of NE, MAO is important in regulating the intracellular level of amines by 
metabolizing any amines which leak into the axoplasm from storage granules. 
The second pathway for CA metabolism is the 0-methylation of the 
catechol ring by COMT (E C 2.1.16), which requires S-adenosylmethionine as 
a methyl donor. NE and Epi are metabolized to the corresponding 3-0 methy-
lamines NM and MET (see Figure 2 ). It is localized extraneuronally, 
primarily in the liver and kidney, as well as in brain tissue (highest in 
the area postrema and lowest in the cerebellar cortex) and within the red 
blood cell, and is responsible for inactivating CAs released into the cir-
culation or in tissues lacking abundant adrenergic innervation. The 0-methyl-
ated metabolites can be conjugated, often with a sulfate or deaminated by MAO 
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to form 0-methylated glycols or acids. COMT is inhibited by dichloromer-
curibenzoate, suggesting it has a sulfhydryl group at the active site. 
Polyphenols such as pyrogallol inhibit COMT in vitro but are less effective 
in vivo. 
~ ------
MAO and COMT act upon CAs to produce physiologically inactive meta-
bolic products, but neither enzyme plays a primary role in terminating the 
physiological actions of CAs. The rapid inactivation of CAs is due to up-
take back into the presynaptic nerve endings. This is an active and specific 
uptake mechanism, which can be blocked by cocaine and antidepressant drugs, 
such as imipramine and some sympathomimetics. 
e. Pharmacological Effects of CAs in the CNS 
Bass (1914) produced sleep when he applied Epi under the dura or 
into the brains of dogs. Leimdorfer (1948) demonstrated that intracisternal 
Epi injections produced drowsiness in cats. Epi and NE injected into the 
lateral ventricle of chronically-implanted cats produced a state resembling 
light anesthesia (Feldberg and Sherwood, 1954). 
Other pharmacological investigations of the role of CAs in central 
phenomena utilized systemic injections of amines (see Rothballer, 1959; 
Jouvet, 1972a, b). In moderate doses, NE and Epi produce cortical activa-
tion paralleling the increase in peripheral sympathetic tone. The principle 
site of action appeared to be in the upper pons and lower mesencephalon, 
since lesions in these areas abolish the activating effect of NE. Weil-
Malherbe et al (1959) demonstrated that NE and Epi did not pass the BBB. 
Key and Marley (1962) compared the effects of injected (IV or IP) sympatho-
mimetics in young chicks, which have an incomplete BBB and older birds, 
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with chronically implanted electrodes. Amines such as NE, Epi and DA pro-
duced behavioral sleep with cortical slowing, while in adults these same 
drugs induced arousal. Mandell and Spooner (1968) summarize over twenty 
studies on the behavioral effects of NE and Epi administered so as to cross 
the BBB (intracisternally, intraventricularly or IV in animals with immature 
BBB). In a variety of species (mice, rat, chick, cat, dog and man) the 
predominent effect was sedation and/or somnolence. Torda (1968) found that 
microinjections of NE into the preoptic area of the reticular activating 
system (RAS) during deep sleep significantly shortened the latency and 
duration of PS and the latency of arousal. NE given during PS resulted in 
arousal almost immediately. Cordeau et al. (1971) found Epi and NE (50 µg-
3 mg) introduced in the third ventricle or cisterna magna of cats produced 
wakefulness and/or excitation. 
Both NE and DA appear to play roles in sleep. Since they do not 
penetrate the BBB, precursors (such as DOPA) are used to elevate their 
central concentration. Precursors or inhibitors of synthesis alter the CNS 
content of both amines produce differing effects due to their dissimilar 
localization and central effects(~ infra). 
Peripheral injection of DOPA greatly increases CNS DA concentration 
and to a lesser extent central NE (Chambers et al., 1971). Accompanying the 
increase in brain CA content is a marked increase in EEG and behavioral 
alerting in chicks and young chickens (Key and Marley, 1962; Spooner and 
Winters, 1965) and in rabbits and cats (Monnier and Tissot, 1958; Jouvet, 
1967a). Ledebur and Tissot (1965) injected DOPA directly into the caudal 
brain stem or in the dorsolateral pontine tegmentum, inducing a fast 
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cortical activity in the rabbit. DOPA, DA (both IP) and amphetamine (SC} 
produced alert EEG patterns in implanted chicks even though the blood 
pressure responses are similar to the rise produced by NE, which is be-
haviorally depressant (Spooner and Winters, 1967). Jouvet (1967b)reported 
that in cats DOPA (30-50 mg/kg) caused an increase in waking, with almost 
total disappearance of SWS and PS for 6 hours. On the other hand, dihy-
droxyphenylserine, the direct precursor of NE, (Blaschko et al., 1950) 
increases both SWS and PS in the rat (Havlicek, 1967). Wyatt~ al. (1970a) 
showed that in htnnans, L-DOPA led to a significant decrease in the duration 
of PS sleep. Gunne et al. (1971) tested L-DOPA in six patients with narco-
lepsy but did not find it superior to amphetamine in its waking action. 
f. Inhibition of Synthesis 
Disulfiram blocks CA synthesis by inhibiting DH (Moore, 1969). 
Wise and Stein (1969) administered disulfiram to rats in a self-stimulation 
bar-pressing paradigm and found that animals stopped pressing the bar and 
appeared sedated. 
AMPT, a relatively specific inhibitor of CA synthesis, inhibits TH 
(Weissman and Koe, 1965), producing a fall in NE and DA content in rat brain 
(Dominic and Moore, 1969). Torda (1968) administered AMPT to rats (80 mg/kg, 
3 times, 6 hours apart, IP or by surgical implant) and found no EEG changes 
for the first 3 hours, but after 18 hours NE was reduced to almost zeroJ SWS 
increased and PS and wakefulness shortened. In AMPT-pretreated animal~. 
microinjections of NE into the preoptic area or RAS "temporarily reversed 
the EEG changes", shortening SWS and lengthening PS. Hartmann~ al. (197la) 
62 
reported that in the rat oral AMPI' (50-100 mg/kg) increased PS while AMPl' 
(75 mg/kg, IP) decreased PS, corresponding to the time of maximum decrease 
in brain NE. In the cat, King and Jewett (1971) found AMPI' (3-400 mg/kg, 
IP) increased PS and brain NE was depressed. Jouvet (1972a)administered AMPI' 
(150-200 mg/kg, IP) to cats with lesions in the raphe system, when behavioral 
and EEG waking was almost permanent (2-6 days after lesioning). Behavioral 
sedation and cortical synchronization began 4-6 hours after AMPI' lasted 24 
hours and then returned to behavioral and EEG insomnia. Weitzman et al. 
(1969) found that in the monkey, AMPI' significantly decreased PS and be-
havioral waking with a proportionate increase in SWS. Wyatt et al. (197lb) 
administered AMPT to five patients, resulting in an elevation in total PS 
(a lengthening of REM episodes instead of a greater frequency of episodes). 
Various effects of AMPT on sleep include increased duration of PS both 
lengthened SWS and PS in the cat (King and Jewett, 1969), increased duration 
of SWS in the rat (Branchey and Kissin, 1970) or no apparent effects in rats 
(Marantz and Rechtschaffen, 1967). 
Several investigators have studied the effects on sleep of alpha-
methyl DOPA, which blocks the decarboxylation of both SH.TP and DOPA, thus 
decreasing 5H.T and DA transiently and NE for several days. Dusan-Peyrethon 
et al. (1968) found methylDOPA (100-200 mg/kg) in cats, caused a profound 
decrease in PS (for 10-22 hours) and a relative increase in SWS. In humans, 
Baekeland and Lundwall (1971) administered alpha-methylDOPA (250 mg, 3 times 
daily and 500 mg at bedtime) and found an increase in PS and a decrease in 
stage 4 sleep. 
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3. Histamine 
Histamine (H, ~-imidazolylethylamine; Fig. 3) was first synthesized 
in 1907 and isolated by Barger and Dale (1910), long before its biological 
significance was known. Dale and Laidlaw (1910) investigated the pharmacology 
of Hand recognized its effects to be similar to those of many tissue extracts. 
They further noticed that the immediate response of sensitized animals to an 
otherwise innocuous protein was the same as H poisoning. It was not until 
1927 that Best, Dale, Dudley and Thorpe isolated H from liver and lung samples. 
Lewis (1927) and coworkers established that H was liberated from cells of the 
skin in allergic responses. For further discussion of some of the peripheral 
actions of H, see Kahlson and Rosengren (1968) and Goodman and Gilman (1970). 
a. Localization. 
H has probably attracted less attention than most other biogenic 
amines in the nervous system because investigations on H have been hampered 
by problems with interfering substances in tissue determination methods and 
the lack of specific inhibitors of s)rnthesis or depletors. These technical 
problems have resulted in a great deal of variation in reported tissue H 
values from laboratory to laboratory. The postganglionic sympathetic nerves 
are high in H content (60 µg/gm, which is about four times their NE content), 
while the spinal cord is lowest (0.1-1 µg/gm). Other nerves have intermediate 
H levels (von Euler, 1956). The regional distribution of His similar to that 
for NE and SIIT. H is highest in the hypothalamus (twice the concentration of 
SHT), intermediate in the MB and lowest in the cortex and white matter. 
Taylor~ al. (1972), using an extremely sensitive and specific H assay, 
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confirmed these results and showed wide differences in H content of various 
brain nuclei. The posterior lobe and stalk of the hypophysis, area postrema, 
choroid plexus and pineal body contain H, although the H in the posterior 
hypophysis may be in mast cells. Mast cells, which contain large amounts of 
Hin the periphery, are virtually absent in the CNS (Olsson, 1968). Several 
studies have examined the subcellular localization of brain H. Michaelson 
and Coffman (1967) reported that H is located primarily in the crude mito-
chondrial pellet, while others demonstrate a greater proportion in the 
microsomal pellet (Carlini and Green, 1963; Kataoka and DeRobertis, 1967). 
Early fluorometric studies of tissue histamine content were hampered 
by the presence of an interfering substance, which has since been identified 
as the polyamine, spermidine. Michaelson (1967) pointed out the overlap of 
fluorescence emission curves of H and spermidine. In the early methods, 
spermidine was extracted and yielded a fluorophor with the same fluorescence 
characteristics as H, thus giving false high H values. 
Tabor and Tabor (1964) and Kremzner ~al. (1970) reported that the 
spermidine concentration is uniformly high in the CNS, although the con-
centration in white matter is three to four times that in gray matter. 
Few studies have examined the pharmacology of spermidine or its 
function and effects in the brain. Friedman and Rodichok (1970) evaluated 
the toxicity of IP spermidine on a 24-hour basis. The LDso pattern is 
bimodal, with peaks just prior to the onset of the dark and light periods. 
Spermidine levels in mouse whole brain, myelencephalon, and liver peak mid-
way through the dark period (Friedman and Rodichok, 1972). Histamine levels 
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in the brain exhibited a similar circadian pattern, corresponding to the motor 
activity rhythms of these animals. 
b. Synthesis 
His formed from histidine (Rd); see Fig. 3 ) by the action of 
Hd decarboxylase (RdDC; EC 4.1.1.22). There is a good, though not exact, 
correlation between the distribution of R and Rd.DC activity in the brain 
(White, 1959). In areas where this correlation fails, such as the area 
postrema, which is rich in H but poor in RdDC activity, R may be concentrated 
from the blood by mast cells. There has been some controversy as to whether 
HdDC was the same non-specific decarboxylase involved in the formation of 5HT 
and DA, but recent evidence indicates that there is a distinct R-forming 
enzyme (Schwartz~ al., 1970). There are two main pathways of R metabolism; 
ring N-methylation by imidazole-N-methyl transferase (HMT, EC 2.1.1.8) to 
form methyl H, while oxidation of the side chain by histaminase forms imi-
dazoleacetaldehyde and then imidazoleacetic acid by aldehyde dehydrogenase 
(see Fig. 3 ). After His formed in the soluble portion by Rd.DC, His 
taken up into a particulate form (probably similar to the vesicles storing 
other biogenic amines) protecting it from destruction by such enzymes as HMT 
which is in the soluble portion. The activity of HMT is very high in guinea 
pig brain but relatively low in rat brain (Brown et al., 1959). White (1959) 
demonstrated in cat brain that methyl H is the major metabolite, indicating 
that histaminase activity is absent. Snyder et al. (1966) found in the rat 
that most of intraventricularly-injected H was recovered as imidazoleacetic 
acid. 
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c. Physiological effects 
1) Histamine and related substances 
Feldberg and Sherwood (1954), by intraventricular H injection 
in cats produced increased respiration, vomiting, muscular weakness as well 
as some sedation lasting about one hour. Sawyer (1955) obtained similar 
results in anesthetized rabbits, and concluded that H activates a rhinen-
cephalic mechanism (olfactory bulb, MFB and basal ganglia), which stimulates 
the adenohypophysis. In unanesthetized or etherized rabbits, H evoked an 
arousal reaction. Monnier et al. (1970) reported that a H infusion of the 
rabbit third ventricle produced marked electrographic arousal with a decrease 
in delta waves. This effect was not blocked by acetylsalicylic acid, in-
dicating that the effect was not merely pain-mediated, but probably due to a 
direct central awakening action, such as on the ascending MB RF and the 
hypothalamic and hippocampal systems. Friedman and Walker (1969) demon-
strated a diurnal fluctuation in CN H in rats, which peaked during the dark 
phase, when animals are awake. Monnier et al. (1970) found a five-fold in-
crease in release of "H-like" substances in the hemodialysate associated with 
arousal compared with relaxed animals. 
Krnjevic and Phillis (1964) found that the activity of single pyra-
midal Betz cells of cats was "slightly moderated" by Hd and more rapidly by 
H iontophoretically-applied. However, the same depressing effect was also 
achieved with CAs, ephedrine, hydroxytryptamine or GABA. Small amounts of 
H depressed cerebral cortical neuron excitability, as did Rd and imidazo-
leacetic acid (Phillis 5:! !!_., 1968). Larger amounts caused both depression 
and excitation, the latter possibly due to the metabolite, methyl H. These 
r 
f 
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effects, as well as the effects of NE, ACh and SHT, were antagonized by anti-
histamines (mepyramine maleate). H applied iontophoretically to thalamic 
neurons had no effect (Curtis and Davis, 1962), perhaps due to the barbitur-
ate anesthesis used. However, Bradley (1968) observed depressant effects on 
50% of the brain stem reticular neurons examined. Curtis et al. (1961) found 
no effect of H on spinal neurons, possibly because of barbiturate anesthesia. 
In cats anesthetized with nitrous oxide and methoxyflurane or anemically-
decerebrated, NE, SHT and H applied extracellularly to spinal neurons increased 
membrane polarization, decreased the amplitude of the EPSP and IPSP and 
blocked synaptic or antidromic invasion of some motoneurons (Phillis et al., 
1968), effects resembling an inhibitory transmitter. However, iontophoretic 
strychnine and IV pixrotoxin failed to antagonize the actions of these amines. 
Sadre and Tiwari (1966) demonstrated that H, like chloropromazine, 
potentiated the hypnotic actions of PB and chloral hydrate in mice. The 
hypnotic effects of PB in rats (Bovet ~al., 1958) and rabbits (Goldstein 
et al., 1963; Monnier~ al., 1967) were reversed by IV H. 
2) Modification of CNS H content by drugs 
Boissier ~al. (1970) administered low doses of Rd (100 mg/ 
kg, IP) and found a maximum increase in cerebral H content one hour later. 
After 90 minutes no significant changes in the H content of several brain 
parts could be demonstrated. Taylor and Snyder (1972) utilized high doses 
of Hd (500 and 1000 mg/kg, IP) and achieved maximum mouse whole brain H 
content elevation of 110 and 169%, respectively, one hour after injection. 
Multiple Hd injections elevated brain H further. One hour after Hd (1000 
mg/kg, IP), H content in all mouse brain parts examined (except medulla 
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oblongata) was significantly increased. 
Taylor and Snyder (1971) studied the effects of various HdDC in-
hibitors on the formation of 3H-histamine from intraventricularly injected 
3H-histidine. Histidine can be decarboxylated to H in mannnalian tissues by 
the "specific" HdDC, which is inhibited by a-hydrazinohistidine or NSD 1055 
(cf. Snyder, 1972), or by the aromatic amino acid DC, which also decarboxy-
lates DOPA and 5HTP and is inhibited by a-methyl DOPA (Lovenberg £!al., 
1962). a-hydrazinohistidine and NSD-1055 administered IP significantly 
lowered 3H-histamine content in the hypothalamus and thalamus-MB. a-methyl 
DOPA failed to affect 3H-histamine concentration in any brain region. None 
of the drugs altered brain levels of 3H-histidine or endogenous Hd. Doses 
of 200-500 mg/kg of a~hydrazinohistidine and NSD-1055 lowered hypothalamic 
H by 40% while a-methyl DOPA had no effect. Taylor and Snyder (1972) studied 
the effect of these inhibitors and 4~thiazolylmethoxyamine on in vitro HdDC 
activity. All four compounds inhibited HdDC activity significantly, although 
the effect of a-methyl DOPA was much less than the others. Menon et al. 
(1971) studied five HdDC inhibitors for their effects on rat brain H, NE, DA 
and 5HT content and behavioral activity. 4-Thiazolylmethoxyamine (100 and 
300 mg/kg, IP) depletes whole brain H to 10% of control 3 days and 1 day, 
respectively, after administration. One day after a dose of 100 mg/kg, 5HT 
content was increased while NE and DA content decreased slightly. After 
three days DA was further decreased, NE slightly elevated and 5HT, approxi-
mately normal. Taylor and Snyder (1972) examined whole mouse brain amine 
content one hour after Hd (1000 mg/kg, IP). 5HT was significantly decreased 
but NE, DA and acid and neutral indoleamines were unchanged. 
70 
Taylor and Snyder (1971; 1972) tested the effect of a large variety 
of drugs on H content of the rat hypothalamus and mouse brain, respectively. 
In the former study, resperine, pCPA, chlorpromazine, pargyline, tranylcy-
promine, atropine, physostigmine, L-DOPA and 6-hydroxydopamine had no effect 
on H content. In the latter study, H content was significantly lowered by 
L-3-methylhistidine and reserpine, while dexbrompheniramine and PB elevated 
it. Adam and Hye (1966) examined in the cat the effects of a number of 
compounds on H content of several areas of the hypophysis, hypothalamus and 
the massa intermedia. Compound 48/80 lowered H in the posterior hypophysis 
and stalk but had no effect in other areas. Reserpine depleted, while 
iproniazid and phenothiazines increased hypothalamic H content. Green and 
Erickson (1964; 1967) demonstrated that chlorpromazine (20 and 40 mg/kg) 
elevated, while diphenhydramine (50 mg/kg) significantly lowered rat and 
guinea pig brain H respectively. Boissier ~al. (1970) examined H content 
in several rat brain areas one hour after diphenhydramine (SO mg/kg), but 
found no significant alterations from control. 
Merritt~ al. (1964) reported sedation in rats and a 63% decrease 
in brain NE, 24 hours after 15 mg/kg, IP of decaborane (DB). Merritt and 
Schultz (1966) showed in whole rat brain that this dose of DB depleted DA 
levels 60% after 4 hours, with a return to normal 24 hours later. They 
suggested that the decarboxylase system might be inhibited by DB. Merritt 
and Sulkowski (1967) demonstrated in ~ that AA.ADC was rapidly and 
completely inhibited by DB (15 mg/kg, IP) within 2 hours and did not begin 
to recover until after 72 hours. Whole rat brain SHT was depleted signifi-
cantly after 4 hours, reaching a maximum at 24 hours, followed by a slow 
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recovery. Medina et al. (1969) reported that DB (15 mg/kg, IP) depleted rat 
brain H to a maximum at 24 hours. H levels recovered slowly, requiring more 
than one week to return to control. They showed that DB inhibited HdDC almost 
90% within 2 hours after administration. Unfortunately, these authors did not 
~easure other biogenic amines, such as NE, DA or SHT, so that their inter-
relationships could be compared. Schayer and Reilly (1971) found that DB 
inhibited brain and stomach HdDC and in vivo H formation in the brain and 
skin. 
4. Acetylcholine (ACh) in the CNS 
The cholinergic system in the CNS has been the subject of several 
recent and thorough reviews (Karczmar, 1969, 1970, 1973; Potter, 1970). 
a. Formation and Localization 
ACh is formed from acetyl CoA and choline, by the enzyme choline 
acetyltransferase (choline acetylase, ChAc, EC 2.3.1.6). In multicellular 
animals, ChAc is found normally only in nerves. The placenta of higher 
primates, although not innervated, contains considerably more ACh and ChAc 
than most nervous tissues (Hebb and Ratkovic, 1962). The highest ChAc 
activity is found in the CN, retina, corneal epithelium and spinal roots 
(3-4 mg ACh/gm/hour synthesized). Dorsal spinal roots and the cerebellum 
contain only trace amounts. Intracellular ChAc is found predominantly in 
the crude mitochondrial fraction(from sucrose density, differential centri-
fugation data) of homogenized mammalian brain. This fraction contains mito-
chondria, membrane fragments and synaptosomes with enclosed synaptic 
vesicles. Upon further resolution, the enzyme is found to be in the 
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cytoplasm and not in the vesicle, therefore it must be concluded that ACh is 
made in the cytoplasm and concentrated in the vesicles. ACh released from 
nerve endings acts postsynaptically and its actions are terminated by acetyl-
cholinesterase (AChE or acetylcholine acetyl-hydrolase, ED 3.1.1.7), which 
hydrolyzes it to form acetate and choline. The choline is taken back into 
the presynaptic ending by an active process, for the resynthesis of more ACh. 
ACh has been established as a transmitter (using the criteria out-
lined by Werman, 1966; vide supra) only in the motor neuron collaterials of 
the Renshaw cells (Eccles, 1969). It is likely that other synapses in the 
CNS are also cholinergic although it is technically very difficult to es-
tablish this conclusively. 
b. Pharmacological Effects 
ACh injected directly into the carotid artery induces a state of 
cortical activation (Bremer and Chatonnet, 1949; Monnier and Romanowski, 
1962; Marczynski, 1967). Yamamoto and Domino (1967) reported the same effect 
after IV injection. In the intact animal, physostigmine, prostigmine and 
nicotine increase cortical and behavioral arousal in the intact animal 
(Jouvet, 1972b). Microelectrophoretic studies have shown that some central 
neurons are excited and others are depressed by ACh (Curtis and Crawford, 
1969). Areas affected by ACh include CN, ventral basal thalamus, cochlear 
nucleus, brain stem and pyramidal cells of the cortex. 
Microinjection of ACh with a chemitrode into the bulbar, mesence-
phalic, pontine or rostral RF produces EEG synchronization and a hypnogenic 
action in the cat, that is identical to the EEG and behavioral appearance 
of SWS (Courville et al., 1962). Similar injections of ACh in encephale 
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isol~ cats produced EEG synchronization comparable to that in unanesthetized 
;;..----
intact cats (without peripheral blood pressure changes), indicating that the 
effect is central. Cordeau et al. (1961) found that the administration of 
ACh with physostigmine produced EEG synchronization and behavioral arousal. 
ACh alone, applied to all areas of the RF produced EEG synchronization and 
sleep. Yamaguchi!:!. al. (1964) placed crystalline ACh into areas of the RF 
rostral to those studied by Cordeau and coworkers, resulting in sleep. The 
effect was more pronounced when ACh was administered in the mesencephalic 
RF. Application of carbachol did not produce sleep. Although the animals 
were catatonic, the EEG was desynchronized. Hernandez-Peon ~al. (1963) 
also obtained arousal when carbachol was applied to the lateral mesencephalic 
RF. They suggested that the mesencephalic arousing system is activated by 
cholinergic influences, as well as adrenergic. Cho et al. (1962) found that 
the potent muscarinic compound, oxotremorine produced flaccid paralysis and 
areflexia, associated with deep sleep, when injected into the brain stem RF 
of conscious cats and dogs. These effects could be antagonized by atropine 
(IV, Il1 or by central microinjection). A descending sleep system has been 
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postulated which follows the MB limbic circuit described by Nauta (1958) 
(ie. the MFB from the preoptic region through the lateral hypothalamus into 
the MB limbic area). ACh injections into this circuit is followed by sleep, 
while lesions or atropine injections made caudally to the ACh injection 
suppress its sleep-inducing effect (Velutti and Hernandez-Peon, 1963). Since 
cholinoceptive neurons are present in the cortex, diencephalon, brain stem 
and other areas, and some sites respond preferentially to muscarinic or 
nicotinic compounds, the exact mechanisms of the EEG activation induced by 
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cholinergic agents is uncertain. 
Jasper and Tessier (1971) measured the rate of liberation of free ACh 
from the surface of prostigmine treated cerebral cortex of freely moving cats 
during sleep and arousal. The rate of release was lowest during SWS and in-
creased during PS and waking, and seemed to be related to the EEG pattern, 
rather than the behavior per ~· Administration of hemicholinium (which 
blocks ACh synthesis) into the lateral ventrical of cats, increased SWS, de-
creased waking and had no effect on PS (Domino and Stawiski, 1971). A number 
of studies have attempted to correlate brain ACh metabolism and the state of 
arousal (cf. Jouvet, 1972b). EEG arousal elicited by midpontine transection, 
mesencephalic RF and septal stimulation via peripheral or central sensory 
stimulation or by amphetamine is accompanied by an increase in ACh release at 
the cortical level and a decrease in bound brain ACh. Cortical synchroni-
zation from precollicular transection or physiological sleep is accompanied 
by a decrease in the cortical release of free ACh and an increase in bound 
ACh. Barbiturate anesthesia further reduces ACh release (Kurokawa et al., 
1963). 
Hanin et al. (1970) reported a diurnal variation of whole rat brain 
ACh. Peak concentrations occur at 1400 hours (2 hours into the light phase) 
and trough between 2200-0600 hours, primarily in the dark, when rats are 
awake. These results are in line with the data cited above, showing that 
arousal is accompanied by a decrease of bound ACh (and a release of cortical 
ACh), while the reverse occurs during sleep. Friedman and Walker (1972) 
found that peak ACh levels of the rat MB and CN occurred at 2400 hours, while 
whole mouse brain ACh levels peaked at 0600 hours. Trough values occurred 
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at 1200 hours in rat MB and 1800 hours for rat CN and mouse brain. These 
results differ from the Hanin study and Saito (1971), who found that whole 
brain ACh content peaks at 6 hours in tie light and troughs throughout the 
dark period. These differences point to the complexity of the system and 
the difficulty of demonstrating a clear-cut correlation between ACh levels 
and the arousal state. Additional aspects of circadian variation of 
cholinergic function is discussed under the biological rhythms section. 
Monnier and Herkert (1972) recently reported that the ACh concen-
tration in hemodialysates of aroused rabbits (via RF stimulation) was 
significantly greater than that from sleeping or sleep-resistant donors. 
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£. Sleep-wakefulness Phenomena 
1. Sleep Phenomenology 
Berger (1930) discovered the electroencephalogram (EEG) and first 
investigated its nature. Numerous investigators have since studied the 
changes occurring in the EEG, when subjects (human and animal) changed from 
the alert, wakeful state to drowsiness, light sleep and deep sleep (as 
measured by the arousal threshold). Mauthner (1890) and von Economo (1926, 
1929) were probably the first to express the idea that sleep was not passive 
but an actively-induced, controlled phenomenon. Hess (1924) argued that sleep 
is a vegatative function to be classified with such activities as respiration, 
circulation, temperature regulation, etc. He further stated that sleep was 
not simply a state of quiescence but was accompanied by active physiological 
processes, under control of the central and autonomic nervous systems. 
The studies of Loomis and coworkers (1937, 1938) and Davis and co-
workers (1938, 1939) revealed that in the transition from the resting awake 
state (with its typical, more or less continous alpha waves 8-12 HZ) to deep 
sleep, the human subject goes through typical stages, which they labelled A-E. 
Stage A is characterized by an intermittent loss of alpha waves. In stage B 
the alpha pattern disappears completely and is replaced by a fast low voltage, 
irregular pattern. In stage C spindle-shaped bursts of 14 Hz are observed. 
Slow (1.5-3 Hz) and finally very slow (0.6-1.5 Hz) delta waves characterize 
stages D and E,respectively. Brazier (1949) observed that during the tran-
Sition from the waking state to sleep, the locus of maximum EEG activity 
shifts from the occipitoparietal towards the frontal region. Some workers 
also point out a characteristic pattern, the K-complex and sharp vertex spike, 
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transient phenomena appearing in the sleep EEG either spontaneously or in 
response to rhythmic sensory stimulation. 
Derbyshire ~al. (1936) and Klaue (1937) observed that states which 
clinically appeared to be deep sleep contained occasional cortical EEG 
desynchronizations. Dement and Kleitman (1957) first studied this new kind 
of sleep, referred to by Jouvet as paradoxical sleep (PS). It is characterized 
by a low voltage, fast cortical EEG pattern, hardly distinguishable from an 
activated pattern. It is accompanied by the appearance of theta waves (4-6 
Hz) in the hippocampus and by spindles of 6-8 Hz in the pontine reticular 
formation. This stage is also known as rapid eye movement (REM) sleep, 
desynchronized sleep, dream sleep, activated sleep and rhombencephalic sleep 
(by Jouvet, who considered that it is probably organized by structures in the 
rhombencephalon). Subjects awakened during this period often recall dreams, 
while they rarely recall dreams when awakened from the other sleep stages. 
Certain characteristic phasic events of this sleep stage include, in addition 
to the eye movements, muscular twitching, cardiorespiratory irregularities 
and bursts of monophasic sharp waves from the pons, lateral geniculate nuclei, 
occulomotor nuclei and visual cortices. These PGO spikes seem to represent 
some sort of primary triggering process for the phasic events, especially the 
eye movements (Dement, 1970). 
Dement and Kleitman (1957) suggested a relatively simplified classi-
fication of the various sleep stages, which has been adapted by many workers 
in the field. Stage 1 is characterized by "modified" alpha waves and cor-
responds to late stage A and stage B; stage 2, showing spindling with low 
background is about equivalent to C; stage 3 is identified by delta waves 
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and spindling; stage 4, containing slow waves only, is comparable to D and E. 
They added a stage 1 REM or emerging stage 1 (from stage 2), which contains 
rapid eye movements and a low voltage, fast EEG pattern. Sometimes stages 
1-4 are referred to collectively as non-REM (NREM) or slow wave sleep (SWS), 
as opposed to REM sleep. Rechtschaffen and Kales (1968) present precise 
definitions of these states in the human, making it possible to classify any 
20-30 second epoch into one of the NREM states, REM sleep or wakefulness. 
In the older EEG terminology, the delta pattern (0.5-3.5 waves per second) 
corresponds to stage 3 and 4; theta (4-7 waves per second) to stage 1 and 2; 
alpha (8-13 waves per second) to awake but not visually stimulated and beta 
(14-25 waves per second) to arousal. 
A characteristic sign of sleep is the low level of muscular activity 
probably related to the reduced reactivity of CNS structures involved in the 
organization of motor output. The electrical threshold of the motor cortex 
is elevated during sleep in the monkey (Lilly et ~., 1956) and the cat 
(Hughes and Mazurowski, 1958). Marchiafava and Pompeiano (1964) found the 
flexor motor output produced by pyramidal tract stimulation to be reduced 
with the onset of SWS and further decreased during low voltage fast sleep. 
The complete inactivity of the neck muscles during PS is so characteristic 
it is used to verify fast low voltage sleep. As first observed by Tarchanoff 
(1894), spinal reflexes such as the "knee jerk" are reduced and often missing 
during sleep. Giaquinto~ al. (1963) and Gassel et al. (1964) found that 
cats with a motor nerve stimulator and monitored for EMP and EEG, spinal 
relexes were only slightly affected during SWS, but during PS monosynaptic 
reflexes were abolished. 
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2. Sleep Deprivation 
Another approach to study sleep-wakefulness phenomena is sleep de-
privation and subsequent biochemical and neurophysiological examination for 
induced changes. There is a physiological need for sleep, since deprivation 
can lead to malfunction, permanent damage and death. Temporary sleep loss 
is made up for by increased total sleep, by an increase in the length of the 
various stages. Extensive reviews of this subject have appeared (Wilkinson, 
1961; Oswald, 1962; Kleitman, 1963). Tyler (1955) found sleeplessness in 
man (30-75 hours) produced symptoms resembling schizophrenia; i.e., instabi-
lity, inattention, memory loss and hallucinations. Rodin et al. (1962) 
studied the EEG of human subjects deprived of sleep for as long as 120 hours 
and found ''marked evidence of drowsiness" within 24 hours after the start of 
the experiment. Pieron (1913) found dogs deprived of sleep for 500 hours were 
hyperirritable but in good condition. Upon microscopic examination of the 
prefrontal cortex of these animals, he found cell shrinkage, vacuolization 
of cytoplasm and disappearance of Nissl substance. The amount of damage was 
proportional to the degree of sleep loss and was apparently reversible. Stern 
(1937) found that the blood-CSF barrier of dogs became more permeable after 
prolonged sleep deprivation. 
a. PS Deprivation 
Jouvet et al. (1964) selectively deprived chronically-implanted 
cats of PS by placing them on small platforms surrounded by water. Animals 
that lapsed into PS, with muscle relaxation would fall into the water, and 
soon learned to develop SWS without PS. Although having the normal amount 
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of slow sleep at the termination of the PS deprivation, animals were sleepy, 
weak·and photophobic. During recovery, PS periods were prolonged and occurred 
at shorter intervals. The recovery of cats deprived of PS by electrical 
stimulation of the reticular formation when they lapsed into PS was studied 
by Siegel and Gordon (1965). They observed PS rebound during the first re-
covery day, in which PS occupied 53% of total sleep, versus only 33% on base-
line days. 
b. Neurochemical Alterations After Sleep Deprivation 
Pujol ~al. (1968) reported that in rats, NE turnover is in-
creased during PS and decreased during PS deprivation. In examining the 
effect of pCPA on sleep, Torda (1967) found that 15 hours of PS deprivation 
increased brain 5HT slightly but not significantly. Tsuchiya et al. (1969) 
found no change in telencephalon (TE), diencephalon (DE) and mesencephalon-
pons-medulla (MPM) ACh, NE and 5HT content after 10 hours of total sleep 
deprivation. After 24 hours of deprivation TE ACh increased and DE NE and 
5HT decreased. After 96 hours of PS deprivation TE ACh decreased, DE and MPM 
NE content decreased but SHT did not change. Stern et al. (1971) measured NE 
and 5HT in the cerebral hemispheres, DE and brain stem of 1) PS-deprived rats 
(3, 5, 6 and 8 days, without allowing recovery), 2) after 5 days of control 
stress treatment and 3) in normal rats. Amine levels in the three regions 
were unchanged after 3-8 days of PS deprivation. Pargyline (20 mg/kg, IP, 
2.5-3.5 hours before sacrifice) after 5 days of PS deprivation or stress in-
creased NE and 5HT over that of normals, suggesting their increased synthesis. 
They concluded that the enhanced amine synthesis after PS deprivation might 
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be due to non-specific stress, rather than loss of PS ~ ~· Steinberg 
et al. (1969) found that human urinary NE and Epi were elevated significantly 
--
following 24 hours of sleep deprivation. NM, MET and VMA were not changed 
significantly. 
Karadzic et al. (1971) examined free amino acids in frontal and 
occipital cortex, CN, thalamus, hippocampus and mesencephalic RF in PS-
deprived, normals and stressed cats. Seven of eleven amino acids measured 
in the brain changed significantly after deprivation. Aspartic acid, cys-
teine, lysine, arginine and glycine increased significantly in several areas 
and gaba and threonine were altered significantly in 4 out of 6 and 5 out of 
6 areas, respectively. Glutamic acid, serine, tyrosine and histidine were 
not altered significantly. 
3. Drugs Acting on Sleep Stages 
a. Reserpine 
In cats reserpine suppresses SWS 12-14 hours and PS for 22-24 
hours which recovers after 5-6 days. It selectively triggers PGO activity 
(30-50 per minute) for 50-60 hours (Jouvet, 1967b). The PGO activity is 
similar to PGO activity of PS, but without the decrease in neck muscle tone. 
5HTP (30-50 mg/kg), 2-3 hours after reserpine totally suppresses the PGO 
activity and induces EEG and behavioral SWS for 4-6 hours. The same dosage 
of DOPA after reserpine increases PGO activity and an almost normal level of 
PS and SWS is evident for 4-6 hours (Matsumoto and Jouvet, 1964). This is 
part of the evidence for Jouvet's theory (1967 a,b) that serotonergic mech-
anisms are responsible for SWS and CA mechanisms are involved in PS. The 
reserpine-induced PGO activity is enhanced by eserine, decreased by atropine 
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(over 1.0 mg/kg) but totally suppressed by PB, imipramine, alpha-methyl DOPA 
and MAOI (Delorme, 1966). 
b. MAO Inhibitors (MAOIS) 
MAOis are potent PS suppressors (Jouvet et al., 1965), although 
there is some species variation in the response to them. Pargyline, niala-
mide, iproniazid and phenylisopropylhydrazine are selective PS suppressors. 
PS is suppressed for 90-100 hours after nialamide (10 mg/kg) and a stepwise 
recovery occurs without any rebound in about a week. Nialamide can even 
suppress PS after 72 hours of operational PS-deprivation. In man after one 
week of MAOI treatment, a progressive and significant reduction of PS occurr~d 
(Wyatt et al., 1969). Karczmar et al. (1970) have demonstrated a pharmaco-
logical model of PS by giving eserine to reserpinized animals, which could 
be abolished by atropine. 
c. a-Methyl-p-tyrosine (AMPT) 
AMPT significantly increases PS in rats (Hartman~ al., 197la) 
Torda, 1968), cats (King and Jewett, 1971) and man (Wyatt~ al., 197la; 
Baeklund and Lundwall, 1971). On the other hand Weitzman et al. (1969) showed 
it decreased PS in monkeys. a-methyl ~-tyrosine (AMMT) or a-methyl DOPA 
reduce PS and increase SWS (Jouvet, 1967b). a-methyl DOPA still reduces PS 
after selective PS deprivation (Dusan -Peyrethon ~al., 1968) 
d. g-Chlorophenylalanine (pCPA) 
A SHr depletor, pCPA, produces waking b~havior (Mouret et al., 
1967; Torda, 1967) and decreased both PS and SWS in cats (Delorme et~., 
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1966b; Koella et al., 1968 Karadzic, 1968; Pujol~ al., 1971). SIITP (10-SO 
mg/kg) restores sleeping patterns to normal (Jouvet, 1968; Pujol et al., 
1971). £-Chloromethamphetamine (lS-30 mg/kg), which also selectively de-
pletes SHT (Pletsdl:!r ~al., 1964) induces a constant state of arousal for 
16-18 hours, with recovery after 60 hours (Delorme~ al., 1966a). 
e. Garrnna-butyrolactone 
Jouvet et al. (1961) demonstrated the gamma-hydroxybutyrate (GHB) 
and gamma-butyrolactone (GBL) at relatively low doses (SO mg/kg) induced both 
types of sleep states (vide infra). The induction of PS was not observed in 
the rat and was inconsistent in the normal cat (Marcus et al., 1967; Winters 
and Spooner, 1966). GHB triggers PGO spikes and PS in chronic pontile cats 
(Jouvet, 1972b). Matsuzake et al. (1964) demonstrated that the PS-triggering 
action of short chain fatty acids was not limited to the C4 butyrate compounds 
but was more pronounced with CS and C6 compounds. The C4 to C6 agents produce 
pS in the decorticated, mesencephalic and pontile cats, but not in cats with 
lesions of the pontine tegmentum (Jouvet et al., 1961) or after midpontine 
transections (Tokizane, 1966). After atropine (which suppresses the final 
tonic phase of PS), GHB or GBL are still able to induce PS in pontile cats, 
while after MAOI (nialamide) which blocks the first phase of PS (PGO activity) 
short chain fatty acids are unable to induce PS (Delorme~ al., 196S). 
4. Localization of "Sleep Centers" 
Attempts to delineate a "sleep center" in the CNS have utilized 
lesioning and electrical and chemical stimulation, coupled with neurophysio-
logical recording to reveal neuronal pathways and/or nuclei which might be 
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involved in the normal sleep-wakefulness cycle. The effects of various CNS 
lesions will first be examined, followed by an analysis of stimulation ex-
periments and finally a discussion of attempts to find humeral sleep-inducing 
factors. 
a. Lesion Experiments 
Bremer (1936) demonstrated that transection of the spinal cord 
.... 
at the first cervical vertebra (encephale isole preparation) resulted in an 
alert animal with a desynchronized EEG. Animals with a mesencephalic tran-
section at the level of the superior colliculus (cerveau isole) were stu-
porous and exhibited a synchronized EEG analagous to SWS. He concluded this 
state was due to exclusion of the bulbomesencephalic RF, assuming that in 
natural sleep the RF is depressed and normal ascending, activating impulses 
are reduced or eliminated. He further stated that the functional depression 
of the RF plays a major or even a primary role in curmnulative "defacilitation" 
because of its central position in the arousal sequence. Ranson (1939), 
using lateral hypothalamic lesions, produced sleep in monkeys which lasted 
4-8 days. Sleep of short duration was produced by lesions in the rostral 
hypothalamus or at the junction of the hypothalamus and thalamus. He con-
eluded that sleep is a deviation from the waking state (deactivation) and 
that wakefulness is largely dependent upon hypothalamic drives. If sym-
pathetic discharge from the descending pathways of the posterior hypothalamus 
is abolished, these waking drives are eliminated, producing sleep. Large 
bilateral lesions of the posterior hypothalamus in cats produced sleep lasting 
several days (Rangstrom: 1947). Sleeping animals could be aroused by various 
sensory stimuli. His conclusion was that the lesions destroyed a large 
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number of cells containing specific hyponogenic substances, which are trans-
ported to other brain areas, to produce sleep. Villablanca (1962) observed 
/ 
that in cerveau insole cats kept alive for 20-60 days the sleep-wakefulness 
cycle (as measured by EEG and behavioral indices) was reestablished. The 
SWS during the first 10 postoperative days was attributed to surgical trauma. 
This indicated that the waking state could be organized by structures rostral 
to the lower MB. Nauta (1946) found that bilateral transection of the hypo-
thalamus in or near the mammillary bodies or suprachiasmatic region pro-
duced sleep, while unilateral or bilateral medial or rostral hypothalamic 
lesions did not alter the S-W cycle in the rat. He concluded that lesions 
which interrupt fiber bundles such as the Vicq d'Azyr and MFB interfere with 
normal waking capacity. These fibers are known to connect the mammillary 
region with the anterior thalamic nuclei, the lateral hypothalamic area and 
septal region. He postulated an "intensive relay" of impulses from the 
posterior hypothalamus ("waking center") through the lateral hypothalamus and 
an active sleep center in the anterior hypothalamus. "Since animals whose 
mammillary and suprachiasmatic areas had been transected behaved like animals 
with transections at the mammillary level only, he deduced that the sleep 
center exerts an inhibitory influence on the waking center and not directly 
on the cortex and other major parts of the nervous system. Nauta suggested 
that the impulses from the anterior sleep center are conveyed to the waking 
center via the medial forebrain bundle. The waking center, in turn, exerts 
an activating influence upon the lateral hypothalamus and thence upon the 
cortex, and inhibitory influence upon a hypothetical center 'L' for 'body 
sleep'" (Koella, 1967, p. 102). 
l 
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Lesions of the basal forebrain (preoptic region, diagonal band of 
Broca) in cats, reduced the time spent in the drowsy state, although the time 
asleep was not altered (Sterman~ al., 1964). Batini et al. (1958) tran-
sected the rostral brain stern at the pons (rostropontine-pretrigerninal pre-
paration), inducing permanent EEG and behavioral sleep. From these experi-
ments Moruzzi (1960) concluded that the "entire reticular formation of the 
midbrain with the support of the tonic sensory inflow which is likely to 
occur through cranial nerves still connected to the cerebrum (I, II, III) 
is by itself not adequate for maintaining a state of vigilence. The phasic 
aspect of EEG activation is still present, however, in the cat whose rnidbrain 
is connected to the cerebrum; clear-cut EEG arousal is elicited in this 
preparation, by olfactory stimuli." Lesions slightly caudal (rnidpontine 
pretigeminal) produce behavioral and EEG arousal. However low doses of bar-
biturate readily evoke slow waves and spindling. In light of this Moruzzi 
(1960) states that"there is a region in the rostral part of the pons which 
seems to be of critical importance for the maintenance of the EEG patterns 
of wakefulness. Since the classical sensory pathways are out both in the 
prepontine and in the rnidpontine preparations, it would follow that the tran-
section does not act by severing fibers from lower levels." 
Hemisection of the MB at the superior colliculus or midcollicular 
level produced slow waves and spindles in the ipsilateral cortex, which 
gradually disappeared within 4-5 days (Cordeau and Mancia, 1959). As such 
patterns also occurred with the lateral sensory paths intact, they con-
cluded that ascending activating influences from the lower brain stern travel 
in two distinct paths to supply the two cortices. Hodes (1963) had similar 
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findings with hemisection or unilateral procaine injections of the cord. 
Jouvet et al. (1966) demonstrated in cats that an 80-90% destruction 
of the raphe system (the medial SHT-containing neurons of the brain stem, 
from the nucleus raphe abscurus to the caudal medulla) resulted in permanent 
wakefulness. After 3-4 days very short periods of behavioral and EEG SWS 
reappear. There was a correlation between the extent of destruction of the 
raphe system, the decrease in cerebral SHT and the loss of sleep. Kostowski 
et al. (1968) and Pujol et al. (1971) obtained similar results. Lesions of 
-- --
the pontine tegmentum selectively abolish PS without significantly impairing 
either waking or SWS (Jouvet, 1962). Histochemical methods show a dense 
group of neurons high in NE content located in the area of the locus coeruleus. 
Total destruction of the locus coeruleus causes complete PS-suppression 
(Jouvet and Delorme, 1965) and produce a significant decrease of NE in the 
brain rostral to the lesion (Roussel, 1967). Control lesions nearby do not 
affect sleep. 
b. Stimulation Experiments 
Hess (1944, 1949) performed the pioneer studies on electrically-
evoked sleep using point by point stimulation of the entire DE and surrounding 
areas of the rat brain. Following repetitive stimulation via low voltage, 
rounded DC pulses, cats exhibited reduced activity and other presomnic signs 
(such as eyelids drooping, smaller pupils, lying down and curling up). 
Soon after they appeared to be asleep. He could reverse the sleep effect 
with higher voltages and/or higher frequencies of stimulation. In these 
animals the electrode tips were in the thalamus, in the lower two-thirds of 
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the massa intermedia, near the midline (medial thalamus). Electrodes placed 
in the surrounding area produced only "partial sleep", with depressed motor 
activity. These findings point to the specificity of the medial thalamic 
area as a hypogenic site and the production of sleep at will, rather than 
coincidently. Hess' findings have since been confirmed by Akert and co-
workers (1950, 1952, 1953) who further showed a striking similarity between 
the behavioral and EEG patterns after the electrical stimulation. Akimoto 
~al. (1956) produced behavioral and EEG sleep in the dog with low voltage, 
low frequency stimulation of the thalamus. Monnier and coworkers (1950, 1963) 
induced sleep by stimulation of the intralaminar thalamic nuclei of cats and 
rabbits. Low voltage and frequency were necessary, as higher frequencies and 
voltages produced arousal. Jouvet (1962) also reported sleep effects of low 
frequency stimulation of the medial thalamic nuclei in cats. Following low 
voltage and low frequency stimulation of the hippocampus of the cat, Parmeg-
giani (1960, 1962) observed a number of presomnic signs. Penaloza-Rojas 
~al. (1964) induced a sleep-like state by low frequency stimulation of 
various areas of the cerebral cortex. Sterman and Clemente (1962 a,b) 
stimulated the preoptic area (basal forebrain) of freely-moving cats and 
observed sleep, which included EEG spindling. 
Moruzzi and Magoun (1949) demonstrated that the brain stem RF is 
responsible for cortical and behavioral arousal through the ascending reti-
cular activating system (ARAS). The ARAS is composed of the brain stem core 
from the medulla to the rostral part of the mesencephalon, with cortical 
projections. They could reproduce the electrocortical features of natural 
wakefulness by stimulation of the ARAS as well as the classical specific 
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afferent pathways, in the periphery of the brain stem. The specific system 
(medial and lateral fillets) ascends the stem outside the RF, and in addition 
sends collaterals to the RF, which merge diffusely and tend to maintain the 
activating tone of the ARAS. The specific system is relatively-unaffected by 
anesthetics, while the nonspecific RF is very sensitive, due to its poly-
synaptic organization (Larrabee and Posternak, 1952). Favale ~al. (1961) 
similarly produced sleep in cats by stimulation of various areas of the brain 
stem RF, such as the MB tegmentum and some nuclei of the medulla. Jouvet 
(1962) also reported sleep effects after stimulation of the MB RF of cats. 
When he stimulated the pontine RF with low voltage stimuli at low frequency he 
produced PS (lasting as long as 15 minutes). Strong stimuli usually produced 
arousal. Caspers and Winkel (1954) produced behavioral and EEG sleep effects 
after stimulation of the MB RF in the rat. Magnes et al. (1961) in cats pro-
duced widespread cortical synchronization by low frequency stimulation near 
the nucleus of the solitary tract. 
Koella (1967) attempted to synthesize the results of lesion and stimu-
lating experiments, to establish the structure of the sleep-controlling appara-
tus. He concluded that all structures which upon stimulation yield sleep or 
sleep-like signs constitute the "sleep center". This heterogeneous structure 
is made up of components which qualitatively and quantitatively subserve dif-
ferent functions. Low rate stimulation of the nucleus of the solitary tract 
produces cortical synchronization (Magnes ~al., 1961), while lesions of this 
area increase the effectiveness of arousal stimuli. The authors interpret these 
findings to mean that there is a two-way network connecting the solitary tract 
nucleus with the ascending mesencephalic RF, forming a negative feedback 
system which limits phasic arousal. Koella considers the bulbar synchroniz-
ing structures a sleep-facilitating apparatus, acting via inhibitory in-
fluences on the activating or arousal system, in a subordinate capacity. It 
is responsible for short, phasic sleep, rather than long, tonic periods of 
sleep. Similarly, the MB RF is important for short, phasic periods of 
awakening. Reduction of the ascending, activating influence therefore, 
results in sleep. Lesions in this area produce semi-permanent sleep in the 
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TE and behavioral sleep signs. Stimulation in this area might activate in-
hibitory pathways, which have been shown to have inputs into the RF from the 
lower brain stem, thalamus and cerebral cortex. Koella considers the basal 
forebrain, including the anterior hypothalamus, as another subordinate con-
trolling structure. Waldvogel (1945) elicited yawning by stimulation of the 
area between the anterior commissure and infundibulum. Parmeggiani (1962) 
evoked many presomnic signs in the cat by hippocampal stimulation and occas-
ionally produced light sleep. The pons seems to control a phase of sleep, but 
acts only when slow sleep is already present. Stimulation of the tegmentum 
also produces sleep signs for a short duration. 
Koella concludes from various lines of experimental evidence that the 
thalamic hypnogenic area qualifies as the "head ganglion" of sleep. Thalamic 
stimulation produces sleep of long duration, preceded by presomnic signs. This 
type of sleep includes PS episodes seen in normal sleep. After repeated stimu-
lation it becomes progressively easier to reinduce sleep after awakening. Lower 
voltages are needed to produce sleep in the thalamus than in other areas such 
as the lower brain stem and hypothalamus. The recruiting response, best 
elicited by low-rate stimulation of the midline thalamus, closely resembles 
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to sleep spindles. The thalamic-induced recruiting response can be recorded 
in the MB RF (as well as the cortex), suggesting a thalamo-reticular pathway, 
which might also convey inhibitory impulses to the ascending activating 
system, as previously mentioned. 
c. Humoral Sleep Factors 
1) Cerebrospinal Fluid (CSF) 
Early studies related to an active induction of sleep en-
visioned a humoral factor primarily responsible for the induction of sleep. 
Legendre and Pieron (1910, 1911) sleep-deprived dogs for as long as 18 days, 
withdrew some of their CSF and injected it into the fourth ventricle of non-
fatigued dogs, which promptly showed signs of drowsiness and sleep for 2-6 
hours. Dogs treated with CSF from non-fatigued animals remained alert. 
Schnedorf and Ivy (1939) confirmed these basic findings but emphasized that 
the central "depressing" effects of the injection was in part due to con-
comitant elevation of intracranial pressure and to hyperthermia, which usually 
followed the intracisternal injection. They attempted without success to 
detect ACh in the CSF. 
Pappenheimer et al. (1967) studied the perfusate from sleep-deprived 
goats whose ventricular systems were cannulated. When injected into the 
ventricular system of cats and rats, the perfusate induced signs of sleep 
(inactivity) lasting up to 18 hours, while there was no change in the activity 
of animals receiving CSF from non-sleep-deprived animals. No EEG studies of 
the recipient animals have been reported. The factor responsible for the 
inactivity has not yet been identified, but it has been reported to be dialy-
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zable (moelcular weight under 1000-2000). Ringle and Herndon (1969) made 
some unsuccessful attempts to induce sleep in rats with CSF from sleep-
deprived rats. 
Drucker-Colin et al. (1970) perfused sleep-deprived cats via push-
pull cannulae inserted in the MB RF. The outgoing perfusate from the cats 
during the PS-rebound induced sleep in recipent cats when injected through 
the push-pull cannulae inserted in their midbrains. 
2) Plasma 
Demole (1927) observed that blood calcium was decreased during 
sleep and predicted that brain calcium would increase during sleep. He in-
jected several microliters containing 0.25-2 mg of CaCl2 into the infundibular 
and tuber cinereum region of the hypothalamus, producing sleep after several 
hours latency. Other areas of the hypothalamus and other brain structures 
were unresponsive. Koella (1967) cites several other studies which confinned 
these results. Cloetta et al. (1934) found calcillln to be increased during 
sleep, particularly in the infundibular region. These findings suggest that 
a shift of calcium from the blood to certain parts of the brain stem might be 
an important hypnogenic factor. The mechanism of this shift is unknown but 
it might be due to an increased permeability of limiting membranes, as indi-
cated by Stern (1937). 
Purpura (1956) utilized a cross circulation arrangement in cats and 
showed that 30-80 seconds after arousal was produced by reticular stimulation 
in the "donor" animal, it occurred in the non-stimulated recipent cat. In 
order to test for sleep-inducing factors in the blood, Kornnuller ~al. 
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(1961) and Monnier, Koller and Graber (1963) used the crossed blood circula-
tion technique in cats and rabbits, respectively. Stimulation of the medio-
central intralaminary thalamus of the donor induces a significant increase in 
cortical waves. Both groups observed that after a delay of less than a 
minute the recipient shows a statistically significant increase in cortical 
slow activity (usually after the fourth stimulation of the thalamus). On 
the other hand, stimulation of the MB RF, which induces arousal in the donor, 
significantly reduces cortical slow waves in the recipient. These results 
suggest that hypnogenic and alerting substances may be transported in the 
plasma and can change the state of consciousness of recipient animals. 
Monnier and Hosli (1964, 1965) demonstrated that a dialysate of cerebral 
blood from rabbits during sleep induced by electrical stimulation of the 
thalamus, when injected into recipient rabbits produced EEG evidence of sleep. 
Recipients receiving a dialysate from non-stimulated control rabbits had 
waking patterns. They excluded changes in visceral activities (blood pres-
sure, heart rate respiration and body temperature), electrolyte concentration 
and pH. The dialysis techniques indicated that the active substances were of 
low molecular weight. Comparisons between the "sleep dialysate" and other 
pharmacological substances indicated that its effects generally resembled 
those of chlopromazine and substance P. Apparently the sleep dialysate 
factor obtained from the rabbit is active only after electrically-induced 
sleep, since Ringle and Herndon (1968) failed to show any sleep-promoting 
effects from the reconstituted plasma dialysates from 72 hours sleep-deprived 
rabbits, in recipient rabbits, rats or mice. The fact that a blood perfusate 
can induce sleep only after stimulation of the thalamus, but not when taken 
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from sleep-deprived rabbits shows that it is necessary to differentiate between 
electrically-induced sleep, normal sleep and the condition produced by pro-
longed sleep deprivation. Hypnogenic factors released under these conditions 
are not necessarily related to substances which are produced during and in-
duce or facilitate the onset of normal sleep. On the other hand, the thalamus 
£er ~ is not involved in the sleep mechanism, since its total destruction 
does not significantly alter the sleep-waking cycle (Angeleri et al., 1969). 
Finally, the fact that Siamese twins, sharing the same blood circulation, may 
sleep independently (Alckseyeve, 19S8) makes it unlikely that sleep depends 
exclusively upon blood-borne factors. 
3) Neurohtnnors 
The studies of Koella and Czicman (1966) reported that intra-
carotid SHI produced an initial brief arousal followed by a prolonged phase 
of hypersynchrony, presumably acting on the area postrema. This stimulating 
effect is transmitted to the neurons in the solitary tract nucleus, which has 
beenruown by Moruzzi (1960) to have hypersynchronizing properties. pCPA 
depletes brain SHI, by inhibiting its synthesis and produces insomnia in the 
cat, which develops and recovers following the time course of brain SHI 
content (Jouvet, 1969). SHIP, the SHI precursor, restores sleep to the normal 
pattern for 10-12 hours when given at the peak of the pCPA effect. In 
addition, Pujol et al. (1971) and others have shown that lesions of the raphe 
system deplete brain SHI and induce permanent arousal. Matstnnoto and Jouvet 
(1964) found that reserpine produced insomnia in the cat; eliminating SWS for 
days and PS for 2-4 days. SHIP restored SWS innnediately without PS while DOPA 
restored PS, indicating SHI was involved in SWS, while CAs were necessary for 
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pS. Feldberg and Sherwood (1954) injected NE and Epi into the lateral ventri-
cle of chronically-prepared cats, producing a sleep-like state after 20 
minutes that lasted about 3 hours. Others have demonstrated alerting actions 
of NE (Torda, 1968; Cordeau et al., 1971). The case for NE in sleep pheno-
mena therefore, is less clear than for SHT. 
Sharpless and Rothballer (1961) and Soderberg (1962) have shown that 
stimulation of the RF may release a blood factor with an activity similar to 
vasopressin. Other studies have shown that stimulation of monoamine bundles 
or terminals might release monoamines (McLennan, 1964; Stein and Wise, 1969; 
Arbuthnott et al., 1970) or monoamine metabolites which might be eliminated 
either in the blood or CSF, where they could act on other (unknown) brain 
areas. Jouvet (1972b) points out that central "hypnogenic" stimulation or 
sleep deprivation might release a greater amount of transmitters or meta-
bolites than physiological sleep. 
The daily fluctuations of brain biogenic amines are discussed in 
detail under the Biological rhythm section but it is appropriate that these 
changes are briefly mentioned here. In newborn rats, which have not yet 
acquired a circadian rhythm of sleep there is no alteration of brain SHT 
(Okada, 1971), while in the adult rat, with a well-established sleep cycle, 
there is a significant increase in endogenous brain SHT during the day (when 
these nocturnal animals sleep) and a decrease during the night (Dixit and 
Buckley, 1967; Friedman and Walker, 1968). The latter investigators found a 
reversedpittern for MB and CN NE content, suggesting that this amine might 
have a waking role. This is supported by the work of Torda (1968) and 
Cordeau ~al. (1971). 
Jouany ~al. (1960) have shown that GHB induces sleep which is not 
distinguishable from natural sleep. At higher doses the effect resembles 
anesthesia. Bessman and Fishbein (1963) have shown that GHB occurs in the 
rat and human brain, where it is derived from GABA. 
Kroll (1933) prepared water extracts from brains of sleeping cats and 
rabbits and injected them intraventricularly or intracisternally into waking 
cats and rabbits. The donor animals had been put to "sleep" by intraventri-
cular injection of cacl2 , by Pernocton (butallylonal) or by electrosleep 
(Passing a current longitudinally through the head). Recipient animals 
promptly slept when treated with the brain extracts from "sleeping" animals, 
while recipients of extracts from waking donors did not sleep. Kroll also 
demonstrated that brain extracts from hibernating hamsters and porcupines 
induced sleep in cats for several days (but not in monkeys). There were 
several uncertainities in these experiments, such as the possibility that the 
extracts might contain sufficient Pernocton or CaCl2 to induce sleep or that 
the electrical current might produce electronarcosis rather than sleep. 
Hunter and Rigal (1966) reported that plasma human growth hormone (HGH) 
was elevated during the night. Quabbe ~al. (1966) suggested that nocturnal 
peaks of HGH might occur preferentially during periods of deeper sleep. 
Takahashi ~al (1968) found that a plasma HGH peak appeared at the onset 
of deep EEG sleep and smaller peaks appeared during subsequent deep sleep 
phases. If sleep was delayed or interrupted, the HGH peak also shifted. Peak 
HGH secretion was not correlated with changes in plasma glucose, insulin or 
cortisol. Honda~ al. (1969) obtained similar results and suggested that 
secretion is inhibited during PS while SWS increases HGH secretion by 
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stimulating the secretion of hypothalamic HGH releasing factor. Sassin et al. 
(1969) supported this conclusion and demonstrated that reversal of the sleep-
wake cycle was accompanied by a concomitant plasma HGH pattern reversal, 
perhaps both due to the same neural mechanism. 
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f. Barbiturates 
Barbiturates belong to the general class of hypnotic-sedatives. These 
agents are general depressants, depressing a wide range of cellular functions 
in many organ systems. The type compound, barbituric acid, first synthesized 
from urea and malonic acid by von Baeyer, is not a central depressant. The 
derivatives of barbituric acid obtained by replacing the two hydrogens on the 
cs position by alkyl or aryl groups are called barbiturates and frequently 
have hypnotic potency. In 1903, Fischer and von Mering introduced diethyl-
barbituric acid (barbital), to medicinal use. 
1. Distribution 
In general, structural changes resulting in increased lipid solu-
bility are associated with a decreased duration of action, a decrease in 
latency to onset of activity, more rapid metabolic degradation and often 
increased hypnotic potency. Barbituric acid derivatives with only one sub-
stituent group are without central depressant activity and the dimethyl or 
ethylmethyl derivatives are very weak. Barbiturates with an ethyl group and 
a longer chain are more potent than barbital, but when the chain length 
exceeds 4 or 5 carbons, activity decreases. The present use of barbiturates 
is well stated by Goodman and Gilman (1970): II more than 2500 barbitur-
ates were synthesized, many were carefully studied pharmacologically, and 
approximately 50 were marketed for clinical use. Today, a dozen or so bar-
biturates are widely used; of these, five or six would probably be sufficient 
to meet most therapeutic needs." 
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A number of factors, both physiochemical and physiological influence 
the hypnotic or anesthetic potency of barbiturates. Some of the former in-
clude water solubility, ionization, distribution between water and lipids, 
rate of entry into the brain compared with other tissues, protein binding, 
volume of distribution in the body and rates of metabolism and excretion. 
There is no impenetrable barrier to barbiturate diffusion, so if the drug is 
in the plasma long enough, it is distributed to all tissues and fluids, 
including the fetal circulation, since it crosses the placental barrier. 
a. Physiochemical Factors 
In their undissociated form, the barbiturates have a rather high 
affinity for non-polar solvents, which correlates with their pharmacological 
properties. The more highly lipid soluble compounds are short-acting agents, 
with a rapid onset of action. A fraction of the barbiturate is reversibly-
bound to plasma proteins, chiefly albumin (Goldbaum and Smith, 1954). Pro-
tein binding appears to depend on the same structural features that determines 
affinity for non-polar solvents. With the exception of body fat, the capacity 
of tissues to concentrate barbiturates depends largely on protein binding. 
Fat depots can contain very high concentrations of the ultrashort acting 
barbiturates which possess high lipid solubility. Highly lipid-soluble drugs, 
such as thiopental, reach maximum concentrations in the brain within two or 
three passages of the blood. During the first few minutes after injection, 
thiopental is found in highest concentration in the brain areas that have the 
greatest blood flow (cortex, geniculate bodies and colliculi). On the other 
hand, barbital and phenobarbital, with low partition coefficients, penetrate 
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the BBB slowly, and 15 minutes or more might be needed for sleep induction 
after IV injection, but they have a longer duration of action. Regional 
differences in brain blood flow have little effect on the distribution of 
slowly-penetrating agents. If the alkalinity of the plasma is increased, 
as after hyperventilation or by infusion of sodium bicarbonate solution, 
the plasma concentration of the undissociated, lipid-soluble form of the 
drug falls. This results in the outward flux of the drug from tissue to 
plasma, lightening anesthesia because brain concentrations of the drug are 
decreased. 
b. Physiological Factors 
Differences in barbiturate metabolism have been shown among 
species (Quinn et al., 1958) and strains (Vessell, 1968a, b). Metabolism 
varies with age, especially between the adult and newborn. In the latter, 
liver metabolizing enzymes are lacking (Jondorf et al., 1958). Dietary in-
fluences, such as deficiencies (Conney~ al., 1961) and fasting, both solids 
(Dixon et al., 1960) and liquids (Borcelleca and Manthei, 1957) alter drug 
metabolism. The differences in drug metabolism between sexes has been shown 
in the rat to be due to the influence of sex hormones (Quinn~ al., 1958; 
Rennner 1958a). The pharmacological action of HB is prolonged after adrena-
lectomy (Rennner, 1958a, b) but decreased after thyroxin pretreatment (Conney 
and Garren, 1961). Barbiturate metabolism is altered by such pathological 
states as the presence of tumors (Rosso et al., 1968), liver disease (see 
below, under Metabolism), CNS lesions (Nair et al., 1970; Kostowski and 
Dolfini, 1969) or X-irradiation (Nair and Zeitlin, 1967). Other drugs can 
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alter barbiturate response through inhibition or stimulation of metabolism 
(see below) or pharmacological antagonism or potentiation. Changes in 
ambient temperature can alter the rate of barbiturate metabolism and its 
pharmacological effects (see below). 
2. Termination of Activity and Metabolism 
Three processes are responsible for termination of the central 
depressant actions of barbiturates: physical redistribution, metabolic 
degradation and renal excretion. These tend to decrease plasma concentration, 
resulting in a withdrawal of the drug from its CNS site(s) of action. Physical 
redistribution plays an especially-important role for the highly lipid soluble, 
ultrashort acting compounds like thiopental. The rapid emergence from hyp-
nosis occurs as the barbiturate shifts from the brain to other tissue com-
partments (Areas of high blood flow such as the brain, exhibit maximum drug 
concentrations within minutes, while areas with lessor blood flow, such as 
muscle and fat, require much longer periods to become saturated.) Thus as 
these tissues slowly take up the drug, plasma concentration drops, causing 
the outward diffusion from the brain and subsequent loss of anesthesia, even 
though very little drug is metabolized, 
Many barbiturates are transformed to inactive metabolites in the 
liver. Their metabolites are usually less lipid soluble, more polar and more 
water soluble, factors which tend to increase their renal excretion. Metabo-
lism is usually via oxidation of the side chains in position 5, although ethyl 
groups are resistant, so barbital is excreted almost unchanged. The reaction 
occurs in vitro in the microsomal fraction of liver homogenates, requiring 
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molecular oxygen and NADPH, to form an epoxide, which is hydroxylated to the 
glycol. Secondary reactions such as oxidation of primary or secondary 
alcohols to carboxylic acids or ketones are carried out by enzyme in the 
nonparticulate fraction of liver homogenates. These products may appear 
in the urine as free compounds or the glucoronic acid conjugates. N-alkyl 
barbiturates may be converted to active metabolites by oxidation, such as 
metharbital and mephobarbital forming barbital and phenobarbital, respectiv-
ely. In addition, desulfuration of thiobarbiturates and ring cleavage occur 
to a very small extent. Only barbital is primarily dependant upon renal 
excretion, although as much as 30/o of phenobarbital, diallylbarbituric acid 
and aprobarbituric acid may be excreted unchanged by the kidney. 
Since barbiturates are metabolized primarily in the liver, it is 
important to know whether they and other drugs have hepatotoxic effects. 
In normal sugjects, hypnotic doses of barbiturates do not alter the results 
of any of the usual clinical tests of hepatic function. The large doses 
ingested daily by barbiturate addicts do not injure the liver in any detect-
able way. Even in patients with severe liver disease, the tests reveal no 
deleterious changes (Sessions et~., 1954). The barbiturates do not dis-
appear less rapidly from the blood than in normal individuals. Experimental 
animals with a large portion of the liver removed surgically or severely 
damaged by carbon tetrachloride do sleep longer than normal controls after 
the administration of most barbiturates. Other drugs, such as SKF S2SA and 
JB 516, specifically inhibit the liver microsomal metabolizing system and 
greatly enhance most barbiturate hypnosis. In experimental animals, nutri-
tional deficiencies, diabetes and obstructive jaundice can prolong the action 
of barbiturates. Stress can prolong barbiturate action, possibly due to 
adrenocortical action on hepatic drug metabolizing enzymes. 
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Of great importance is the fact that barbiturates can induce the 
enzymes responsible for their own metabolism. All barbiturates are not 
equally effective in this respect; phenobarbital has a very prominent action, 
while HB is quite weak. This accounts, in part, for the development of 
tolerance (and cross tolerance) to barbiturates. This phenomena can even be 
seen on the ultrastructural level in the liver, in terms of greatly increased 
amounts of endoplasmic reticulum (which contains the degradative enzymes) 
after only several doses of the barbiturate (Chedid and Nair, 1972). In 
addition, the barbiturates stimulate the production of enzymes responsible 
for metabolizing many other drugs, such as that of the coumarin anticoagulants. 
Barbital, which is not metabolized by the liver (and whose effects therefore 
are not prolonged by severe liver injury as mentioned above or environmental 
temperature changes as mentioned below), markedly enhances the enzyme activity 
responsible for metabolizing other barbiturates. 
In vitro study of drug metabolism by microsomal enzyme has shown that 
a narrow temperature range is imperative to retain enzyme activity (+37°C. 
for rat liver; Leadbeater and Davies, 1964). Rink~ al. (1956) found that 
in the isolated perfused rat liver a temperature fall from +37° to +24°C. 
extended the half-life of thiopental from 46 minutes to 537 minutes. This is 
equally important for in vivo experiments. The response produced by the drug 
should be correlated with body temperature, and one should consider the in-
fluence that alters physiological temperature regulation. Barbiturates 
render most laboratory animals almost poikilothermic, since these drugs 
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paralyze temperature regulation (Fuhrman, 1947). Sotaniemi (1967) sunnnarizes 
several studies related to temperature and barbiturate metabolism and con-
cludes "that the duration of sleep produced by short-acting barbiturates was 
extended in cold environment, whereas no similar prolongation of sleep was 
noted with long-acting barbiturates, such as barbital and phenobarbital". 
3. Central Effects 
Barbiturates are similar to the gaseous anesthetics in producing all 
degrees of CNS depression, ranging from mild sedation to coma and death. The 
degree of depression depends on the particular compound, dose, route of ad-
ministration, certain physiological factors (see above), the degree of CNS 
excitability and previous experience with drugs which might alter metabolism. 
The principal use of barbiturates is the production of sleep. In 
controlled studies, they shorten the average time of onset to sleep and 
lengthen the duration of sleep (Lasagna, 1956). Superficially barbiturate-
induced sleep resembles physiological sleep, but, as should be apparent by 
now, normal sleep is extremely complex, and drug-induced sleep adds further 
to this complexity. In some individuals, small doses of barbiturates may 
produce excitement instead of sedation, probably because of an action similar 
to what is seen with ethanol intake; ie. by selective depression of inhibition. 
Subtle distortions of mood and impairment of judgement, vigilance, fine and 
gross motor movements and auditory discrimination can occur after barbiturate 
administration and can persist for many hours beyond the hypnotic effects. 
Some of these effects might be due to brain or plasma levels of metabolites, 
which are usually without effect but do remain in the body long after the 
105 
parent drug concentration has fallen to low levels. 
a. EEG Effects 
Small doses of barbiturates increase the high frequency EEG (15-
35 Hz), producing "barbiturate activation", which appears first in the frontal 
cortex and then spreads to the parietal and occipital cortex. It is accom-
panied by clouding of consciousness and occasionally euphoria. As the dose 
is increased, large amplitude, random slow waves (2-8 Hz) similar to those 
occurring during normal sleep appear and consciousness is lost, although 
response to strong, painful stimuli is retained. Higher doses further de-
crease the amplitude with occasional brief periods of electrical silence---
the "burst suppression" pattern. The periods of electrical activity disap-
pears, a pattern similar to the depression produced by volatile anesthetics. 
The EEG during barbiturate-induced sleep resembles normal sleep except for 
the occasional bursts of spindles (14 Hz) and REM episodes, often preceded 
by several seconds of "saw tooth" waves (2-3 Hz). During the regular ad-
ministration of barbiturates, the amount of REM sleep per night is reduced 
at first, but gradually returns to normal, as tolerance to the REM-suppression 
develops. When the drug is discontinued, there is a rebound increase in REM 
sleep and irregularities in REM sleep may continue for many nights. 
b. CNS Excitability 
In anesthetic doses, all barbiturates are effective antidotes to 
convulsant drugs and are capable of suppressing convulsions of strychnine 
poisoning, tetanus and status epilepticus. Phenobarbital has a selective 
anticonvulsant action, making it useful for symptomatic prevention of 
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epileptic seizures, especially of the grand mal type. Unlike other barbitu-
rates, in anesthetic doses it completely abolishes the electrical excitability 
of the monkey motor cortex. In smaller doses, in most structures it elevates 
the threshold for minimal motor response and initiation of an afterdischarge 
shortens the duration of the afterdischarge and prolongs the recovery time for 
convulsive capacity. 
c. Analgesia 
Barbiturates, unlike the volatile anesthetics, lack significant 
ability to obtund pain in doses not impairing consciousness. Any analgetic 
effects are probably due to reduction of the psychic phase of the pain, 
rather than to a changed perception of pain. Ultrashort barbiturates such 
as thiopental, RB and methoxital are conunonly injected IV to induce or sustain 
surgical anesthesia; to supplement inhalation anesthetics. They provide a 
rapid and pleasant induction, absence of salivation and reduce post-anesthetic 
excitement and vomiting. 
d. Respiration 
Barbiturates are respiratory depressants, affecting the drive to 
respiration and the rhythmic respiratory movements. These drives include that 
of the respiratory centers in the medullary and pontine RAS (neurogenic), a 
chemical drive, dependent on PC02 and arterial and CSF pH and a hypoxic drive. 
In the waking state approximately two-thirds of normal ventilation is due to 
the neurogenic drive. Sleep induced by hypnotic doses of barbiturates in-
volves no more respiratory depression than occurs in normal sleep. With 
higher doses the neurogenic drive is first affected, leaving the direct 
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action of COz and hydrogen ions on the respiratory centers, which also is 
lost as the dose is increased further. Death from barbiturate poisoning is 
usually attributed to respiratory failure by direct paralysis of the medul-
lary respiratory center. The neural elements controlling muscles for 
respiration are resistant to barbiturates and can continue to discharge 
after other rhythmic activity has ceased. Analeptics, such picrotoxin and 
pentylenetetrazol stimulate respiration either by resensitizing the medullary 
center to co2 or acting directly on the center. 
4. Peripheral Effects on Barbiturates 
a. Cardiovascular (CV) 
In sedative or hypnotic doses barbiturates do not produce signi-
ficant CV effects, except for a slight decrease in blood pressure and heart 
rate and a slight increase in cerebral blood flow, such as occur in normal 
sleep or in a recumbent position. Larger or IV doses produce a marked 
hypotension for several minutes in normals and hypertensives. Doses large 
enough to cause anesthesia generally produce a sustained decrease in the 
mean arterial and pulse pressure. The action or heart rate is variable, but 
the tendency is for an increase. In high doses barbiturates can exert 
direct effects on cardiac and vascular musculature, such as reducing con-
tractile force. Cardiac output may be reduced, probably due to blood 
redistribution into the splanchnic bed and extremeties. The important 
circulatory effect of barbiturates comes from their central depressing in-
fluence on vasomotor tone and control. Barbiturates do not sensitize the 
heart to Epi and are beneficial in reducing irregularities produced by 
cyclopropane. 
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b. Gastrointestinal (GI} 
The oxybarbiturates tend to decrease GI tone and the amplitude 
of the rhythmic contractions. Hypnotic doses decrease colon and small in-
testine motility and increase the motility but decrease emptying time of 
the stomach, similar to that during normal sleep. Gastric and pancreatic 
juice secretion is reduced. In vitro barbiturates depress intestinal loop 
activity and reduce histamine-stimulated secretion in gastric pouches. 
c. Urogenital 
Hypnotic doses of barbiturates have only slight effects on 
urinary excretion, possibly due to sleep alone. In adults anesthetic doses 
decrease glomerular filtration rate, urine flow and electrolyte excretion. 
Large doses depress the tone and contractility of the ureters and urinary 
bladder. The uterus is resistant to barbiturates and hypnotic doses do not 
significantly impair uterine activity during labor, however anesthetic doses 
do decrease the force and frequency of uterine contractions and since they 
cross the placental barrier, may impair the infants' respiration. 
5. Mode and Sites of Action 
As general depressants, barbiturates depress the activity of nerves 
skeletal, smooth and cardiac muscle and reduce tissue oxygen consumption, as 
well as respiration of cell-free preparations of liver and brain mitochondria. 
These effects require a wide range of concentrations, generally higher than 
those necessary to produce CNS depression and it is unlikely that a conunon 
mechanism is involved. 
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a. Biochemical Effects 
During barbiturate anesthesia there is a decrease in energy-
yielding reactions in the brain; oxygen uptake and lactate and heat pro-
duction are decreased. Certain barbiturates have been shown to depress 
uptake of inorganic phosphate in mitochondrial preparations with only a 
slight decrease in oxygen uptake, therefore it has been suggested that this 
"uncoupling" of phosphorylation from oxidation might be responsible for their 
depressant effects. Unfortunately not all barbiturates produce this un-
coupling and some compounds which do are not hypnotics (eg. salicylates). 
In vivo effects include a decrease in the level of brain inorganic phosphate, 
an increase incorporation of phosphate into ATP and an increase in the level 
of phosphocreatine. These results suggest that the depression of oxygen 
consumption is due to reduced neuronal activity (Jenkins, 1969, p. 239). 
Doses of barbiturates which cause sedation without loss of conscious-
ness are without effect on cerebral circulation or metabolism (Kety et al., 
1948). However larger doses always decrease cerebral oxygen consumption, 
with variable effects on blood flow. It seems that barbiturates exhibit no 
direct action on cerebral vasculature and changes are secondary to other 
effects. 
b. Neurophysiological Effects 
It is generally believed that the synapse is the site of action 
of hypnotic compounds, since chemical transmission is more susceptible to 
interference by barbiturates than is conduction along nerve or muscle fibers. 
At skeletal neuromuscular junctions barbiturates render the postsynaptic 
membrane insensitive to the depolarizing effects of ACh (Thesleff, 1956). 
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Barbiturates enhance the neuromuscular blocking effects of d-tubocurarine 
and decamethonium. The response of intestinal smooth muscle and certain 
neuroeffector organs, such as the submaxillary gland, to ACh and other 
spasmogenic agents is reduced by barbiturates. Little work has been done 
on the effect of barbiturates on adrenergic junctions, but some barbiturates 
may cause presynaptic liberation of transmitter. Barbiturates selectively 
depress sympathetic ganglia transmission in concentration without effect on 
nerve conduction, junctions or smooth muscle (Exley, 1954). The response of 
ganglion cells to preganglionic stimulation and choline esters is diminished 
by barbiturates, but they are not depolarized and respond to potassium 
chloride. Transmission is severely impaired by doses that do not prevent 
the release of ACh from preganglionic endings, although high doses of barbitu-
rates may also reduce the efflux of ACh from stimulated fibers. This effect 
might account for the fall in blood pressure produced by some barbiturates. 
Using intracellular recording techniques, the monosynaptic EPSP has 
been shown to be depressed by barbiturates in concentrations that have no 
effect on resting transmembrane potentials or the electrical properties of 
the membrane, probably by decreasing the release of transmitter (L0yning 
et al., 1964). Polysynaptic pathways are somewhat more susceptible to 
barbiturates than monosynaptic reflexes (Wikler, 1945) but this cannot 
account for their hypnotic effects, since more selective polysynaptic de-
pressants (eg. mephanesin) have little hypnotic effect. 
Barbiturates have some local anesthetic action, increasing the 
threshold to electrical stimulation, reducing the amplitude of the spike 
potential and negative afterpotential, prolonging the relative and absolute 
, 
111 
refractory periods and slowing conduction velocity (Heinbecker and Bartley, 
1940). Large doses elevate the threshold for sensory stimulation. Schoepfle 
(1957) demonstrated that a solution of thiopental was five times more potent 
than equivalent amounts of procaine in rendering single fibers of frog 
sciatic nerves completely inexcitable with little or no effect on resting 
membrane potential or transmembrane resistance. In lobster axons, barbitu-
rates reduce the maximum sodium and potassium transmembrane conductance and 
slow the rate of onset of sodium conductance after small depolarizing 
potentials. 
c. Reticular Activating System (RAS) 
Although attempts have been made to localize the action of bar-
biturates to certain gross regions of the brain stem, such as the MB tegmen-
tum or hypothalamus, drugs of this class apparently act at all levels of the 
nervous system. Nevertheless, the complex RF is exquisitely sensitive to the 
depressant effects of the barbiturates and other anesthetic agents. Whatever 
their effects elsewhere in the nervous system, it is the effect on the 
reticular system that seems to be responsible for the inability to maintain 
wakefulness under the influence of barbiturates. The present view of the 
importance of the RF in drug-induced sleep is based on a large body of evi-
dence accumulated since the pioneering work of Moruzzi and Magoun (1949) 
(see review by Killam, 1962). In doses that only slightly affect transmission 
in the primary sensory pathways, barbiturates increase the threshold of the 
RF to direct electrical stimulation and depress the potentials evoked in the 
system by a variety of sensory stimuli. Lesions in the MB RF can reproduce 
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the characteristic EEG of barbiturate-induced sleep, while lesions of the 
primary sensory pathways do not. 
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G· Gannna-butyrolactone 
1. Sedative Actions. 
The sedative or hypnotic activity of short chain fatty acids (from 
c2 to ClO) was studied by several investigators (Samson and Dahl, 1955; 
White and Samson, 1956; Holm~vist and Ingvar, 1957) before the introduction 
of modern techniques of continuous EEG recordings. Primary interest has 
since focused on two C4 compounds, ganuna-hydroxybutyrate (GHB) and gannna-
butyrolactone (GBL), a cyclic form that is converted to GHB by the action 
of a liver and plasma lactonase (Roth and Giarman, 1966; see Fig. 4 ). 
Jouany et al., (1960) who observed that low doses of butyric acid produced 
sleep and higher doses, anesthesia, were subsequently prompted to examine 
the action of the derivatives, GHB and GBL. Benda and Perles (1960) and 
Laborit et al. (1960) examined the EEG and physiological responses after GBL 
and GHB. They observed sleep-like states and anticonvulsant activity, as well 
as general anesthesia at higher doses. After a short latency, 50 mg/kg of 
GBL or GHB induce both states of sleep and a secondary increase in PS (Jouvet 
~al., 1961). The induction of PS was inconsistently found in the normal 
cat and was not observed in the rat (Marcus ~al., 1967; Winters and Spooner, 
1965 ). CS and C6 compounds are even more effective than the C4 agents in 
triggering PS (Matsuzaki et al., 1964; Delorme et al., 1966a). In decorti-
cate, mesencephalic or pontile cats, PS can always be induced almost inunedi-
ately after IV injection, provided the compound is injected after the absolute 
refractory period (of 10-15 minutes) following the last PS episode. After a 
short latency, C4 and C6 compounds consistently produce a typical PS phase. 
The C4-C6 compounds appear to act at the level of the pons, since they still 
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induce PS in pontile cats but are ineffective after mediopontine transection 
(Tokizane, 1966; Matsuzaki, 1969) or after lesions of the dorsolateral pontine 
tegmentum (Jouvet et al., 1961). These compounds antagonize the inhibitory 
effects of atropine upon PS in pontile cats but are ineffective in inducing 
pS during the PS-suppressor effect of MAOis (Delorme et al., 1965). 
2. Active Form 
Jenny et al. (1962) and others reported a similarity of the EEG patterns 
between anesthetic doses of GHB and PB. Winters and Spooner (1965; 1966) 
showed that at high doses (200-600 mg/kg), GHB produces a polygraphic pattern 
similar to PB and alpha-chloralose. They reported that after GHB a pro-
gression of various types of epileptiform EEG patterns were obtained. They 
suggested that GHB induced a state similar to generalized non-convulsant 
epilepsy, which could act to disconnect the cortex from subcortical regions. 
An alternate conclusion is suggested by the finding of Wikler (1952), who 
demonstrated a "divorce" or dissociation phenomena between the EEG and be-
havioral effects of several drugs. 
The aforementioned studies stimulated neurochemical investigations of 
the mechanism of action of these compounds. There has been a great deal of 
controversy as to whether GHB or GBL is the active product and which of these 
is a normal constituent in the brain that might play a role in normal sleep, 
as a "natural hypnogen". Giarman and Roth (1964) initially were unable to 
demonstrate GHB in the brain, although Bessman and Fishbein (1963) did. 
Subsequently Roth and Giarman (1970) corroborated this finding when they 
utilized a more sensitive technique than in their earlier studies. Bessman 
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and Skolnik (1964) reported that the onset and duration of anesthesia cor-
related with the presence of the lactone in the brain, after either GHB or 
GBL was administered to rats. On the other hand, Giarman and Roth (1964) 
found that when rats were given GBL (500 mg/kg, IV) high brain concentrations 
(10-2M) were achieved within one minute, followed by a decline due to re-
distribution from the brain and rapid conversion to GHB. When brain GHB 
content reached about 70 µg/gm, the righting reflex was lost. Recovery 
occurred when brain GHB fell below this critical level, suggesting that 
anesthesia is related to brain GHB content and not GBL. Guidotti and Ballotti 
(1970) obtained similar results. Roth!:!., al. (1966) added further evidence 
that GHB was the active form in experiments that examined the effects of GHB 
and GBL in blockingtransmission through the SCG and after direct injection 
into the CNS. Only GHB produced depression in the rat after intracisternal 
injection, while a greater delay in the onset of transmission blockade in the 
SCG was seen with GBL than GHB, suggesting that the delay might be due to 
conversion to the active form. When administered into the thalamus and 
hippocampus of unanesthetized monkeys by micro-injection, GHB innnediately 
produced a slow-wave, high-amplitude EEG. GBL was without effect. Besson 
et al. (1971) found that anesthetic doses of GHB greatly reduced the dorsal 
root potential produced by segmnetary stimulation, while the dorsal root 
potential produced by cortical stimulation was unaffected. They previously 
described (Besson et ~ 1968) a similar action connnon to a variety of 
anesthetics, which act presumably by a presynaptic mechanism. 
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3. GABA in the CNS and Relationship to GBL 
The close structural similarity between GBL and GABA (cf. Fig. 4 ) 
suggested that GBL might act on the GABA system. The physiological actions 
of GABA are interrelated with L-glutamic acid (GA), the main precursor of 
GABA (cf. Fig. 4 ). This conversion is catalyzed by the enzyme glutamic 
acid decarboxylase (GAD; EC 4.1.1.15) and is essentially irreversible (cf. 
Roberts, 1960). The major pathway of GABA degradation is via transamination 
(GABA: 2-oxoglutarate aminotransferase; EC 2.6.1.19) with a-ketoglutarate to 
form GA and succinic semialdehyde, requiring pyridoxal phosphate as a cofactor 
(Baxter and Roberts, 1958). 
High levels of GABA are found in the peripheral nerves of crustaceans 
and in the mammalian CNS (Awapara et al., 1950; cf. Baxter, 1970). Kuffler 
and Eyzaguirie (1955) proposed that GABA might play an inhibitory role in the 
CNS. An inhibitory factor (Factor I) isolated from the brain was found to 
consist primarily of GABA (Bazemore et al., 1957). In the monkey brain, GABA 
levels are highest in the substantia nigra, globus pallidus and hypothalamus 
(Fahn and Cote, 1968). The thalamus and cerebral cortex contain lesser amounts, 
while white matter contains the least. Cerebellar GABA content is highest in 
axons of cells shown electrophysiologically to be inhibitory (Purkinje, basket, 
stellate and Golgi type II), supporting the theory that GABA has an inhibitory 
role in the CNS. GA is the most abundant amino acid in brain tissue (Tallan, 
1962). Highest levels are found in the cerebrum and lowest levels in the 
spinal cord (Shaw and Heine, 1965). Extracellular administration of GABA 
produced hyperpolarization and increased membrane conductance in cortical 
neurons (Krnjevic and Schwartz, 1967), Deiter's cells (Obata et al., 1967) 
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and spinal motoneurons (Curtis~ al., 1968) and is capable of blocking most 
types of cortical activity (Bradley, 1969). Peripheral injection of GABA 
produces no significant effects on evoked cortical potentials and intra-
carotid injections have only brief, transient effects (cf. Baxter, 1970), 
probably due to the lack of penetration of the BBB. Young animals have in-
complete BBB. In chicks, GABA (1.5 mg/kg) produces ataxia, incoordination, 
depression and a lack of responsiveness to visual stimuli (Scholes, 1965). 
A number of recent studies have attempted to correlate the central 
levels of GABA and related compounds with the physiological state and pharma-
cological treatment of the animal. A homeostatic function for GABA during 
hypoxia is possible since after exposure of rats to 8% oxygen for 10 minutes 
brain levels are significantly elevated (Wood, 1967). Exposure of animals to 
hyperbaric oxygen lowers brain GABA content and induces seizures. Seizure 
susceptibility is inversely proportional to GABA levels (Wood et al., 1969). 
GABA injections (IP) protect animals against hyperbaric oxygen-mediated con-
vulsions, but the effect is not specific and can be achieved with other amino 
acids and salts (Wood and Watson, 1964). Some convulsant drugs (eg. semi-
carbazide and thiosemicarbazide) lower brain GABA content, while others (such 
as hydrazine) elevate GABA levels (cf. Baxter, 1970). Anticonvulsant agents 
(such as hydroxylamine and glutamic acid hydrazide, GAH), which elevate GABA, 
do not protect against the convulsant effect of thiosemicarbazide at times 
when CNS GABA levels are distinctly elevated. Although GAH, hydroxylamine and 
AOAA all elevate GABA levels, only the latter two protect against pentylene-
tetrazol convulsions, illustrating that there is no direct correlation with 
convulsions and CNS GABA content. 
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Apart from the possible involvement of GHB and GBL with GABA, only 
limited evidence links GABA with sleep phenomena. Deprivation of sleep 
(Mandel and Godin, 1964; Micic ~al., 1967) and induction of sleep with 
strong light (Godin and Mandel, 1965) elevate rat brain GABA. In cats with 
brain stem transections at the upper MB (cerveau isol~), the cortical EEG 
shows continuous spindling characteristic of sleep. This "activated sleep" 
is accompanied by a release of GABA from the perforated cortical pial surface 
of 2 µg/hr./cm2 . This rate is three times that in normal, intact, aroused 
animals or animals with brain stem transections of the upper cervical cord 
(encephale isole) with aroused EEG patterns (Jasper et al., 1965) The 
pattern is reversed for the rate of release for GA. In rats treated with 
ethanol and GBL or GHB, the combination produced sleep (loss of the righting 
reflex) of much greater duration than that obtained by adding the durations 
of individual components (McCabe et al., 1971). 
Several alternate routes of metabolism for GABA have been proposed, 
based on the product recovery and isolation of enzymes capable of catalyzing 
these transformations. Their physiological significance is unclear but the 
fact that several of them involve other brain amines, suggests an inter-
relationship of these amine systems. GABA can combine with arginine to form 
gamma-guanidobutyric acid, which is found in the CNS and has an inhibitory 
action when applied to the mammalian cerebral cortex (Takahashi~ al., 1961). 
Large amounts of gannna-guanidobutyric acid have been found at the epileptic 
focus of human cerebral cortex (Jinnai et al., 1966). Two histamine related 
products are formed from GABA, homocarnosine (GABA-histidine) and homoan-
serine (GABA-L-methyl histidine). Both compounds are found in the brain. 
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Ga.mma-amino-~-hydroxybutyric acid (GABOB) was detected in rat brain and has 
inhibitor actions (Hayashi, 1959) although there is some controversy about 
itS presence in the CNS. GABOB has been used clinically to treat epilepsy 
(Nishimato et al., 1964). GABA is trimethylated in brain tissue in vitro 
to form ganuna-butyrobetaine (Hosein et al., 1962) and this product can be 
hydroxylated in vivo and in vitro to carnitine, although no significant 
amount of carnitine is formed from 14C-GABA administered peripherally to rats 
and mice (Lindstedt and Lindstedt, 1965). Gannna-butyrobetaine, carnitine and 
the CoA esters, acetyl-L-carnitine and acetyl-L-carnityl CoA have "ACh-like" 
actions (Hosein and Orzeck, 1966). Ganuna-aminobutyrylcholine is found in 
the brain and although it does not cross the BBB, it has anticonvulsant 
effects. Homopantothenic acid and alpha-gamma-diaminobutyric acid which are 
structurally related to GABA have also been found in the brain. 
4. Involvement of Other AJilines with GBL 
Giarman and Schmidt (1963) demonstrated that GHB increased ACh content 
in the brain stem (the dorsal pontine tegmentlllll). Parenteral administration of 
GHB, GBL or 1,4-butanediol (which is also converted to GHB, in vivo) results 
in a marked increase in brain DA with little or no effect on such amines as 
NE and SIIT (Gessa et al., 1966; Roth and Suhr, 1970) or GABA (Giarman and 
Schmidt, 1963). Roth and Suhr (1970) showed that the elevated brain DA has 
the same regional distribution as the normal endogenous amine. Aghajanian and 
Roth (1970), utilizing fluorescence microscopy, demonstrated that the select-
ive increase in DA occurs exclusively within the terminals of DA-containing 
neurons. This is in contrast to the generalized increase in brain fluorescence 
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after MAOis. The GHB-induced increase in DA is due to newly-formed DA, since 
it does not occur after inhibition of DA synthesis with AMPr, but is still 
seen after amine depletion with reserpine (Gessa ~al., 1968). These in-
vestigators showed that GHB and related compounds do not inhibit MAO or COMT. 
rn addition to the elevation in DA, Roth and Suhr (1970) and Roth (1971) 
demonstrated a corresponding reduction in subcortical HVA. The former study 
also reported that GBL produced a selective increase in the specific activity 
of brain DA, but not NE, in rats injected with 14c-tyrosine (IV). They con-
eluded that GBL (and GHB) increase brain DA primarily by selectively blocking 
its release from DA-containing neurons. 
5. Mechanism of Action 
A number of mechanisms of action for GBL and GHB have been proposed, 
ranging from physical to neurochemical, and are surmnarized here. These 
compounds might inhibit the metabolic activity of cerebral tissue, as they do 
in muscle and yeast (Samson et al., 1956). They might act upon cerebral 
metabolism by affecting the pentose shunt (cf. Laborit, 1964) or the meta-
bolism of GABA (Fishbein and Bessman, 1964; Roth and Giarman, 1969). Mitoma 
and Neubauer (1968) demonstrated that GHB is converted to GABA, although there 
is no elevation of brain GABA after GHB administration. Godin et al. (1968) 
demonstrated that GHB increases cerebral glucose, decreases lactate and the 
incorporation of glucose carbon into GA, glutamine, aspartic acid and GABA in 
rat brain. A similar elevation of glucose in mouse brain, without a corre-
lation with sedation or anesthesia was reported by Leonard and Watkinson 
(1971), Godin~ al. (1968) showed that GHB can form succinate or GABA after 
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o~idation to succinic semialdehyde by lactate DH (cf. Fig. 4 ). DeFeudis 
and collier (1970) reported a similar conversion of GHB to GABA and indicated 
that it proceeds via Krebs cycle intermediates. 
The selective increase in brain DA and ACh (and decrease in HVA) 
suggests that the action of GBL might involve these amines. Since the locus 
coeruleus contains both ACh and DA (Shute and Lewis, 1966; Gerardy ~al., 
1969) and pontine neurons seem to participate in triggering PS, the effects 
of the C4-C6 compounds might be related to their selective effect on the pons. 
rn the intact animal, the effects upon striatal DA might conceal the pontine 
effect. 
Several investigators have suggested that the C4-C6 fatty acids might 
act at the membrane level (Dahl, 1968; Rizzoli and Galzigna, 1970) by reacting 
with membrane lipids and perhaps interfering with the movement of critical 
ions. Butyrate can bind with lecithin (in synaptic structures), SHT and 
DA by forming a molecular complex when it passes through synaptic membranes. 
The formation of this complex might alter the equilibrium in the synaptic 
cleft and induce the release of additional transmitter or it might interfere 
with ACh release (Rizzoli and Galzigna, 1970). This hypothesis might also 
explain the absolute refractory period, when it is impossible to trigger PS 
pharmacologically or electrically because insufficient transmitter is avail-
able in the nerve terminals. When a sufficient amount of transmitter is 
subsequently synthesized, the fatty acids are then able to trigger PS 0 
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g. Alteration of Drug-induced Sleep 
Various physiological and pharmacological factors have been shown to 
alter the effects of hypnotic drugs. Environmental light is one which can 
bring about circadian changes in the effects of a variety of drugs, including 
hypnotics. This aspect of drug effectiveness, only recently considered, 
probably deserves consideration in almost all pharmacological studies and 
will be discussed in the section on Biological rhythms. Other factors also 
discussed below, are under the headings of physiological and pharmacological 
changes. 
1. Physiological Effects 
Vesell (1968a, b) thoroughly examined the duration of action of hexo-
barbital (HB) anesthesia (125 mg/kg, IP) in a number of species of mice. 
Some species sleep longer and have correspondingly lower liver hexobarbital 
oxidase (HBO) activity than animals that have short sleep durations. Genetic 
crosses between long-sleepers retained the long sleep duration and HBO 
activities, while crosses between long and short sleeping species had sleeping 
times and HBO activities intermediate to the two. The trait of male mice 
sleeping longer than females was maximal in inbred strains and diminished 
by outbreeding. The duration of RB-sleep in a NIH strain decreases pro-
gressively and significantly from one week of age and plateaus at three weeks, 
corresponding to the time-course of development of liver HBO activity. The 
age, sex, strain and species of experimental animals therefore are important 
in drug response. HB sleeping time decreased, while HBO activity increased 
in animals removed from their usual hardwood bedding and placed on red cedar 
(softwood) bedding for six days. Softwoods contain enzyme-inducing substances, 
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such as terpenes. The changes in sleeping time and enzyme activity were 
reversed by putting the mice back on hardwood bedding. A painful stimulus 
applied at regular intervals significantly shortens HB sleep without altering 
HBO activity. Crowding of animals also tends to shorten HB sleep. Mice 
maintained at 20°C. slept longer and had correspondingly lower HBO activity 
than those kept at 25°C. or 30°C. However, mice given HB are unable to 
survive environments of 15°C, or 37°C. 
a. Temperature 
Fuhrman (1946) sunnnarized some of the earlier work done in 
mannnals and lower animals on body temperature and drug action, including 
toxic and hypnotic effects. A number of investigators report that rats and 
mice at lower environmental temperatures sleep longer with a given dose of a 
barbiturate. Fuhrman (1946) reported that mice maintained at 27°C. slept 
almost four times as long after the onset of PB-induced sleep as those main-
tained at 37°C. There was no difference in sleeping time for barbital-
treated animals at the two temperatures, indicating that the prolonged PB 
sleep was due to its decreased metabolism. Buchel and Tanguy (1967) reported 
similar findings in mice for doses of PB and HB producing sleep of a duration 
greater than 50 minutes. Mice maintained at a simulated altitude of 18,000 
feet (hypobaric) for five days had a shorter loss of the righting reflex 
with HB, zoxazolamine and mephenesin but not with PB (Hawkins et al., 1971). 
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b. Diet 
Kalyanpur et ~· (1968) examined the influence of dietary 
factors on PB and barbital-induced sleep duration. These include high pro-
tein and high carbohydrate diets as well as vitamins (thiamine, nicotinic 
acid, tryptophane, and the B complex) and steroids (desoxycorticosterone, 
4-chlorotesterone, aldosterone, progesterone, stilbestrol, with the latter 
three administered on both an acute and chronic basis). Thiamine, nicotinic 
acid, biotin, progesterone, high carbohydrate and high protein diets signi-
ficantly prolong PB sleep. Tryptophane, nicotinamide and pyridoxine and the 
steroids (except for progesterone administered acutely) decreased PB sleep. 
Lamson et al. (1951) tested glucose and related substances for their ability 
to restore hypnosis to guinea pigs awakening from barbiturate hypnosis. IP 
doses of glucose, galactose, levulose, several Kreb's cycle intermediaries, 
ascorbate, yeast, glutamic acid, glycerol and epinephrine were effective in 
"re-introducing" sleep in awakening animals, while sucrose, nicotinamide, 
pantothenic acid, glycine, alanine, ATP and DPN were not. There were marked 
species differences in the response; guinea pigs reacted to all active sub-
stances, while rabbits, hamsters, pigeons and chickens respond to a lesser 
extent. Rats do not respond to glucose but do to lactate and pyruvate. Mice 
respond very slightly, while goldfish and tadpoles do not respond at all. 
Lactate, pyruvate and glutamate decreased the onset of barbital anesthesia, 
presumably by increasing its rate of entry into the brain. The effect was 
antagonized by ACh. The authors hypothesized that the various active meta-
bolites act by decreasing ACh synthesis, since they inhibit choline acetylase, 
which in turn would allow for a higher level of brain barbital. 
126 
c. Sex 
The duration and intensity of drug response is often greater in 
the female adult than in the male adult rat. Brodie (1956) reported that 
female rats given HB slept four times as long as males, and had correspond-
ingly lower metabolizing enzyme activity. Female rats administered testos-
terone slept less and had higher enzyme activity than controls, while males 
given estradiol slept longer and had lower enzyme activity than controls. 
These results indicate that the female is not more sensitive to the drug, 
but that the sex hormones influence drug metabolism. However, Brodie (1956) 
further stated that in mice, guinea pigs, rabbits and dogs such sex differ-
ences were not demonstable. 
Selye (1947, p. 59) demonstrated that steroids themselves are able 
to induce sleep. In order of decreasing potency, the steroids listed are: 
pregnanQdione, desoxycorticosterone acetate, progesterone, testosterone and 
estadiol. Winter and Flataker (1952) studied the effects of steroids on the 
response of mice to HB anesthesia. Sleep duration was shortened by cortisone 
(SC)and ACTH (IP) treatment but not by dexoxycorticosterone acetate (SC). 
Rupe et al. (1963) demonstrated that in rats stressed by hind leg ligation 
for 2.5 hours prior to testing, the duration of sleep from PB, HB and 
meprobamate, decreased in comparison to unstressed controls. The effect was 
absent in adrenalectomized rats and could be restored by treatment with ACTH 
or corticosterone. Similarly, Bousquet et al (1965) showed that the duration 
of response to HB, PB) meprobamate and zoxazolamine was significantly reduced 
in stressed animals, while that to barbital and phenobarbital was unaffected. 
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The duration of response to RB in adrenalectomized or hypophysectomized rats 
~as unalterable, suggesting that the effects of stress on drug response are 
mediated over the pituitary-adrenal axis. Rumke and Noordhoek (1969) reported 
that lynestrenol (a progesterone-like compound) decreased HB sleeping time, 
~hile enhancing its in vivo liver metabolism. 
d. Hormones 
Feeding mice 2% desiccated thyroid in their food prolonged PB 
and thiopental-induced sleep (Prange~ al., 1966). Propylthiouracil (0.2% 
in the drinking water) decreased PB sleep but not thiopental sleep. In rats, 
thyroxin (100-1000 µgm, IM) only slightly prolonged PB in sleep, while thy-
roidectomy greatly prolonged PB sleep. The authors concluded that propyl-
thiouracil and thyroid feeding of mice prolonged sleep by decreasing the 
activity of the metabolizing system, even though in rats thyroxin produced 
only slight increases in PB-sleep. Prolongation of PB in thyroidectomized 
rats is probably due to the general decrease in metabolic rate and the 
accompanying decreased body temperature. Conney and Garren (1961) reported 
that pretreatment of male rats with thyroxin prolonged the duration of action 
of HB by decreasing the activity of the liver enzyme metabolizing system. 
e. Pathology 
Kostowski and Dolfini (1969) reported that lesions of the midbrain 
raphe increase PB sleep in rats, even though such lesions have been shown to 
decrease SWS (Mouret~ al., 1967) and cause persistent behavioral and EEG 
arousal (Kostowski et al., 1968). Bilateral lesions in the posterior hypo-
thalamus suppress HBO activity, while lesions in the caudate nucleus, 
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hippocampus, preoptic hypothalamus or cerebral cortex produced no change 
(Nair~ al., 1970). However sleeping time was significantly prolonged after 
hippocampal, preoptic and posterior hypothalamic lesions. Caudate but not 
cortical lesions decreased HB sleep. They suggested that HBO activity is 
regulated by the posterior hypothalamus, possibly through the release of 
hypophyseal tropic hormones. Exposure of young rats to sublethal X-irradia-
tion inhibited the normal rapid increase in HBO activity occurring at three 
weeks of age, but was reversed three weeks later (Yam and DuBois, 1967). 
The X-irradiation appears only to delay the increase of enzyme activity. 
Exposure of the head only or hypophysectomy without irradiation also inhibit 
development of the HBO system, indicating a possible involvement of central 
hormonal regulation of HBO activity. Starvation prolonged HB sleep (Dixon 
et al., 1960; Fujii et al., 1968) while cache.xia produced by feeding rats a 
rancid, standard biotin deficient diet decreased PB sleep (Peters and Boyd, 
1966). 
2. Pharmacological Effects 
Kato and Chiesara (1962) reported that a number of centrally-acting 
drugs decreased the duration of PB sleep (25 mg/kg, IP) in rats. They 
include phenobarbital, phenaglycodol, glutethimide, nikethamide, meprobamate, 
chlorbutol and chlorpromazine. The effect developed 24 hours after treatment 
and was maximal after another 24 hours. PB metabolism in liver slices of 
similarly-treated animals was increased. Boissier et al., (1967a,b) examined 
the central effects of sympatholytics on a subhypnotic dose of PB (25-30 
mg/kg) in mice and rats. At the higher doses employed, phenoxybenzamine, 
r 
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dibenzamine, phentolamine, yohimbine, dihydroergotamine, propranolol, 
guanethidine, a-methyl-DOPA and chlorpromazine caused a high percentage of 
mice to sleep, when administered 35-65 minutes prior to PB and they reduced 
spontaneous activity and rectal temperature. Bretylium (8-32 mg/kg) was 
without effect. Consolo~ al. (1965) and Sadre and Tiwari (1966) also re-
ported the prolongation of PB sleep by chlorpromazine. Peters (1972) studied 
the prolongation of PB hypnosis in mice by the ~-blocker, alprenolol. The 
increased duration of sleep was not related to an altered tissue distribution 
or hypothermia. Alprenolol decreased NADiri"' phosphate oxidase, cytochrome c 
reductase and cytochrome P450 reductase activities and cytochrome P450 
content. Naik et al. (1969) demonstrated potentiation of PB sleep by the 
analeptics nikethamide and pentylenetetrazol and antagonism by picrotoxin. 
Paradoxially, all three compounds produced a similar elevation in brain PB 
levels. 
The effect of pretreatment with a-methy-L-tyrosine (same as AMPT) 
on the duration of PB sleep, alone and in combination with chlorpromazine) 
reserpine or meprobamate was tested by Menon~ al. (1967). The only signi-
ficant increases in PB sleep occurred in AM.PT-treated animals concomitantly 
given reserpine or chlorpromazine. Richards ~al. (1965) examined) with 
respect to sleep duration and arousal time (from an electrical stimulus)) 
the effects of pretreatment of mice with chlorpromazine, reserpine) mepro-
bamate and hyroxyzine, given immediately before HB (100 mg/kg, IP). All 
prolonged sleep significantly at the higher doses and at their lowest doses 
With meprobamate and hydroxyzine. Smith (1961) reported that reserpine 
(100 µgm/kg, SC) given 20 hours prior to barbital (200 mg/kg, IP) significantly 
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potentiated barbital sleep in rats. LSD (1 mg/kg) given 30 minutes prior to 
barbital antagonized this effect of reserpine. However, Salmoiraghi and Page 
(1957) demonstrated that low doses of LSD or bromo LSD (2 µgm/kg, one hour 
prior to RB) enhanced the prolongation of RB sleep (70 mg/kg) produced by 
SHT (20 mg/kg, 10 minutes prior to RB) and reserpine (5 mg/kg, one hour prior 
to RB). Child et al. (1961) demonstrated that reserpine ( 2 mg/kg, IP) pre-
treatment, 1-6 hours before its administration, shortened barbitone-induced 
sleep. Sleep returned to normal by the 2nd day, increased on days 3-4 then 
became normal again. The rate of penetration of barbitone into the brain as 
measured by brain levels was reduced by reserpine pretreatment. 
To produce stress in rats, Bousquet~ al. (1965) administered hista-
mine (5 mg/kg, IV) 2.5 hours prior to RB and obtained decreased RB sleeping 
time. Winter and Flataker (1952) demonstrated in mice that the antihistamine, 
diphenhydramine (10 mg/kg, 30 minutes prior to the anesthetic) prolonged 
sleep induced by RB or ether. Winter (1948) reported that the antihistamines, 
diphenhydramine, pyranisamine, tripelennamine, and promethazine, prolonged 
HB (100 mg/kg, IP) sleep in mice and that diphenhydramine prolonged PB (50 
mg/kg, IP) sleep. He also found that diphenhyramine prolonged PB-sleep (35 
mg/kg, IP) in guinea pigs. Pierre and Cahn (1956) found that 5HT (5 mg/kg and 
20 mg/kg) administered 5 minutes and 10 minutes respectively after thiopental 
(40 mg/kg, IP) significantly prolonged sleep, but not after PB, thialbarbital, 
urethane or ether. Buchel et al. (1960) also reported prolonged sleeping 
times in mice after SHT (SO mg/kg, IP and SC) which decreased after iproniazid 
(150 mg/kg, IP) or JB 516 (10 mg/kg, IP) given 24 hours prior to the HB. 
Iproniazid was effective in blocking the prolongation of RB sleep produced 
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by 5 HTP (25 mg/kg, IV) given 5 minutes prior to HB. Baldieri (1965) showed 
that pargyline (2.5-10 mg/kg, IP), given 15 minutes prior to PB (30 mg/kg, 
IP) prolonged PB sleep in rats. 
Proctor et al. (1964) demonstrated that several anticholinesterases 
enhanced the hypnotic activity of HB in mice. TEPP prolonged HB sleep and 
its effect could be antagonized by atropine but not by atropine methyl bromide. 
perphenazine combined with TEPP greatly enhances HB sleep and was similarly 
blocked by atropine but not atropine methyl bromide. Barnes andMeyers (1964) 
reported that eserine, given concomitently with PB, decreased sleep, as did 
amphetamine, alone or with eserine. Neostigmine had no effect on PB sleeping 
time, suggesting that the cholinergic mechanisms activated were central. 
Significant prolongation of PB sleep (65 mg/kg) in mice was produced 
after a one hour pretreatment with aminopyrine and phenylbutazone (both at 
25 mg/kg; Eckhardt et al., 1958). Prednisone (25 mg/kg), morphine (1 or 
25 mg/kg) or acetylsalicylic acid (25 or 250 mg/kg, orally) were without 
effect. The effective drugs significantly elevated brain PB content. How-
ever, Coldwell and Peters (1968) reported that a one hour pretreatment with 
acetylsalicylic acid (0.2-1.9 mg/kg, orally) significantly potentiated 
hypnosis in rats, at several doses of PB or thiopental. Quinine and quini-
dine (both SO mg/kg, IP) prolonged PB-induced sleep in mice and rats (Boulos 
~al., 1970). Both drugs decreased the rate of loss of PB content in goat 
plasma, without a change in the volume of distribution and were potent com-
petitive inhibitors of PB metabolism in rat liver homogenates. Quinine did 
not alter PB brain levels significantly in mice, 5 minutes after PB or upon 
awakening. 
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Seto and Keup (1969) tested a number of alkylmethoxybenzene and 
alkylmethylene-dioxybenzene essential oils on PB (50 mg/kg) and ethanol 
(3.5 gm/kg)-induced sleeping time in female mice. Myristicin, isomyristicin, 
safrole and elemicin at doses of 20 mg/kg double PB sleeping time. At a 
dose level of 50 mg/kg, asarone, isoelemicin, ortho-anethole, eugenol methyl 
ester and isoeugenol methyl ester double sleeping time over controls. 
Asarone (at 75 mg/kg) was the only essential oil capable of doubling the 
sleeping time over control, ethanol-treated mice. Several other essential 
oils tested were much less effective in prolonging PB or ethanol-induced 
sleep. Jori et al. (1969) reported that in rats eucalyptol (500 mg/kg, SC, 
18 or 36 hours pretreatment) significantly decreased PB sleeping times and 
brain PB content. Other constituents of essential oils, such as guaiacol, 
menthol, oil of Pinus pumilio, a- and ~-pinene, are not effective in altering 
PB sleep duration. 
Conney (1967) reviewed the pharmacological implications of liver 
microsomal enzyme induction by a wide spectrum of drugs, including hypnotics, 
anesthetic gases, CNS stimulants, anticonvulsants, tranquilizers, muscle 
relaxants, antihistamines, alkaloids, insecticides and steroids. Some of 
these act as competitive inhibitors of drug metabolism, in oxidative and 
demethylation reactions. Rennner (1962), Conney and Burns (1959) and other 
investigators demonstrated the stimulating effect of barbiturates on micro-
somal metabolizing enzymes. Most inducers are like phenobarbital. They 
stimulate various pathways of metabolism by the liver microsome system, 
including oxidation, reduction, glucuronide fromation and deesterification. 
Polycyclic aromatic hydrocarbons stimulate a more limited group of reactions, 
133 
such as some hydroxylating pathways. The course and intensity of induction 
also differs. Phenobarbital, given daily, produces a maximum in induced 
enzyme activity (3-10 fold increase over control) after at least three days, 
while a single IP injection of dieldrin (40 mg/kg) or DDT (200 mg/kg) in rats 
elevates HB and acetophenetidin metabolism to maximum (2-3 times control) 
in 5-10 days (Ghazal et al., 1964). Enzyme induction results in a more rapid 
metabolism and usually a decreased drug effect, i.e., diminished toxicity or 
duration of hypnotic sleep. In some cases, however, the metabolite might be 
the active form, leading to exaggerated effects. 
Brodie (1956) described the potent enzyme inhibitory action of SKF 
525A. Animals treated with this compound and then administered a hypnotic, 
such as HB, sleep much longer than controls. SKF 525A, which has no sedative 
action of its own, also prolongs the action of amphetamine. It acts by in-
hibiting hydroxylation, N-dealkylation, some O-dealkylation, deamination, 
sulfoxide formation, reduction of azo and aromatic nitro compounds, some 
hydrolysis reactions and the formation of glucuronides. However, there are 
species and drug exceptions to the above. 
The alteration of the effects of the non-barbiturate hypnotics, 
chloral hydrate and ethanol should be briefly considered. Fastier et al. 
(1957) reported that chloral hydrate (250 mg/kg, IP) sleeping time was pro-
longed by adrenaline, noradrenaline, phenylephrine, methoxamine, 5HT, 
histamine, ergotamine, yohimbine and atropine. They stated this effect was 
not due to circulatory actions but possibly due to lowering body temperature. 
Buchel et ~· (1960) demonstrated in mice that SHT (10 mg/kg, SC) produced 
sleep when given 3 hrs prior to a subhypnotic dose of chloral hydrate 
r 
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(26 mg/kg, IP). (The peak effect occurred 30 minutes after SHT). Chloral 
hydrate sleep (32S mg/kg, IP) was prolonged by SHT (SO mg/kg, SC and IP, up 
to 60 minutes prior) or SHTP (2S mg/kg, IV, S minutes prior). Buchel and 
Levy (1960) found that in mice, reserpine (S mg/kg) produced sleep after a 
subhypnotic dose of chloral hydrate (200 mg/kg), which was antagonized by 
JB Sl6 (S-10 mg/kg) and ipronized (S0-100 mg/kg). Reserpine (2 and S mg/kg) 
prolonged a hypnotic dose of chloral hydrate (300 mg/kg), which was anta-
gonized by JB Sl6 (2.S and S mg/kg, 20 minutes prior) and iproniazid (SO 
mg/kg, 22 and 46 minutes prior) but not by iproniazid (2S mg/kg). 5HTP 
(5-25 mg/kg, IV) and DOPA (10-2S mg/kg, IV) reinduced sleep in animals 
awakening from chloral hydrate (200-22S mg/kg). The effects of both com-
pounds were antagonized by iproniazid (lSO mg/kg, IP) given 24 hours prior 
to the hypnotic. Sadre and Tiwari (1966) showed that histamine (10 mg/kg) 
and chlorpromazine (10 mg/kg), alone or together, prolonged sleep induced by 
chloral hydrate (400 mg/kg) in mice. Lechat and Levy (1969) reported that 
in mice, DL-DOPA (lSO mg/kg, IP) 10 minutes prior to chloral hydrate (250 
and 325 mg/kg, IP), doubled sleep duration, and was antagonized by the MAOI 
furazolidone (500 mg/kg, orally, 24 hours prior). 
Blum et al. (1971) reported that in mice, pyrazole, an inhibitor of 
liver alcohol dehydrogenase, produced a dose-dependant prolongation of 
ethanol-induced sleep, when given 30 minutes prior to ethanol. Blum et al. 
(1972b) showed that glycine (0.9 mmoles/100 gm, IP) given 5 minutes after 
ethanol significantly prolonged sleep over controls. This effect appears 
to be due to central actions and not to altered ethanol metabolism. 
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carlsson et al. (1972) demonstrated in rats and mice that AMPT (40 or 200 
--
mg/kg), which in itself causes no significant depression of motor activity, 
reduced the normal increase in motor activity produced by small doses of 
ethanol (1 or 2 gm/kg). Blum~ al. (1972a) found that AMPT (3 x 80 mg/kg 
or 400 mg/kg) enhanced ethanol-induced sleep time in mice. AMPT-L-DOPA 
treated animals had a reduction of the AMPT-alone increase in ethanol sleep, 
with a 60% increase in whole brain DA. L-DOPA alone (3 x 400 mg/kg/day) 
appears to prolong ethanol sleep, although they did not mention if this 
increase was significant. 
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III. MATERIALS AND METHODS 
A. Experimental Animals 
Male albino rats of the Sprague-Dawley strain (Holtzman Breeders, 
Madison, Wisconsin) weighing 300-400 grams each, were used in these experi-
ments. Males were chosen in order to reduce variability introduced by 
hormonal cycles, which is greater in the female. They were housed in groups 
of six in stainless steel wire mesh cages, 29 x 23 x 23 cm. A uniform 
mixture of Pel-e-cel (absorbant compressed cellulose; Paxton Products, 
Paxton, N. J.) and Litter-green (McFadden Industries, Inc., Kansas City, 
Missouri) was used in trays beneath cages, such that animals had no direct 
contact. 
Male albino mice of the Swiss-Webster strain (Simonson), weighing 
20-35 gm each, were maintained in clear plastic cages, 28.5 x 18 x 13 cm, 
6 -8 per cage . 
Purina Rat Chow pellets and tap water were provided ad libitum. 
The composition of the Rat Chow consisted of approximately 23% protein, 5% 
fat, 4% crude fiber and 6% ash, plus vitamins and minerals (figures provided 
by Ralston Purina Co., St. Louis, Missouri). Feeding, watering and cage 
cleaning were performed at random times of day to prevent these procedures 
from causing an exogenous rhythm. 
B. Animal Housing Conditions 
The rack of animal cages was kept in a quiet, well ventilated, 
windowless room, measuring 2.7 x 3.7 x 4.1 meters. Stable ambient tempera-
ture of 23 ±. l°C,, relative humidity of 25 + 5% and barometric pressure of 
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730-760 nun of mercury were monitored by a Lambrecht KG recorder. 
Animals were adapted to a lighting schedule of 0800-2000 hours 
c.s.T. light and 2000-0800 hours dark, using an automatic 24-hour timer. 
Fluorescent Vita-lites supplied by Duro-Test Corp. (North Bergen, N. J.) 
provided a lighting spectrum approximating daylight. Cages were 5-6 feet 
from the lights, resulting in a radiation intensity of 20-50 µ watt/cm2, as 
measured on a radiant flux meter (12-46 footcandles, using a Gossen Luna-Pro 
light meter). All animals were adapted to these conditions for a minimum of 
three weeks prior to use in experiments. 
During the dark phase, various procedures, such as feeding, drug 
injections, etc., were performed under red light (25 watts, about 750 µ watts/ 
cm2 radiant energy but about 8 footcandles of light). 
C. Experimental Procedures 
1. Measurement of drug-induced sleep. 
The duration of drug-induced sleep was measured as the time 
from the loss (onset) to the recovery of the righting reflex. Recovery is 
defined by Vesell (1968b) as the ability of the animal to place both fore-
feet simultaneously on the ground twice within 15 seconds, when placed on 
its back. According to Vesell (1968a, b) unstimulated animals will sleep 
longer than stimulated ones. In order to standardize stimulation the tails 
of the animals were pinched approximately every three minutes, once they 
began to emerge from deep sleep (as evidencaiby slight movements of their 
limbs). 
The durations of PB-sleep were first determined for the various 
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pretreatments at each of the four times (0600, 1200, 1800, 2400 hours) during 
the 24-hour period. A second set of animals were given the same pretreatment 
dosages and PB at these times, but sacrificed half-way through the previously-
determined sleeping times (t 1/2). Vehicle-treated controls were sacrificed 
at the same time as treated animals. From these results a control curve 
could be established, showing a time course for monoamine changes at the four 
times. The amine content of brain parts from treated animals could then be 
compared with the control curve at the appropriate time. During the dark 
phase, injected animals were maintained under red light or in darkness, and 
removed quickly to an adjacent, dimly-lit room for decapitation. 
2. Drug dosages 
Pentobarbital sodium (PB) was dissolved in 0.9% saline (25 
mg/ml) and administered (50 mg/kg, IP) to control groups which received only 
the vehicle used in pretreatment, and treated groups, which received one of 
the pretreatments described below. Gamma-butyrolactone (GBL), a liquid, was 
diluted with saline, to yield a final GBL concentration of 350 mg/ml in 0.9% 
saline. GBL (350 mg/kg, IP) was administered to controls and pretreated 
animals. In order to examine their effects with respect to the time of day, 
these drugs were administered at six-hour intervals. 
To investigate the role of biogenic amines in drug-induced sleep, 
several pretreatments which alter CNS amine levels, were utilized prior to 
testing for the duration of sleep produced by PB or GBL. Pretreatments in-
clude amine depletors and precursors. Pretreatment drug doses and times of 
administration were chosen to optimize the change in CNS levels of one or 
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more monoamine being studied. These were selected, whenever possible, from 
previously-published reports. 
The DA (and NE) precursor, DL-DOPA, was administered at a dose of 
500 mg/kg, IP (equivalent to 250 mg/kg of L-DOPA, the active isomer), one 
hour prior to the sleep-inducing drug. Because of the low water solubility 
of this high dose, and the desire to use low injection volumes (about 1.0 ml 
or less), the DOPA was suspended in 1% methyl cellulose (250 mg/ml). Pargy-
line, an MAO inhibitor (6 mg/kg, IP, in 0.9% saline) was given 30 minutes 
after DOPA. This treatment primarily elevates DA and NE to a lesser extent 
(Chamber~ al., 1971). The DOPA-pargyline treatment is used to raise and 
maintain the elevated brain amine levels. Alpha methyl £-tyrosine (AMPT, 
200 mg/kg, IP, dissolved in lN NaOH and neutralized with an equal volume of 
lN HCl to produce a fine suspension, 66.67 mg/ml) was administered 4 hours 
prior to· PB or GBL. This amine acid analogue of tyrosine depletes NE stores 
by competing for tyrosine hydroxylase. £-Chlorophenylalanine (pCPA) has been 
shown by several investigators to deplete brain SHT while only decreasing CA 
concentrations slightly (Koe and Weissman, 1965; Mouret et al., 1967). Three 
doses of 100 mg/kg, IP (in 1% methyl cellulose) were administered 72, 48 and 
24 hours prior to the administration of PB. 
A set of experiments were conducted in mice, testing the effect of 
cholinergic drugs on PB-sleep. Neostigmine or physostigmine (0.3 mg/kg, IP) 
were administered 30 minutes prior to PB (SO mg/kg, IP). 
The following table lists the drugs used, summarizes their doses 
and the intervals prior to the administration of PB or GBL. In every 
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instance, the hypnotics were given at six-hour intervals (i.e., 0600, 1200, 
1800 and 2400 hours). The pretreatments were always timed with respect to 
these times. Injections, during the dark phase, were conducted under red 
light. (Some of the drugs used are shown in Fig. S). 
TIME PRIOR TO 
Q.fil!.Q. DOSE (mg/kg) HYPNOTIC INJECTION 
pCPA 3 x 100 72, 48, 24 hours 
L-AMPT 200 4 hours 
DL-DOPA- soo 1 hour 
pargyline 6 30 minutes 
1-Hd 100 1 hour 
soo 1 hour 
1000 1 hour 
L-TP soo 1 hour 
DPH so 1 hour 
DB lS 24 hours 
M 2S (same time) 
so II 
DL-SlITP 100 1 hour 
Neostigmine 0.3 30 minutes 
Physostigmine 0.3 30 minutes 
5MT 20 1 hour 
N-acetyl 5HT 20 1 hour 
5HIAA 20 1 hour 
5MIAA 20 1 hour 
REFERENCE 
Koe and Weissman, 1966 
Hollinger, 1969 
Walker et al., 1971 
Boissier ~al., 1970 
Taylor and Snyder, 
1972 
Taylor and Snyder,1972 
Campcsand Jurupe, 1970 
Moir and Eccleston, 
1969 
Campos and Jurupe,1970 
Boissier et al., 1970 
Medina~ al., 1969 
Barchas et al., 1967 
Proctor~ al., 1964 
Proctor et al., 1964 
p 
Pen to barbital 
12-chlorophenylalanlne 
OCH2CHNH I 2 Cl COOH 
Decaborane ( 8 H ) 10 14 
o<-methyl-p-tyrosine 
0 yOOH CH2y-NH2 HO CH~ 
Diphenhydramlne 
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3. Brain Dissection 
Rats were decapitated by means of a Harvard decapitator. 
The skin covering the skull was incised with a pointed surgical scissors 
and the brain exposed by an incision beginning at the foramenmagnum and 
following the midline suture. The dura was incised ventral surface upward. 
The brain was freed from the skull by severing the cranial nerves and placed 
on a saline-moistened gauze pad which rested on an ice-cold aluminum block. 
using fine curved tweezers, the hypothalamus (Fig. 6 ) was removed by under-
cutting it from the rest of the brain and placed in liquid nitrogen within 
2 minutes after sacrifice. The brain was reoriented to its normal position, 
the cerebral hemispheres separated to expose the caudate nuclei (CN, Fig. 6 ), 
which were removed by undercutting and then placed in the liquid nitrogen 
(-195 8°C). The cerebrum was removed by cutting the cerebral peduncles 
above the stria terminalis. This constitutes the anterior border of the 
tissue designated "midbrain" (MB, Fig. 6 ) . The posterior limit was cut 
from the top of the pons on the ventral side to the bottom of the inferior 
colliculi on the dorsal side. The tissue was then placed in liquid nitrogen. 
Midbrain includes the thalamus and subthalamus, as well as the subcollicular 
tissue. The cerebellum was removed from the remaining brain. The region 
designated as "stem" (lower brain stem) (Fig. 6 ) was obtained by cutting 
posteriorly at the decussation of the pyramidal tracts (sulcus medianus 
dorsalis). This tissue was placed in liquid nitrogen in less than 5 minutes 
after sacrifice. The tissues were maintained in liquid nitrogen for several 
minutes to insure complete freezing. The brain parts were then sealed in 
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Hypothalamus 
DORSAL VENTRAL 
Mid brain 
.., Brain stem 
Figure 6: Brain Dissection 
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parafilm) labelled and stored in the deep freezer (-25°C.) until they were 
analysed for amines (vide infra). 
The reasons for selecting brain areas instead of utilizing the whole 
brain for analyses are as follows: It has become increasingly clear that 
analysis of the amines of the whole brain results in a "homogenizing" of 
important differences among various brain areas) which have unique anatomi-
cal, physiological and neurochemical characteristics. The hypothalamus 
(Hpth), a center for autonomic function, has high concentrations of NE and 
lesser amounts of 5HT. It contains a number of nuclei which send fibers out 
to other areas of the brain and peripheral nervous system. The MB lies above 
the Hpth and is often combined with it for amine analysis. The MB contains 
moderate amounts of NE and lesser amounts of 5HT. It includes NE-containing 
areas and the head of the 5HT-containing raphe system, which are involved in 
the control of sleep. The MB includes the superior and inferior colliculi 
which are involved in visual and auditory reflexes, respectively, processes 
that are modulated during sleep. The brain stem, caudal to the MB, contains 
the NE-containing locus coeruleus, as well as the main portion of the raphe 
system. The CN is important because it is part of the basal ganglia, which 
is involved with motor control. The CN has very high concentrations of DA 
and high ACh concentrations and high AChE activity. 
4. Brain Amine Analysis 
Monoamine levels in the CNS were determined fluorometrically 
using slight modifications of the method of Shellenberger and Gordon (1971). 
The basis of this and similar methods (Chang, 1964; Ansell and Beeson, 1968) 
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is the adsorption of catecholamines on alumina (batch technique) and the 
removal of serotonin from the remaining supernatant by organic extraction. 
An acid eluate of the alumina is buffered to neutral pH and oxidized for form 
a fluorescent trihydroxyindole derivative. Serotonin is determined by reaction 
with ninhydrin in a pH 7.0 buffer to form the fluorescent compound. 
a. Reagents: 
1. 0.4 N perchloric acid: to 56.8 ml of 70.8% solution 
per liter of distilled water, add 1.0 gm sodium metabisulfite (Na2S304) and 
0.5 gm disodium EDTA per liter. 
2. Tricine solution: 17.9 gm Tricine (N-tris(hydrocy-
methyl) methylglycine) and 25 gm disodium EDTA in each liter of 0.52SN NaOH 
(42 ml per liter of distilled water of a SOio NaOH solution, 12.S N. 
3. 0.5 M borate buffer, pH 10.0: 30.92 gm per liter of 
distilled water of boric acid (results in pH of about 3.4) then adjusted to 
pH 10 with NaOH pellets and saturated with NaCl and ~-heptanol (about 1 ml). 
4. 0.05 M phosphate buffer, pH 7.0: 3.11 gm HaHzP04 · 
H20 and .34 gm Na2HP04 per liter distilled water. 
5. Phosphate buffer - EDTA solution: Add 9.0 gm disodium 
EDTA to 1.0 liter of 0.1 M phosphate buffer (4.27 gm NazHP04 and 9.52 gm KHz 
Po4 per liter distilled water) and adjust to pH 7.0 with 5.0 N NaOH (made 
from 50% NaOH) . 
6. 0.1 N iodine reagent: 4.0 gm KI and 1.0 gm iodine 
are dissolved in distilled water and~ to a final volume of 80 ml. 
7. Alkaline sodium sulfite: Dilute 1.0 ml (250 mg/ml 
in distilled water), sodJum sulfite (kept in freezer until used), to 10 ml 
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with 5.0 N NaOH 
8. 0.1 M ninhydrin: 445.4 mg ninhydrine dissolved in 
25 ml distilled water (the ninhydrin solution is stored in the freezer). 
b. Amine Separation 
At the time of analysis individual brain parts are weighed 
on a Roller-Smith torsion balance (Model LG) and placed in 3 mls of cold 0.4 N 
perchloric acid contained in Kontes Duall tissue grinder tubes (size 22) and 
maintained in crushed ice (see Fig. 7 ). The tissues are then homogenized 
using a· motor-driven Teflon pestle (Kontes). After homogenization the tubes 
are kept in ice for about 10 minutes and then centrifuged for 10 min. at 
maximum speed (2200 rpm or 1000 g) on an IEC Model K centrifuge (radius head, 
7.5 inches). The supernatant was removed and placed in 35 ml Wilkens-Anderson 
reaction vessels. The pellets were rehomogenized in 2.5 ml of 0.4 N per-
chloric acid, centrifuged and the second supernatants added to the first. 
Standard tubes were prepared at this point utilizing high and low concen-
trations of each standard in 5.5 ml of 0.4 N perchloric acid. Perchloric 
acid alone served as a reagent blank. 
The pH of each supernatant is then adjusted to 7.8 ±. 0.2 (usually 
7.8 - 7.9) with Tricine buffer, using a Beckman fine tip combination elect-
rode calibrated to pH 8.0 with standard buffer on a Beckman Model 72 pH meter. 
To this supernatant about 300 mg of activated alumina was added. The alumina 
(aluminum oxide, Woelm) was prepared by washing several hundred grams in tap 
water overnight in a Hurricane Photo Washer. In this device water enters 
from the bottom and agitates the alumina constantly so that the fine parti-
cles are washed away. The remaining alumina was washed in boiling HCl 
Ill"'" 
Figure 7: Amine analysis flowsheet 
TISSUE 
homogenized in 
3.0 and 2.5ml of 
0.4N perchoric acid 
adjust to pH 7.8 with TRIGINE 
SHAKE WITH 300mg ALUMINA, centrifuge 
ALUMINA(CAs) ------- ------ Supn(5HT) 
1) wash with distilled ~O 
2) elute with 0.05N perchloric 
acid, take l.Oml aliquots 
3) ADD l.5ml phospbate buffer, pH 7.0 
+ 
0.2ml iodine , wait 2 min. 
+ 
0.5ml alkaline sulfite 
+ 
0.4ml glacial acetic acid 
4) HEAT 2 min.@ 95°c., then 
cool in ice bath 
5) READ NE, 380nmA, 495nm E 
6) reheat for 10 min. 
7) cool, wait 30 min. 
READ DA, 325nm A~ 380nm E 
1) NaCl saturate, add 15.0ml heptanol 
2) adjust to pH 9.8 with K2co3 
3) vortex mix 1-1 0 5 min., centrifuge 
4) aspirate aqueous phase 
5) wash heptanol with pH 10 borate buffer, 
centrifuge 
6) transfer 13.5ml heptanol 
ADD 2.5ml phosphate buffer, pH 7.0 
7) SHAKE, centrifuge 
8) aspirate heptanol 
9) to l.Oml aliquots, 
ADD O.lml ninhydrin 
HEAT 25 min. @ l00°c., cool 1 hour 
10) READ 5HT, 385nm A, 190nm E 
-~ 
~ 
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(Anton and Sayre, 1962), then in distilled water until the pH of the water 
reached 3.4. It was dried in batches in a large watch glass under a General 
Electric infrared heat lamp and stored in sealed polyethylene (Nalgene) 
bottles in a dessicator. 
The reaction vessels were then shaken by hand and a horizontal shaker 
for a total of 20 min. to suspend all the alumina, and centrifuged for 5 min. 
at 1000 r.p.m. (200 g). The supernatants were transferred to another set of 
reaction vessels for the 5 lIT analysis. The alumina was washed twice with 
20 mls deionized, distilled water, pH 7.0 (distilled water from the tap 
passed through Barnstead mixed resin cartridge, D5041). Most of the first 
wash was aspirated. After the second wash the alumina was centrifuged at 
1000 r.p.m. for 5 min., and the wash aspirated carefully and completely. The 
washed alumina was stored during the isolation of 5IIT in the refrigerator 
(4°C.), until the catecholamines were eluted for analysis. To the superna-
tant from the alumina, containing the 5IIT about 3 gms of NaCl was added and 
shaken to assure salt and saturation. 15 ml of ~-heptanol (redistilled from 
Eastman 381) to remove impurities which cause high blanks and lower recoveries) 
was added to the salt-saturated solutions. (Vacuum distillation of the 
heptanol is necessary if SIIT recoveries from heptanol are low, because of 
interfering impurities.) To extract the SIIT from the aqueous to the organic 
phase, the solutions were adjusted to pH 9.8 + 0.4 using about 300 mg 
K2co3 (0.3 ml of a 1 gm per ml distilled water solution). Immediately after 
addition of the K2co3 each vessel was shaken to avoid SIIT loss resulting from 
localized regions in the solution of high pH. All reaction vessels are mixed 
on a vortex mixer for 3-5 min., then centrifuged at 1000 r.p.m. Using a 
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water-vacuum aspirator with a Pasteur pipette on the end and a small hole in 
the tubing just above the top of the pipette, the tip of the pipette is 
plunged quickly through the upper heptanol layer into the aqueous phase, the 
crystals of NaCl and K2co3 gently dislodged and the bottom layer aspirated by 
covering the hole in the tubing with the index finger. With care and practice 
this can be done with very little loss of heptanol. The heptanol layer was 
then washed twice with 50 ml of pH 10 borate buffer, vortex mixed for 60-90 
seconds, and centrifuged at 1000 r.p.m. for 5 min. The borate buffer layer 
could be removed by aspiration as described above or directly by careful 
pipetting (in either case without any borate contamination) 13.5 ml of the 
upper heptanol layer and placing it in a clean reaction vessel. 2.5 ml of 
0.05 M phosphate buffer, pH 7.0, was added to the 13.5 ml of heptanol and the 
vessels were vortex mixed for 40-60 seconds, centrifuged at 1000 r.p.m. for 
5 min and the heptanol aspirated (using a vacuum flask to save it for dis-
tillation and reuse). 1.0 ml samples of the phosphate buffer are removed for 
SHT analysis, taking care to exclude heptanol, which interferes with the 
fluorescence after the ninhydrin reaction. 
c. Estimation of the amines: 
To 1.0 ml of the phosphate buffer placed in Corning dis-
posable culture tubes, 0.1 ml of 0.1 M ninhydrin reagent was added and heated 
in an oven at 100°C. for 25 min. after removal before reading the fluorescence 
in an Aminco-Bowman SPF. The samples are left at room temperature for 1 hour. 
An activation peak of 385 nm and emission peak of 490 nm (uncorrected) are 
~sed. For tissues blanks duplicate 1.0 ml samples of the phosphate buffer 
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aliquots, heated and cooled without ninhydrin, are read immediately after 
adding 0.1 ml ninhydrin reagent. 
3.0 ml of 0.05 N perchloric acid was added to the washed alumina, 
vortex and hand shaken for about 5 min to elute the catecholamines, then 
centrifuged for 5 min at 1000 r.p.m. 1.0 ml aliquots of the perchloric acid 
eluate are placed in disposable test tubes and brought to pH 6.5 + 0.2 with 
1.5 ml of 0.1 M phosphate-buffer-EDTA. 0.2 ml of 0.1 N iodine reagent are 
added to each tube, shaken immediately and exactly 2 min later 0.5 ml of the 
alkaline sulfite are added and shaken. After 2 min the samples are acidified 
to pH 4.4 - 4.8 with 0.4 ml of glacial acetic acid. Duplicate 1.0 ml ali-
quotes for tissue blanks are developed by adding the alkaline sulfite first, 
then the iodine and acetic acid. The tubes were heated in a water bath 
(95 - 100°C.) for 2 min, cooled in ice water for 3-5 min, then NE fluorescence 
read at room temperature (activation peak at 380 nm, emission peak at 495 nm, 
uncorrected). After reading for NE, the tubes were returned to the water 
bath and heated for 10 min to develop the DA fluorophore, then removed and 
transferred to an ice bath for cooling. The fluorescence produced in this 
manner is stable indefinitely as long as the samples are kept at 4°C but will 
decline 15-20% after 30 min at room temperature before becoming stable indefi-
nately. The DA fluorescence is read after 30 min or the next day at an 
activation peak of 325 nm and emission peak of 380 nm (uncorrected). 
Tissue content of amines is calculated to give µg/mg tissue weight, 
after correcting for tissue blank readings, by comparison with standards 
extracted through the procedure. After correcting standards and samples for 
the blanks, the fluorescence units of the standards are plotted on the Y-axis 
versus the concentration on the x-axis. 
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The corrected fluorescence units for the samples are used with the standard 
plots to detennine the tissue concentration of each amine. Results are 
expressed in terms of µgm/gm wet tissue weight by multiplying the tissue 
content times the tissue factor (1.0 divided by the tissue weight in grams). 
All drugs utilized in these studies were extracted through the amine 
procedure, to check for possible interference with the amines themselves. 
The only drug found to produce interference was DOPA, which interfered with 
the DA analysis. To remove the DOPA, the CAs were eluted with two 2 ml ali-
quots of 0.05 N perchloric acid, adjusted to pH 6.5 with tricine buffer and 
applied to pH 6.5 buffered AG 50 W-X4 resin colunms (Glisson et al., 1972). 
NE and DA are adsorbed, while DOPA is not. NE and DA were eluted with 12 mls 
of 1 N HCl, the pH readjusted and processed in the usual manner. 
5. Fluorometry Utilizing the Aminco-Bowman Spectrophotofluoro-
meter 
Detenninations of tissue amine levels by fluorescent methods 
were performed on an roninco-Bowman Spectrophotofluorometer (SPF) with th~ 
off-axis attachment and transistorized photomultiplier microphotometer with 
a RCA 1P21 photomultiplier tube. After the xenon lamp has warmed up for 
about thirty minutes, the photomultiplier is switched on, and its voltage 
set at· 800 volts. The microphotometer is then adjusted to zero. Before each 
reading session the lamp is adjusted to peak response (greatest sensitivity) 
against a quinine sulfate standard (2.5 µg/ml in 0.1 N sulfuric acid) using 
an activation wavelength of 250 nm and emission at 350 nm (uncorrected). In 
this case, as with other standards, the wavelengths cited are uncorrected and 
for each reading session activation and emission wavelengths must be deter-
l 
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mined precisely by "peaking" them with the respective standards (usually 
within 5-10 nm of the "uncorrected" wavelengths cited). Reading the quinine 
standard first provides a day-to-day check on the sensitivity of the total 
SPF system. If the reading has dropped off, the lamp position is adjusted 
to restore readings to previous levels. If the reading cannot be restored 
by these procedures, it indicates that the mirrors might require cleaning 
or that the lamp is failing. 
The low concentration internal standard was usually set at 40 on the 
microphotometer scale, the other standards read and tissue samples compared 
with the standard curve established, plotting concentration (x-axis) versus 
corrected fluorescence units (y-axis). 
6. Rectal Temperature 
Rectal temperature was measured in rats using a Yellow Springs 
Telethermometer, with a rectal temperature probe (No. 401). The probe was 
lubricated wi~h the light mineral oil and inserted approximately 7 cm into 
the colon, for 1.5 - 2.0 minutes before the temperature was recorded. 
In control and treated animals, rectal temperatures were obtained 
every 15-20 minutes. Temperature was plotted on the y-axis, versus time on 
the x-axis. In order to compare the temperature pattern of controls and 
treated animals, the intercepts of the plots for individual animals were noted 
at ten-minute intervals (i.e., 5, 15, 25, 35 minutes, etc.) and the means at 
each time determined and replotted to represent an average pattern for con-
trol and treated animals. This permits comparison of differences between 
control and treated groups, as well as between different times of day. 
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7 0 Statistical analyses 
a. Calculation of mean, standard deviation and standard error 
of the mean 
The calculation of the arithmetic mean (X), the standard 
deviation (S.D.) and the standard error of the mean (s.E.) were computed on a 
Smith-Corona Cogito 1016PR calculator utilizing the tape input (Iota 1) to 
enter prerecorded programso The program provided by Smith-Corona (Statistics 
1001) uses the following formulas: 
x = "2!.x/N 
S.D. = J(X - XJN) 
N - 1 
where X individual values 
N total number of X values 
As the program is written, after all entries have been made, the calculator 
prints out values corresponding to the following: 
N, x, x2, X, S.D. and S.E. 
b. Calculation of t and determination of Py the degree of 
significance 
The unpaired t-test utilized, computed t as follows: 
t 
x1 - x2 
(Ni-l)(S.D. 1) + (N2-l)(S.D. 2 ) ) (ki' kJ 
(N1-l) + (N2-l) 
I 
I \ 
I 
! 
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The output from the program gives the value of t for a comparison between the 
two groups, when the group size(N), mean(X) and the standard deviation(S.D.) 
for each group are entered. The P value corresponding to the t calculated is 
found in a table of the signi1icance limits of the Student i-test distribution, 
using the appropriate degrees of freedom. The P values obtained are expressed 
as being less than a degree of confidence (per cent probability), read on the 
2P scale. A value of P less than 0.05 (95% confidence limit) was used as the 
criterion for significant differences between groups. 
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IV. RESULTS 
A. Duration of Hypnotic Sleep on a 24-Hour Basis 
1. Pentobarbital 
The duration of sleep produced by PB (50 mg/kg, IP) was examined by 
two procedures. Initially it was administered to untreated groups of rats at 
0600, 1200, 1800 and 2400 hours and the duration of PB-induced sleep determined 
(Table 1, Fig. 8). The duration of sleep with PB alone is maximal at 1200 hours 
and minimal at 2400 hours. The difference between the peak and trough are 
significant at the P < .01 level. The peak value also differs significantly 
from that at 1800 hours (P < .01). The results at 1800 and 2400 hours do 
not differ significantly from each other. There is no significant difference 
when results at 0600 hours are compared with the other times. However, the 
difference between 0600 and 2400 hours has borderline significance (P < 0.1, 
>0.05). 
A second pattern for PB-sleep was obtained by the administration of 
PB together with the pretreatment vehicle, at the same time that the drug 
treated group received their drug doses. This vehicle-treated group con-
stituted the "CONTROL" group, for comparison with the treated groups. 
Several controls were rw1 with each treated group. They were pooled with 
other similar controls to obtain the control values at the four times in the 
24-hour period. As seen in Fig. 8, this pattern does not exhibit the sharp 
peak and trough seen with the PB-alone. However, because of the large number 
of animals used for this pooled control, significant differences were 
Table 1: The duration of pentobarbital sleep 
Pentobarbital 
(alone) 
Pentobarbital 
(pooled) 
0600 
10408+18.6 (5) 
115.5+11. 7 
(18) 
1200 
115.6+17.8 (5) 
119.5+ 9. 7 
(17) 
1800 
87.3+ 8.1 
(6) 
109.3+1401 
(17) 
2400 
86.7+ 809 D E+ 
(6) 
101.3+ 809 Cd E+ 
(16) 
Table indicates the duration of drug-induced sleep, in minutes, for animals receiving PB alone 
and the pooled controls receiving the vehicles used in the drug pretreatment studies. Sleeping times 
are means ~standard deviation, with the number of animals used in parantheseso 
+Letter designations indicate point to point comparisons within each 24-hour patterns as follows: 
aA (0600 vs 1200 hours), bB (0600 vs 1800 hours), cC (0600 vs 2400 hours), dD (1200 vs 1800 hours), 
eE (1200 vs 2400 hours) and fF (1800 vs 2400 hours). Lower case indicates P <0.05 and capitals indicate 
P < 0 0 01 for sj gnificant differences. 
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Figure 8: Pentobarbital-Induced Sleep 
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obtained at 0600 and 2400 hours (P < .001), 1200 vs 1800 hours (P < .02 and 
1200 vs 2400 hours (P < .001). 
--------
The results obtained by both procedures corrobate earlier studies 
demonstrating a peak duration of drug-induced sleep during the light period 
and a trough during the dark period. 
2. Ganuna-butyrolactone 
The effect of administration of GBL (350 mg/kg, IP) at six-hour in-
tervals can be seen in Fig. 9,(Table 9, GBL (alone) and GBL (pooled)). The 
duration of sleep with GBL (alone) was longest during the light phase, at 
1800 hours and differs significantly from the trough at 0600 hours at the 
0.05 level. The peak also differs significantly from the adjacent measure-
ments (1200 and 2400 hours) with P < 0.05. The sleep pattern of saline in-
jected (GBL (pooled) animals (vide infra) differed quantitatively but not 
qualitatively from GBL (alone). 
B. Effects of Drug Pretreatment on Pentobarbital Sleep Duration 
1. Drugs Affecting the NE and DA Systems 
a. DOPA-pargyline 
DOPA-pargyline pretreatment (500 and 6 mg/kg, IP, respectively) 
very significantly prolongs the duration of PB-sleep over controls at all 
times tested, with P < 0.001. (Figs. 10 - 12, Table 3). Although these in-
creases over respective controls ranged from 103% at 0600 to 146.3% at 2400 
hours, the pattern must be considered flat from a statistical examination 
since there are no significant increases in sleep duration between any of 
the DOPA-pargyline-treated groups, during the 24-hour period. 
.........-~ 
- ;, 
Table 2: The duration of gamma-butyrolactone sleep 
0600 1200 1800 2400 
GBL (alone) 68 0 2+9 0 3 (5) 
79 0 3+6 0 7 (3) 
110.3+16.3 
(4) 
77 .0+11.2 (5) 
B d F+ 
GBL (pooled) 911 0 0+3 0 6 (6) 110 0 1+4.5 (8) 
96 0 4+16 0 2 
(11) 
88.3+10.0 (7) 
A c d E+ 
Table indicates the duration of drug-induced sleep, in minutesj for animals receiving GBL (350mg/ 
kg) alone and the pooled controls also receiving the vehicle used in the drug pretreatment study. 
Sleeping times are means ~ standard deviation 1 with the number of animals used in parentheses. 
+For explanation of letter designations see Table 1. 
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Table 3: The duration of pentobarbital-sleep after pretreatment with drugs affecting the NE and DA 
systems 
Treatment 
CONTROL 
DOPA+ 
pargyline 
AMPT 
0600 
115.5+11. 7 
(18) 
234.5+37.9** 
(5) 
112.8+13.5 
(6) 
1200 
119.5+ 9. 7 
(17) 
245.5+22.8** 
(4) 
143.1+23.7* 
(4) 
1800 
109.3+14. l 
(17) 
237 .3+14. l** (5) 
106~8+ 7.0 
(3) 
2400 
101.3+ 8.9 Cd E+ 
(16) 
249.6+22.8** 
(5) 
177.3+14.5** Ce y+ 
(~ 
Table indicates the duration of drug-induced sleep, in minutes, for animals receiving the pre-
treatments plus PB (50mg/kg~ IP). Sleeping times are means±. standard deviationJ with the number of 
animals used in parentheses. Significant differences from controls are indicated by* (P<0.05) and 
** (P<0.01). 
+For explanation of letter designations see Table 1. 
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Figure 12: Circadian pattern of pentobarbital-induced sleep after pretreat-
ment with druga affecting the NE and DA systems. (Open cire les 
indicate significant differences from CONTROL, P<0.05 or gr~ater; 
for explanation of letter designations see Table 1). 
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b. Alpha-methyl p-tyrosine 
The effects of pretreatment with AMPl' (200 mg/kg, IP) are more 
complex (Figs. 10-12, Table 3 ). A biphasic pattern is obtained, with peaks 
at 1200 and 2400 hours. There is no significant difference in the duration 
of sleep between control and AMPT-treated animals at 0600 and 1800 hours. 
However, there are significant increases in sleep duration over controls 
at the two peaks, viz. at 1200 (19.8% increase) and 2400 hours (75.0% in-
crease), at the 0.05 and 0.001 level, respectively. There are also signifi-
cant differences in sleep duration of AMPT-treated animals, when the following 
comparisons are made: 0600 vs 2400 hours (P < 0.001); 1200 vs 2400 hours 
(P < 0.05) and 1800 vs 2400 hours (P < 0.005). 
2. Drugs Affecting the 5HT System 
a. p-Chlorophenylalanine 
pCPA, a 5HT depleton, very significantly prolongs PB-sleep at 
each point in the 24-hour pattern (P < 0.001 level; Figs. 13-17, Table 4 ). 
The increases over control are as follows: 0600 (19.5%), 1200 (34.4%), 
1800 (49.8%) and 2400 hours (45.9%). The pattern is diurnal, peaking at 
1200 to 1800 hours (Fig. 17 ). The duration of sleep differed significantly 
between 0600 and 1200 hours (P < 0.05) and between 0600 and 1800 hours 
(P < 0.005) but not between other time points. 
b. Tryptophan 
TP, of secondary precursor of 5HT, significantly increased 
PB-sleep over control at each point in the curve (P < 0.001 (Figs. 13-17, 
Table 4 ), as follows: 43.4% (0600), 32.3% (1200), 59.1% (1800)and 
• 
Table 4: The duration of pentobarbital-sleep after pretreatment with drugs affecting the 5HT system 
0600 1200 1800 2400 
Treatment 
CONTROL 115.5+ll. 7 ll9.5+ 9. 7 109~3+14.l 101.3+ 8.9 Cd E+ 
(18) (17) (17) (16) 
pCPA 137.9+12.7** 161.1+17 .3** 163.7+ 8.6** 147.9+24.5** a··B+ (6) (i) (5) (5) 
TP 165.6+15.5** 158.0+22.l** 173.8+ 7.3** 154.0+16.6** f+ 
(9) (6) (6) (5) 
5HTP 131.3+16.3 144.0+15.4** 104.3+ 5.5 146.3+21. l** n+ 
(3) (6) (3) (3) 
M25 ll4.6+22.2 155.8+ 6.6** 131.2+10.3* 125.2+ 9.3** A D E+ 
(4) (4) (4) (5) 
M50 192.3+32.0** 157.3+13.0** 141.5+15.4** 159.8+24.,l** b+ (3) (4) (5) (4) 
Table indicates the duration of drug-induced sleep, in minutes, for animals receiving the pre-
treatments plus PB (50mg/kg, IP). Sleeping times are means ~standard deviation, with the number of 
animals used in parentheses. Significant differences from controls are indicated by* (P<0.05) and 
** (P < 0 0 01). 
+i<'or explanation of letter designations see Table 1 0 
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52.0% (2400). The pattern was relatively flat. The only significant 
variation in the duration of sleep was the decrease from the 1800 hour 
value at 2400 hours (P<0.05). 
c. 5-Hydroxytryptophan 
172 
5HTP, the primary precursor of 5HT, produced a relatively 
flat pattern in PB-sleep duration (Figs. 13-17, Table 4). Significant 
differences from control occurred at 1200 and 2400 hours (in each case, P 
< 0.001), while the difference between the sleep duration at 0600 hours 
and controls was approximately P<0,05. The increases over control were 20.5% 
at 1200 hours, 34.7% at 2400 hours and 13.7% at 0600 hours. The only sig-
nificant differences among treated groups was between the 1200 and 1800 
hour groups (FC0.01). 
d. Melatonin 
Melatonin, (M), which was administered at two dose levels(25 
and 50 mg/kg, IP), yielded qualitatively and quantitatively different results 
for each dose (Figs.13-17, Table 4). Both increase PB-sleep at every time 
point (except for the 25mg/kg (M25) dose at 0600 hours). Melatonin-modi-
fied sleep at a dose of 25mg/kg peaks at 1200 hours during the light period, 
while at the higher dose (50mg/kg, M50) the curve is shifted to peak at 
0600 hours, during the dark period. The M25 dose significantly increases 
PB-sleep duration over controls at 1200 hours (P<0.001; 30.4%), 1800 hours 
(P<0.05; 20.0%) and 2400 hours (P<0.001; 23.6%). At this dose signifiurnt 
differences occur between treated groups for 0600 vs, 1200 hours (P<O" OG), 
1200 vs. 1800 hours (P<0.05) and 1200 vs. 2400 hours (P<0.001). At the 
M50 dose, the PB-sleep duration for all treated groups is significantly 
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greater than their respective controls (F(0.001). It ranges from 29.5% at 
1800 hours to 66.6% at~ hours. In a comparison of M25 with M50 treatment 
the only significant difference occurs between the 0600 and 1800 hours groups 
(P<0.05). 
e. Compounds Structurally- related to 5HT 
The effects of several compounds structurally related to 5HT 
were tested in mice for their ability to enhance PB-sleep at a single time 
point (1500 hours) during their normally-quiescent period. The compounds 
were administered one hour prior to PB, at a dose of 20mg/kg ( in 1% methyl 
cellulose). Table 5 shows significant increases in PB-sleep is produced by 
5-methoxytryptamine (P<0.02; 74.6%) and N-acetyl 5HT (P<0,025; 105.4%), 
a precursor of M. 5HIAA and 5-methoxy indoleacetic acid are without signi-
ficant effects. 
3. Drugs Affecting the Histamine System 
The possible role of CNS histamine (H) in PB-induced sleep was ex-
amined utilizing its precursor, histidine (Hd), a depletor, decaborane(DB) 
and an antihistamine, diphenhydramine (DPH). 
a. L-His tid ine 
Three doses of L-Hd, were administered to rats. The lowest doae 
(100 mg/kg, HdlOO) significantly increases PB-sleep over controls at 0600 
hours (P<0.05; 15.6%), 1200 hours (P<0.001; 22.0%) and 2400 hours (K0.05; 
21.2%) (Figs.18-22, Table 6). The only significant difference between 
treated groups is betwHn the 1200 and 1800 hours groups (P<0.05) . The 
intermediate Hd dose (500mg/kg, Hd 500) increases PB-sleep significantly 
over controls at 1800 hours (P<0.001; 47.6%), but decreases PB-sleep 
r 
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Table 5: The effects of compounds structura Hy-related to 5HT on pentobar-
bital-sleep, in mice, 
Compound PB-sleep duration 
CONTROL 31. 9+5. 1 (7) 
5MT 55.6+12.4 (8)* 
N-acetyl 5HT 65.4+11, 7 (7)* 
5HIAA 40.5+13,3 (8) 
5MIAA 40.5+10.4 (8) 
Table indicates the duration of drug-induced sleep, in minutes, for 
animals receiving the pretreatment plus PB (50mg/kg, IP) at 1500 hours only. 
Sleeping times are means.:!: standard deviation, with the number of animals 
used in parentheses. Significant differences from controls are indicated by 
Table 6: The duration of pentobarbital-sleep after pretreatment with drugs affecting the histamine 
system 
.QiQQ !&QQ 1800 2400 
Treatment 
CONTROL 115.5+11. 7 119.5+ 9.7 109.3+14.l 101~3+ 8.9 C t't E+ 
(18) (17) (17) (16) 
HdlOO 133.5+12.2* 145.8+ 9.7** 124 0 0+11.0 122.8+18.7* d+ (4) (4) (3) (5) 
122.3+14.0 131.8+25.9 161.3+27.6** 87.8+ 9.3* + Hd500 c e F 
(3) (4) (3) (4) 
HdlOOO 152.3+ 3.5** 142.3+34.7* 168.4+19.2** 114.6+20.6* c F+ 
(3) (4) (5) (5) 
DB 196.0+35.6** 202.0+59.5** 213.5+27.9** 217.7+52.4** 
(6) (6) (4) (6) 
DPH 289.8+38.7** 230.3+12.4** 177 .8+54.1** 281.8+60.4** a b f+ (4) (4) (4) (4) 
Table indicates the duration of drug-induced sleep, in minutes, for animals receiving the pre-
treatments plus PB (50mg/kg, IP). Sleeping times are means.±. standard deviation, with the number of 
animals used in parentheses. Significant differences from controls are indicated by* (P<0.05) and 
** (P ( 0 0 01) 0 +:For explanation of letter designations see Table 1. 
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significantly at 2400 hours (P < 0.05; 13.4%). The trough value for this 
treatment occurs at 2400 hours and differs significantly (P < 0.05) from the 
values at 0600, 1200 and 1800 hours. The highest dose of Hd (1000 mg/kg, 
\ Hd 1000) produces a similar pattern, exhibiting a peak duration of PB-sleep 
at 1800 hours and a trough at 2400 hours. PB-sleep duration increases signi-
ficantly over controls at 0600 hours (P < 0.001; 31.9%), 1200 hours (P < 0.05; 
19.1%), 1800 hours (P < 0.001; 54.1%) and 2400 hours (P < 0.05; 13.1%). The 
trough value at 2400 hours differs significantly from the peak value at 1800 
hours (P < 0.05) and from the value at 0600 hours (P < 0.05). Differences 
observed between the dosage groups at a given time are as follows: at 0600, 
the difference in the duration of PB-sleep between the HdlOO and HdSOO groups 
is not significant, but the difference between the Hd 1000 value and that for 
Hd 500 is significant (P < 0.025) and borderline for the Hd 100 dose. There 
are no significant differences between the doses at 1200 hours. At 1800 hours 
there is a significant difference in sleep duration between the Hd 100 and Hd 
1000 groups (P < 0. OS). The Hd 500 value at 2400 hours differs significantly 
(P < 0.05) from the other two groups. 
b. Decaborane 
Pretreatment with DB very significantly prolongs PB-sleep over 
controls at each point tested (P < 0.001; Figs. 18-22, Table 6 ). The 
increases over controls were as follows: 0600 hours (69.8%), 1200 hours 
(69.1%), 1800 hours (95.4%) and 2400 hours (114.8%). The pattern doe~ not 
exhibit a significant diurnal variation. No significant differences in 
sleep duration occur between the treated groups at the times tested. 
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c. Diphenhydramine 
DPH significantly increases PB-sleep at each experimental time 
point (P < 0.001; Figs. 18-22 , Table 6 ). The increases over control are 
as follows: 0600 hours (151.0%), 1200 hours (92.7%), 1800 hours (62.7%) and 
2400 hours (178.1%). The pattern is circadian, with a peak at 2400-0600 
hours and a trough at 1800 hours. The differences in PB-sleep duration at 
the peak (2400-0600 hours) and the trough are significant (P < 0.05). 
4. Drugs Affecting the Cholinergic System 
The effect in mice of physostigmine (0.3 mg/kg, IP) and neostigmine 
(0.3 mg/kg, IP) tertiary and quaternary anticholinesterases, respectively, 
on hypnosis induced by PB (SO mg/kg, IP) was examined. The pattern for saline 
pretreated is relatively flat and the controls do not exhibit significant 
dirunal fluctuations, (Fig. 23 ) although there appears to be a peak at 1800 
hours and a trough at 2400 hours. 
With physostigmine the only significant increase over controls occurs 
at 2400 hours (P < 0.05; 71.8%; Fig. 23 Table 7 ) . There are no significant 
differences between each of the physostigmine-treated groups. Neostigmine 
pretreatment produces significant increases in sleep duration at each ex-
perimental time point. The following increases were noted: 0600 hours 
(105.2%; P < 0.001), 1200 hours (67 .6%; P < 0.01), 1800 hours (57 .8/0 ; P < 
0.06) and ~hours (101.8%; P < 0.02). 
Table 7: The duration of pentobarbital-sleep after pretreatment with two cholinesterase inhibitors, 
in mice 
0600 1200 1800 2400 
Treatment 
CONTRDL 36.3+22.2 36.5+22.5 41.7+26.0 26.3+18.3 
(12) (11) (9) (11) 
Neostigmine 61.1+ 8.2** 65.8+19.8 53.0+23.4* c+ (9) (8) (8) 74.4+17. l** (9) 
Physostigmine 41.0+28.l 55.2+19. 7 45.1+18.2* 
(ll) (10) (9) 
44.7+30.5 
(Io) 
Table indicates the duration of drug-induced sleep, in minutes, for mice receiving the pretreat-
ments plus PB (50mg/kg, IP). Sleeping times are means :!:. standard deviation, with the number of 
animals used in parentheses. Significant differences from controls are indicated by *(P(0.05) and 
** (P<0.01). 
+.For explanation of letter designations see Table 1. 
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Figure 23: Pentobarbital-induced sleep after pretreatment with two anti-
cholinesterases. (Open circles indicate significant differences 
from CONTROL, P<0.05 or greater; for explanation of letter desig-
nations see Table 1). 
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C. Effects of Histidine Pretreatment on GBL Sleep Duration 
Pretreatment of rats with Hd (100 and 500mg/kg, IP) one hour 
prior to GBL (350mg/kg, IP) resulted in only one significant difference in 
GBL-sleep duration over saline-treated controls. It occurred at 1800 hours 
for the Hd500 (29.7%, P 0,05; Table 8). 
D. CNS Amines at t ! Following Pretreatment and PB Regimens 
1. Time-course for Amine levels in Controls 
Vehicle-treated controls were sacrificed at approximately the same 
time as tre ted animals (i.e., t ! or half-way through the previously-
determined sleep duration for each pretreatment drug) and the brain amine 
concentrations determined at the four experimental times during the 24-hour 
period. The time-course of amine concentrations are plotted for each of the 
four experimental times (Figs24-27). The X-axis represents the time after 
the induction of PB-sleep. The times plotted on the X-axis depend on the 
t t time at which each pretreatment group (control and treated) was sacri-
ficed. The Y-axis represents the amine concentrations (ugm/gm wet tissue 
weight)o 
........---~~~~~~~~-
Table 8: The duration of gannna-butyrolactone-sleep after pretreatment with histidine 
0600 1200 1800 2400 
Treatment 
CONTROL 98.0+ 3.6 llO. l+ 4.5 96.4+16.2 88.3+10.0 A c d E+ (6) (8) (11) CD 
HdlOO 91.9+1 .9 108.7+ 1~5 100.1+15.l 91.5+15.6 
(4) (3) (4) (4) 
Hd500 98.3+ 9.5 103.1+13.l 125.0+ 5.7* 93.8+ 4.0 b F+ (4) (8} (2) (6) 
Table indicates the duration of drug-induced sleep, in minutes, for animals receiving the histidine 
pretreatment plus GBL (350mg/kg, IP). Sleeping times are means ±.standard deviation, with the number of 
animals used in parentheses. Significant differences from controls are indicated by * (P< 0 0 05). 
+.For explanation of letter designations see Table 1. 
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At 0600 hours, the only significant alteration in the MB amine time-
course pattern (Fig. 24) occurs between the 5HT values at 60 and 70 minutes 
(P < 0.02). There is a significant reduction of CN NE levels at 120 minutes 
as compared with the value at 145 minutes (P < 0.02). Brain stem 5HT is 
elevated significantly at 120 minutes, over the values at 85 or 145 minutes 
(both P < 0.001). Hypothalamic DA concentrations exhibit a significant 
difference between the values at 70 and 85 minutes (P < 0.05). 
At 1200 hours MB NE levels differ significantly between 80 and 100 
minutes (P < 0.05). MB DA levels exhibit significant differences between 80 
and 100 minutes (P < 0.01) and 100 and 115 minutes (P < 0.025). There are 
significant variations in CN DA concentrations between the following times: 
70 vs. 80 minutes (P < 0.05), 80 vs. 100 minutes (P < 0.001) and 115 vs. 125 
minutes (P < 0.01). Hypothalamic DA content at 145 minutes is increased 
significantly from that at 115 minutes (P < 0.05)(Fig. 25). 
At 1800 hours, significant differences between MB DA levels occur 
between 60 and 65 minutes (P < 0.01) and 80 and 90 minutes (P < 0.05). MB 
5HT content between 60 and 65 minutes differs significantly. Brain stem DA 
reaches a minimum at 90 minutes, which differ significantly from the value at 
120 minutes (P < 0.05). Hypothalamic NE levels at 60 minutes are elevated 
from that at 65 minutes (P < 0.025). Hypothalamic 5HT content is reduced 
significantly at 90 minutes, and differs from 80 minutes (P < 0.05) and 120 
minutes (P < O.OOl)(Fig. 26), 
At 2400 hours there are significant differences in MB NE levels 
between the following times: 75 vs. 85 minutes (P < 0.01), 85 vs. 110 
minutes (P < 0.001) and 110 vs. 125 minutes (P < 0.005). Between 75 and 85 
r 
r 
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minutes and 125 and 145 minutes MB DA levels differ significantly (both 
P~0.005). MB 5HT is elevated at 125 minutes, differing significantly from 
that at 100 (P<0.002) and 145 minutes (P~0.05). CN NE concentration is de-
creased significantly at 110 minutes from the values at 85 minutes (P<0.02) 
and 125 minutes (P<-0.05). There are several significant differences between 
CN DA concentrations: 50 vs. 60 minutes (~0.005), 75 vs. 85 minutes (P< 
0.02) and 110 vs. 125 minutes (P<0.025). Brain stem NE levels are signi-
ficantly lower at 110 minutes than at 125 minutes ( P<0.02 ). Brain stem 
DA levels vary significantly: 75 vs. 85 minutes ( P<0.05 ), 85 vs. 110 
minutes ( P<0.02 ), 110 vs. 125 minutes ( P<0.02 ) and 125 vs. 145 minutes 
( P<0.05 ). Hypothalamic DA concentrations reach a minimum at 145 minutes 
differing significantly from the value at 125 minutes ( P<0.01). Hypotha-
lamic 5HT concentrations differ significantly between the 85 and 110 
minutes determinations ( P~0.05) (Fig. 27 ). 
2. Drugs affecting the NE and DA systems 
a. DOPA-pargyline 
DL-DOPA ( 500 mg/kg, IP ) and pargyline ( 6 mg/kg, IP ) 
administered to rats one hour and 30 minutes, respectively, prior to 
PB ( 50 mg/kg, IP). DOPA-pargyline treatment significantly increased 
DA ( P<0.05 or less ) above control in almost all parts of the brain 
examined ( 15/16 ). (Table 9, Figs. 28 - 29 ). At 0600 hours the 
following increases were obtained: MB ( 724.7%, P<0.02 ), CN ( 44.0%, 
P<0.05 ), brain stem ( 1045.7%, P<0.005) and hypothalamus ( 1457.5% 
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Table 9: CNS concentrations of NE, DA and 5HT after DOPA-pargyline 
pretreatment with PB, on a 24-hour basis. 
0600 1200 1800 2400 
MB NE 
c ,69+.14 • 88+. 03 .81+.17 ,75+.04 (3) (2) (3) (3) 
T .74+.05 .93+.08 . 79+.17 .79+.02 (3) (4) (4) (4) 
Hpth NE 
c 1. 79+.25 2.52+.54 2 .02+.25 2 .55+ .4·1 (3) (2) (3) (3) 
T 1. 97+. l 7 2.41+.18 2.37+.62 2. 71+.21 (3) (4) (4) (4) 
CN NE 
c . 08+. 03 .19+.06 .18+.02 .17+.05 (3) (2) (3) (3) 
T .19+.04* .32+.07 .42+.14* .44+.07** (3) (4) (4) (4) 
Stem NE 
c .83+.04 . 93+.16 .85+.13 .96+.08 
(3) (2) (3) (3) 
T .92+.02* . 99+ .13 1.00+. 26 1. 08+.19 (3) (4) (4) (4) 
MB .M 
c .15+.005 .13+.008 .26+ .13 .16+. 03 
(2) (2) (3) (3) 
T 1.21+.29* 1.13+.40* 3.09+.22** 2.64+.46** (3) (4) (3) (3) 
Hpth DA 
c .18+.06 .42+.04 .18+.05 .35+.04 
(3) (2) (3) (2) 
T 2.74+.67** 4.17+. 96** 9.81+.75** 6. 55+1. 41 ** (3) (4) (4) (3) 
CN DA 
c 6.81+1.58 8.47+.61 7.37+2.04 6.12+.93 
(3) (2) (3) (3) 
T 9.80+.33* 10.41+.88 12.49+2.66* 11. 54+2. 18* (3) (3) (4) (3) 
Stem DA 
c .10+.04 .ll+.07 .17+.0l .23+.004 
(3) (2) (3) (2) 
T 1.15+.28** 1.30+.44* 3.66+.89** 2.26+.52* 
(3) (3) (4) (3) 
r 
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Table 9 (continued) 
0600 1200 1800 2400 
MB 5HT 
c . 56+. 11 .57+.03 1. 02+. 23 1. 00+.15 (3) (2) (3) (3) 
T .37+.06 .44+.05 .36+.06* .40+.08** (3) (3) (2) (3) 
Hpth 5HT 
c .49+.15 .85+.16 2.03+.06 .39+.15 
(3) (2) (2) (3) 
T .48+.10 .87+.09 2.26+.92 1.16+.22** (3) (3) (3) (3) 
CN 5HT 
c .22+.05 .42+.12 .40+.12 .30+.13 
(3) (2) (3) (3) 
T .25+.05 . 60+.15 .47+.10 .29+.07 
(3) (3) (3) (3) 
Stem 5HT 
c .73+.02 .85+.07 .74+.17 . 60+' 12 
(3) (2) (3) (3) 
T .57+.10 .65+.07* .44+.08 .48+.09 
(3) (3) (3) (3) 
Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in 
midbrain (MB), hypothalamus (Hpth), caudate nucleus (CN) and brain stem 
(Stem) of rats receiving DOPA-pargyline pretreatment and PB (50mg/kg, IP). 
Animals were sacrificed midway through the previously-determined sleeping 
time. Values are means + standard deviation, with the number of animals used 
in parentheses. Significant differences from control are noted by* (P<0.05) 
or** (P<0.01). 
C = Control; T= Treated 
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p 0.005). NE levels also increase in the .Q'i. (13705%, P 0 0 02) and brain 
stem (10.4%, P <:0.025). At !,gQQ, hours, DA levels increase as follows: MB 
(745.5%, P<.0.05), ~ ~ (111203%, P<Oo05) and hypothalamus (891.6%, 
p(0.01). On the other hand, 5HT levels decrease significantly in the brain 
stem (23.Q%, P ( 0.05). At 1800 hours DA concentrations are significantly 
elevated in the MB (1094.4%, p( 0.001), CN (69.6%, P<Oo05), brain stem 
(1992.4%, p <o.005) and hypothalamus (5394.6%, P <0.001). MB 5HT decreases 
significantly (64.4%, P<0.05), while .Q'i. NE increases significantly (132.1%, 
p <0.05). At g!Q.Q. hours the significant increases in DA levels were: MB 
(1536.6%, P <0.001), .Qli (89 0 0%, P < 0.02), brain stem (879.5%, P <Oo02) and 
hypothalamus (1753.4%, P<0.01). Significant increases occur for CN NE 
(154.1%, P < 0 0 005) and hypothalamus 5HT (200.4%, P ( 0.01). Of the 24-hour 
patterns obtained for the three amines, 9 of 12 are circadian, while the 
remainder are unvarying. Fluctuation of patterns was found for NE in the MB, 
CN and hypothalamus; for DA in MB .. brain ~ and hypothalamus and for 5HT in 
Qi, brain stem and hypothalamus. For details of this aspect of the study 
refer to Figs. 28-29, Table 9 and to Appendix B • 
b. Alpha-methyl-E,-tyrosine 
.AMPT (200mg/kg, IP) was administered four hours prior to PB. 
In almost all cases, NE and DA levels are significantly decreased from con-
trols (TablelO, Figs,30-31 ). At 0600 hours, NE concentrations are signif-
icantly lower in the MB (52.6%, P<0.005), CN (61.2%, p<0.001), ~stem 
(45 0 8%, P ( 0 0 005) and the hypothalamus (53 0 9%, P<,0.005)o DA levels are 
reduced significantly in the CN (77 .8%, P < 0.001) and hypothalamus (86.3%, 
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Table 10: CNS concentrations of NE, DA and 5HT after AMPT pretreatment 
with PB, on a 24-hour basis 
0600 1200 1800 2400 
MB NE 
c .69+.04 .70+.12 .82+.08 .92+.04 
(4) (4) (3) (4) 
T . 33+ .14** .39+.03** .37+.04** .38+.05** 
(4) (4) (5) (4) 
Hpth NE 
c 2.27+.44 2.12+.34 2.62+.13 2.94+.59 
(4) (6) (3) (4) 
T 1.05+.15** 1.01+.23** 1.03+.19** 1.11+.18** 
(4) (4) (5) (4) 
CN NE 
c .17+.10 .16+.04 .19+. 03 .23+.06 (2) (5) (3) (4) 
T .07+.04** .13+.03 .10+. 03* .17+. 05 
(4) (4) (5) (4) 
Stem NE 
c .94+.13 .83+.09 .84+.08 .92+.15 
(4) (6) (3) (4) 
T .51+.02** .43+.05** .40+.07** . 45+. 03** 
(3) (6) (5) (4) 
-----
MB DA 
c .12+.02 .13+.05 .25+.0l .25+.01 (3) (3) (2) (2) 
T .11+. 02 .09+.0l .10+.02** .14+.03*-ll-(3) (4) (4) (4) 
Hpth DA 
c .36+.10 .18+.07 .54+. 17 . 44+.15 (3) (4) (3) (4) 
T .05+.02* .15+.07 .30+. 09 .12+.07* (3) (4) (2) (3) 
CN DA 
c 8 .24+1. 00 9.26+1.52 7.33+1.49 10. 02+1. 88 (4) (5) (3) (4) 
T 1.83+.39** 1.99+.53** 2.20+.81** 2 .87+ '.~:i** (4) (4) (5) (4) 
Stem DA 
c .11+. 05 .13+.06 .26+.08 .02+.00;3 (3) (4) (2) (2) 
T .08+.006 .29+.10* .17+.06 .03+.03 (3) (6) (5) (3) 
r 
r 
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Table 10 (continued) 
0600 1200 1800 2400 
MB 5HT 
c .30+.08 .53+.08 .35+.06 A8+.20 
(4) (3) (2) (4) 
'I' ,60+.02** .85+.14** .39+.07 .48+.08 
(3) (3) (3) (3) 
Hpth 5HT 
c .59+.09 .96+.18 L 00+.13 .52+.05 
(4) (3) (3) ( 3) 
T .68+.18 .53+.07* (.97) .48+.23 
(4) (3) (1) (4) 
CN 5HT 
c .33+.21 .37+.0l .34+.17 
(4) (3) (4) 
T .31+.06 .37+.05 .16+.05 
(3) (3) (4) 
Stem 5HT 
c .39+.04 . 68+. 05 .19+,04 
(3) (4) (3) 
T .58+.05** ,92+.28 .16+.05 
(3) (3) (3) 
Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in 
the four areas indicated in Table 9, for animals receiving AMPT pretreatment 
and PB (50mg/kg, IP). Animals were sacrificed midway through the previously-
determined sleeping time. Values are means ± standard deviation, with the 
number of animals used in parentheses. Significant differences from control 
are noted by* (P<0.05) or** (P<0.01). 
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P<0.01). On the other hand, 5HT concentrations are elevated significantly 202 
in the MB (99.9%, P<0.005) and brain stem (48.3%, P<0.01). 
- --
At !_gQQ hours, NE levels decrease signigicantly in the MB ( 43. 6%, P< 
0.01), brain stem (48.2%, P<0.001) and hypothalamus (52.1%, P<0.005). DA 
concentrations are lowered significantly in the CN (78.5%, P<0.001), but 
increase in the brain stem (131.8%, P<0.05). 5HT levels increase signifi-
cantly in the M!!_ (60.3%, P<0.025), but decrease in the hypothalamus (44.5%, 
P<O. 02). 
At 1800 hours NE levels decrease significantly in the MB (55.4%,P< 
0.001), CN (43.9%, P<0.02), brain stem (51.6%, J>'(0.001) and hypothalamus 
(60,5%, P<0.001). DA concentrations are reduced significantly in the MB 
(58.6%, P<0.001) and CN (70.Q%, P<0,001). 
NE levels at 2400 hours are decreased significantly in the MB (58.9%, 
P(0.001), brain stem (50,8%, P<0.001) and hypothalamus (62.2%, P<0.001) 
and there is a significant reduction of DA levels in the MB (44.0%, P<0.01), 
CN (71.4%, P<0.001) and hypothalamus (74.7%, P<0.02). Of the 12 amine 
patterns, after AMPT treatment 7 display diurnal rhythms. These can be 
examined in detail in Figs.30-3l,Table 10 and in Appendix B . 
3. Drugs Affecting the Serotonin System 
a. £-Chlorophenylalanine 
pCPA (3 x lOOmg/kg, IP) depletes brain 5HT significantly in all 
brain tissues examined, at each time point studied, with relatively minor 
effects on CAs (Table 11, Figs.32-33). At 0600 hours, 5HT concentratio.1s 
are reduced significantly in the MB (97.0%, P<0.01), CN (87.8%, P<0.01), 
brain stem (94.8%, P<0.01) and hypothalamus (P<0.01). At 1200 hours, 5HT 
203 
Table 11: CNS concentrations of NE, DA and 5HT after pcPA pretreatment 
wi.th PB, on a 24-hour basis 
0600 1200 1800 2400 
MB NE 
c .67+.08 ,69+.06 . 74+. ll . 68+ .10 
(3) (3) (4) (3) 
T .65+.03 '64+. 11 .59+ .14 .67+.10 
(3) (5) (5) (5) 
Hpth NE 
c 2.11+.21 1. 99+,31 2.18+.23 2.00+.18 
(3) (3) (4) (3) 
T 1. 94+.53 1. 76+,27 1. 28+. 20** 2.03+.34 
(3) (4) (5) (5) 
CN NE 
c .16+.03 .19+.07 ,23+.06 .16+,04 
(3) (3) (3) (3) 
T .19+.02 .19+.04 .14+.03* .18+.02 
(3) (5) (5) (5) 
Stem NE 
c .97+.12 ,97+.18 .87+.09 ,82+.10 
(3) (3) (4) (3) 
T .86+.13 .70+,05* '70+. 07** .67+.10 
(3) (5) (5) (5) 
MB DA 
c .09+.03 '11+. 02 .16+,0l . 09+. 03 
(3) (3) (3) (3) 
T ,09+.02 '08+. 02* .11+. 03 .10+.03 
(3) (5) (4) (5) 
Hpth DA 
c .26+.02 .29+,06 .44+.12 .26+.06 
(3) (2) (3) (3) 
T .28+,05 ,25+.06 .12+,03** .18+.08 (3) (5) (4) (4) 
CN DA 
c 6.35+1.05 6.42+,87 10,06+2,78 5. 17+1. 03 
(3) (3) (3) (3) 
T 4. 71+1.16 4.87+.80* 7.33+.49 5 .4.i .80 (3) (5) (5) (5) 
Stem DA 
c .09+.02 ,08+.02 ,07+.02 .08+.01 
(2) (3) (4) (3) 
T ,03+.04 ,08+.0l .08+,03 ,07+.04 
(3) (5) (4) (5) 
204 
Table 11 (continued) 
0600 1200 1800 2400 
MB 5HT 
c .93+.31 .70+.20 . 71+.20 .61+.09 (3) (2) (4) (2) 
T ,03+.0l** .08+.04** .08+.02** .36+.09* 
(3) (5) (4) (4) 
Hpth 5HT 
c .40+. ll .72+.20 .87+.15 .89+.41 
~-) (3) (2) (3) 
T ~)** .24+.12** ,08+.07** . 05+. 003* (5) (3) (3) 
CN 5HT 
c ,33+.07 . 24+. 02 ,38+.13 .49+.14 (3) (2) (4) (3) 
T ,04+.07** .02+.02** .10+. 03** .13+.0l* 
(3) (4) (4) (3) 
Stem 5HT 
c .46+.14 .75+.09 . 64+.12 .50+. 08 
(3) (3) (2) (3) 
T .02+.04** .10+.03** .03+.02** .07+.03** 
(3) (5) (4) (5) 
Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in 
the four areas indicated in Table 9, for animals receiving pCPA pretreatment 
and PB ( 50mg/kg, IP). Animals were sacrificed midway through the previousl,v-
determined sleeping time. Values are means ±standard deviation, with the 
number of animals used in parentheses. 
Significant differences from control are noted by* (P<0.05) or** (P<0.01). 
C =Control; T =Treated 
Figure ;32 
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Legend for Figure 32 
The effects of pCPA pretreatment with pentobarbital, on the CNS concentrations 
of NE, DA and 5HT -- CONTROL. For complete explanation of notations of figure, 
see legend to Figure 28. 
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Legend for Figure 33 
The effects of pCPA pretreatment with pentobarbital, on the CNS concentra-
tions of NE, DA and 5HT -- TREATED. For complete explanation of notations 
of figure, see legend to Figure 28. 
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levels decrease significantly in the MB (89.3%, P<0.001), CN (92.1'.~. 
P<0.001), brain stem (86.8%, P<0.001) and hypothalamus (6G.9?~. P(0.01). 
DA levels decrease significantly in the MB (29.1%, P<0.05) and CN (24,2%, 
P<0.05), while NE is reduced in the brain stem (27.7%, P::::0.02). 
At 1800 hours 5HT content is reduced significantly in the MB (89.0%, 
P<0.001), CN (74.5%, P<0.005), brain stem (95.0%,P<0.001) and hypothalamus 
(90.5%, P<0.001). NE levels are reduced in the CN (39.7%, P<0.02), brain 
~ ~~-
stem (19.9%, P<0.01) and hypothalamus (41.6%, P<0.001). Hypothalamic DA 
is reduced significantly (72.7%, P<0.005). At 2400 hours there is a si~ni-
ficant decrease of 5HT in the MB (40.4%, P<0.05), CN (72.9%, P<0.02), brain 
stem (86.6%, p<0.001) and hypothalamus (94,1%, P<0.025). Fluctuating patterns 
were seen in 8 of 12 amine patterns studied. For additional details, cf. 
Figs.32-33, Table 11 and Appendix B. 
b. Tryptophan(Figures 34-35, Table 12) 
TP (500mg/kg,IP) was administered one hour prior to PB. At 
0600 hours 5HT concentrations in treated animals are increased significantly 
in the ~B (40.5%, P<0.005) and the hypothalamus (130.7%, P(0.005), ~in the 
hypothalamus is reduced significantly (15,7%, P<0.05), At 1200 hours TP 
decreased DA significantly in the MB (30.4%, P<0.05), brain stem (81.0%, 
P<0,005) and hypothalamus (29.3%, p<o,05). CN NE levels decrease signifi-
cantly (48.5%, P<0.05). Atl800 hours, hypothalamic 5HT is increased E"i~-
nificantly (692.0%, P<0.01), while MB NE decreases significantly (26.:2"1'., 
P<O. On). J\ t 2400 houn1, bra in stem 5HT levels increase significantly 
(42.9%, P<0.05), while hypothalamic DA decreases significantly (42.0%, P< 
r 
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Table 12: CNS concentrations of NE, DA and 5HT after 'TP pretreatment 
with PB, on a 24-hour basis 
0600 1200 1800 2400 
MB NE 
c ,67+.04 .69+.06 .98+.08 '68+ .10 
(3) (3) (2) (3) 
T . 62+. 03 .65+.05 ,73+.ll* .70+,09 
(4) (5) (5) (5) 
Hpth NE 
c 2' 07+ .11 L99+. 31 L 96+. 02 2.01+.rn (3) (3) (2) (3) 
T L 75+. l 7* 2, 10+.50 2,21+.35 2,04+.27 
(T4) (5) (5) (5) 
CN ~'E 
c .13+.02 .19+.07 .19+.03 ,16+.04 
(3) (3) (2) (3) 
T ,12+.02 .10+.02* ,15+.04 .14+. 04 (4) (5) (5) (5) 
Stem NE 
c .79+.04 .97+.18 1.10+.14 . 82+' l 0 
(3) (3) (3) (3) 
T .76+.08 . 80+. 03 .92+.08 .79+.08 
(4) (5) (5) (5) 
MB DA 
c .12+.05 .12+.02 .11+. 002 . 09+' G:3 
(3) (3) (2) (3) 
T .12+.006 .08+.02* .13+.05 '14+. 03 
(4) (5) (4) (5) 
Hpth DA 
c .18+.03 .29+.06 ,22+.0l .26+,06 
(3) (2) (2) (3) 
T .28+.14 .20+.02* ,22+.12 .15+.02* 
(4) (5) (4) (4) 
I'\ DA 
c G.63+1.17 6.42+.87 7 .58+ 0 10 G. 17 + l, 0.'3 
(3) (3) (2) ( :1) 
T 4.06+.73 5.31+.82 6,99+,81 6.5F+ .. 74 (4) (5) (5) Cs) 
:'t"'m DA 
c ,08+.005 • 08+. 02 . 04+. 03 .08+.006 
(2) (3) (2) (3) 
T .08+.02 .01+.0l** . ll+. 04 .08+.02 
(4) (3) (5) (5) 
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Table 12 (continued) 
0600 1200 1800 2400 
MB 5HT 
c .47+.04 0 70+.20 .80+.07 (. 55) 
(3) (2) (2) (1) 
T .60+.12** .79+.16 L49+.43 .6:~+.20 
(4) (5) (4) (5) 
Hp th 5HT 
c .31+.04 .72+.20 .31+.0l .89+.41 (3) (3) (2) (3) 
T .72+.ll** .82+.05 2.47+.44** .80+ .11 (3) (4) (3) (5) 
Ci\ 5HT 
c .28+.06 .24+.02 .34+.08 .49+. 14 
(3) (2) (2) (3) 
T .29+.06 .37+.08 .51+.19 .45+.12 
(4) (5) (5) (5) 
Stem 5HT 
c .46+.02 .76+.09 .49+.05 .. 50+. 08 (2) (3) (2) nn 
T .53+.13 .78+.08 .67+.16 .72+.1;3+-
(4) (5) (5) (5) 
Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in 
tlw four areas indicated in Table 9, for animals receiving TP pretreatment 
and PB (50mg/kg, IP). Animals were sacrificed midway through the previousJy-
determined sleeping time. Values are means .±.standard deviation, with the num-
ber of animals used in parentheses. Significant differences from control are 
noted by* (P 0.05) or** (P 0.01). 
r = Control; T = Treated 
r 
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Legend for Figure 34 
The effects of TP pretreatment with pentobarbital, on the CNS concentrations 
of NE, DA and 5HT CONTROL. For complete explanation of notations of figure, 
see legend to Figure 28. 
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A majority (10/12) amine patterns showed significant variation over the 
24-hour experimental period. Details of these findings can be seen by refer-
ring to Figs.34-35, Table 12 and Appendix B. 
c, Melatonin(Figures36-37, Table 13) 
M (25mg/kg, IP) was administered simultaneously with PB, At 
0600 hours M increases MB 5HT levels significantly (76,3%, P<0.01) from con-
trols, while MB DA decreases significantly (43.9%, P<0.02) (Table 13, Figs.36-
37). At 1200 hours brain stem 5HT levels are reduced (46.3%, P<0.01) and 
hypothalamic DA decreases (76,1%, P<0.02). Atl800 hours, M lowers CN DA 
significantly (11.8%, J><0.05). Diurnal variations were obtained in 8/12 
amine patterns. These are described in detail in Fig.37, Table 13 and in 
Appendix B. 
4. Drugs affecting the Histamine System 
a. L-Histidine 
L-Hd (500mg/kg, IP) was administered one hour prior to PB. At 
0600 hours, MB 5HT is significantly increased over controls (107.8%, P<0.02). 
DA concentrations are reduced in the brain stem (67.1%, P(0.05) but elevated 
in the hypothalamus (332,8%, P<0,005). At 1200 hours, brain stem 5HT de-
creases significantly (28.3%, P<0.02). At 2400 hours, significant elevat ons 
occur in MB DA (135.0%, P<0.005) and hypothalamic 5HT (73.6%, P<0.01) 
concentrations. Details of the diurnal fluctuBtions of amine patterns (7 of 
12) after Hd500 are indicated in Fig.39, Table 14 and Appendix B. 
b. Decaborane(Figures40-41, Table 15) 
DB (15mg/kg, IP) was administered 24 hours prior to PB. The 
Table 13: CNS concentrations of NE, DA and 5HT after M25 pre- 213 
treatment with PB, on a 24-hour basis 
0600 1200 1800 2400 
MB NE 
c .69+.04 .69+.06 .61+.12 .70+.10 (4) (3) (3) (3) 
T .73+.12 .63+.08 .64+.ll .68+.04 
(4) (4) (5) (5) 
Hpth NE 
c 2.27+.44 1.99+.31 1. 76+.40 2.13+.21 (4) (3) (3) (3) 
T 1. 98+.49 1.69+.49 1.75+.19 1.99+.41 (5) (4) (5) (5) 
CN NE 
c .17+.10 .19+.07 .14+.09 .14+.04 
(2) (3) (3) (3) 
T .14+.04 .10+.02 .15+.0l .14+.02 
(4) (4) (5) (5) 
Stem NE 
c .94+.13 .97+.18 .91+.07 .85+.05 
(4) (3) (3) (3) 
T .89+.14 • 79+.14 .91+.14 .87+.04 
(5) (4) (5) (5) 
MB DA 
c .12+.02 • ll+.02 .13+.0l .09+.04 (3) (3) (2) (3) 
T .07+.0l* .09+.05 .12+.0l .09+.03 
(4) (4) (4) (4) 
Hpth DA 
c .26+.09 .29+.06 .18+.03 .26+.09 (3) (2) (2) (3) 
T .17±..01 .07±..03* .16±..03 .22±..01 
CN DA 
c 8.24+1.00 6.42+ .87 8.12+ .19 6.83+ .11 
(4) (3) (3) (3) 
T 6.90+ .87 7 .06+1.37 7.17+ .58* 7 .15+1. 09 (5) (3) (5) (5) 
Stem DA 
c • ll+.05 .08+.02 .10+.03 .05+.05 (3) (3) (2) (3) 
T .06+.02 .05+.03 .05+.03 .03+.001 (5) (3) (5) (4) 
r 
Table 13 (continued) 214 
0600 gQQ 1800 2400 
MB 5HT 
c .30+.08 • 70+ 020 0 85+ 009 048+ 008 (4) (2) (3) (3) 
T .53+.09** 1.05+.21 .97+.17 .61+.15 
(4) (4) (5) (5) 
Hpth 5HT 
c .59+.09 .72+.20 .61+.25 .30+.04 (4) (3) (3) (2) 
T .64+.15 .84+.05 .38+.21 .28+ 010 (5) (4) (4) (4) 
CN 5HT 
c .33+.21 .24+.02 .28+.04 036+ 0 04 (4) (2) (3) (2) 
T .43+.09 .26+. 02 .47+.13 .46+.13 
(5) (4) (5) (4) 
Stem 5HT 
c .39+.04 .76+.09 .66+.ll .41+.07 
(3) (3) (3) (3) 
T .60+.31 .41+.,12** .82+ 014 0 38+ 018 (5) (4) (5) (4) 
Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in 
the four areas indicated in Table 9, for animals receiving M25 pretreat-
ment and PB (50mg/kg, IP). Animals were sacrificed midway through the 
previously-determined sleeping time. Values are means ~ standard deviation, 
with the number of animals used in parentheses. Significant differences 
from control are noted by * (P (0.05) or ** (P< 0,01). 
C = Control; T = Treated 
Figure 36 
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Legend for Figure 36 
The effects of M25 pretreatment with pentobarbital, on the CNS concentrations 
of NE, DA and 5HT -- CONTROL. For complete explanation of notations of 
figure, see legend to Figure 28. 
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The effects of M25 prt>treatment with pentobarbital, on the CNS concentrations 
of NE, DA and 5HT -- 'l'REATED. For complete explanation of notations of 
figure, see legend to Figure 28. 
Table 14: CNS concentrations of NE, DA and 5HT after Hd500 pre-
treatment with PB, on a 24-hour basis 217 
0600 1200 1800 2400 
MB NE 
c .69+.04 .70+.12 • 74+.ll .77+ 010 (4) (4) (4) (4) 
T .70+.08 .75+.08 .76+~13 .85+.08 (4) (5) CD (4) 
Hpth NE 
c 2.27+.44 2.12+.34 2'.18+.23 2.11+.35 (4) (6) (4) (4) 
T 2.57±_.46 2.31±..53 2.13±_.37 1 0 17±_037 
CN NE 
c .17+.10 .16+.05 .23+.06 .21+.08 (2) (5) (3) (4) 
T .52+.14 .17+.04 .22+.03 .18+.04 (3) (5) (7) (4) 
Stem NE 
c .94+.13 .83+.09 .87+.09 .90+.ll (4) (6) (4) (4) 
T .89+.14 • 78+~ 10 .93+~10 .90+.ll (4) (5) (7) (4) 
MB DA 
c .12+.02 .13+.05 .16+.0l .21+.07 (3) (3) (2) (3) 
T .26±_. l 7 .26±_.07 .11±_.04 .50±_.05** 
Hpth DA 
c .26+.09 .18+.07 .44+.12 (.35) (3) (4) (3) ( 1) 
T 1.11+.28** .22+.07 .37+. 11 ( .29) (4) (3) (6) ( 1) 
CN DA 
c 8.24+1.00 9.26+1.52 10.06+2.78 10.48+ .87 (4) (5) (3) (3) 
T 7.91+1.28 ll.96+3.02 9.06+1.46 9.82+1.84 (3) (2) (7) (4) 
Stem DA 
c 0 11+ 005 .13+.06 .07+o02 .08+.02 (3) (4) (4) (3) 
T .04+.02* .09+.03 .07+.0l .13+.07 (4) (2) (2) (3) 
Table 14 (continued) 21 8 
0600 .!_gQQ 1800 2400 
MB 5HT 
c .3o+.o8 .53+~07 .71+.20 .64+.19 (4) (3) (4) (4) 
T .63;t.18* ~ 60;t.14 .66;t.15 0 80;t .. 13 
Hpth 5HT 
c .59+.09 .98+.18 .87+.15 .45+.10 (4) (3) (2) (4. 
T .73+.24 .79+.15 1.02+.04 .78+.10** (4) (4) (2) (3) 
CN 5HT 
c .33+.21 .36+.007 .38+.,13 .41+.08 (4) (2) (4) (4) 
T .30+.15 .29+~12 .39+.09 o44+. 10 
(4) (2) (5) (3) 
Stem 5HT 
c .39+.04 .68+.05 .64+.12 .51+.19 
(3) (4) (2) (4) 
T .35+.ll .49+. 10* • 65+. 14 • 62+. 17 
(4) (5) CD (3) 
Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in the 
four areas indicated in Table 9, for animals receiving Hd500 pretreat-
ment and PB (50m.g/kg, IP). Animals were sacrificed midway through the 
previously-determined sleeping time. Values are means ±. standard deviation, 
with the number of animals used in parentheses. Significant differences 
from control are noted by * (P < 0.05) or ** (P < 0.01). 
C = Control; T = Treated 
Figure 38 
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Legend for Figure 38 
The effects of Hd500 pretreatment with pentoharbital, on the CNS concentra-
tions of NE, DA and 5HT -- CONTROL. For complete explanation of notations 
of figure, see legend to Figure 28. 
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The effects of Hd500 pretreatment with pentobarbital, on the CNS concen-
trations of' NE, DA and 5HT -- TREATED. For complete explanation of 
notations of figure, Rf'e legend to Fib,rure 28. 
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Table 15: CNS concentrations of NE, DA and 5HT after DB pretreatment 221 
with PB, on a 24-hour basis 
0600 gQ2 1800 2400 
-
MBNE 
c .68+.09 .56+.02 • 90+.12 
.40+.02 (3) (2) (3) (2) T .28+.05** 
.22+.03** .24+.03 
.17+.0l** (5) (5) (4) (3) 
Hpth NE 
c 1.93+.18 2.04+.22 1.99+.14 
.96+.09 (3) (3) (3) (2) T .42+.19** 
.43+.09** 
.47+.07** 
.23+.09** (4) (4) (4) (4) 
CNNE 
c .10+.02 .14+.02 
.18+.02 
.05t1-03 (3) (3) (3) (2) T .l0+.06 .07~03 .09+.02 .05+.0l (5) (5 (3) (4) 
Stem NE 
c .81+.04 
.7ll+.14 
.97+.13 
.66+.006 (3) (3) (3) (2) T .37+.05** 
.35+.04** 
.33+.04** 
.31+.06** (5) (5) (4) (4) 
MB DA 
c .13+.03 .04+.003 
.18+.06 
.16+.07 (3) (2) (3) (2) T .39+.12* .13+.05 
.17+.07 
.10+. 02 (5) (5) (3) (3) 
Hpth DA 
c .18+.04 .12+.007 .20+.03 .23+.02 (3) (2) (3) (2) 
T .76+.05** .14+. 05 .21+.03 .12+.06 (4) (3) (4) (2) 
CN DA 
c 6.22+1.37 11. 63+ • ll 7.47+1.07 9.81+ .86 (3) (3) (3) (2J 
T 8.21+ .57* ll.71+ .• 10 ll.64+ .28 10.47 + .56 (5) (5) (3) (4) 
Stem DA 
c .09+.02 
.08+.03 • ll+. 03 .03+.02 (3) (3) (3) (2) 
T .31+.14** .10+.04 
.39+.13* .43+.07** (4) (4) (3) (3) 
Table 15 (continued) 222 
0600 1200 1800 2400 
-
MB 5Irr 
c .52+.07 .76+.04 .89+.15 .33+.,09 (3) (2) (3) (2) 
T (.28) .54+.08* .19+.02** .14+.02* 
(1) (3) (3) (3) 
Hpth 5HT 
c .40+.14 .84+.09 .95+.53 .35+.05 (2) (3) (3) (2) 
T 1.77+.52* .18+.05** .14+.06 .07+.04** (3) (4) (4) (4) 
CN 5IIT 
c .25+.05 .35+.14 .37+.10 .13+.05 (3) (3) (3) (2) 
T .67+.52 .20+.03* 
.lOE)OOl* .06+.03 (4) (5) (2 (3) 
Stem 5HT 
c .59+. 02 .53+.15 .62+. 11 .03+.02 (3) (2) (3) (2) 
T .21+.04** .82+.18 .16+.07* .10+.02 (2) (3) (2) (2) 
Table indicates amine concentrations (ugm/gm) of NE 1 DA and 5HT in 
the four areas indicated in Table 91 for animals receiving DB pretreat-
ment and PB (50mgjkg, IP). Animals were sacrificed midway through the 
previously-determined sleeping time. Values are means .:!:. standard deviation, 
with the number of animals used in parentheses. Significant differences 
from control are noted by * (P<0.05) or ** (P<0.01). 
C • Control; T • Treated 
Figure 40 
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Legend for Figure 40 
The effects of DB pretreatment with pentobarbital, on the CNS concentrations 
of NE, DA and 5HT -·-· CONTROL. For complete explanation of notations of 
figure, see legend to Figure 28. 
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Legend for Figure 41 
The effects of DB pretreatment with pentobarbital, on the CNS concentrations 
of NE, DA and 5HT -- THEA TED. For complete explanation of notations of 
figure, see legend to Figure 28. 
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control values for the 0600 group at 100 minutes were obtained by inter-
polating between the amine values determined for 85 and 120 minutes, in order 
to compare differences between tre treated and control groups at this time. 
At 0600 hours, there is a significant decrease of MB NE (58.1%, P<0.001) 
but MB and CN DA increase (19004% and 32% respectively, each P<Oo05). Brain 
stem NE levels decrease significantly (54,8%, P~O.OOl)o Brain stem DA 
------
increases and 5HT is reduced from control (65.2% and 65.4% respectively, 
each P<0.005). Hypothalamic NE decreases (78.1%, P<0.001), while signifi-
cant increases occur in the levels of hypothalamic DA (325.5%, P<0.001) and 
5HT (340.6%, P<0.02) values. 
At 1200 hours NE levels are reduced significantly in the MB (61.1%, P< 
0,001), CN (49.3%, P<0.02), brain~ {55.6%, P<0,001) and hypothalamus 
( 78. 7%, P<O. 001). 5HT concentrations are decreased significantly in the MB 
(29.0%, P<0.05), CN (4405%, ]l('0,05) and hypothalamus (78.9%, P<0.001). At 
1800 hours, only a single control animal was available, limiting the oppor-
tunity for statistical analyseso Relative to this control, NE levels appear 
reduced in the MB, CN, brain stem and hypothalamus, while DA levels are 
Plevated in the MB, CN and brain stem. 5HT levels appear to be decreased in 
the MB, CN, brain stem and hypothalamus. 
At 2400 hours, NE levels are significantly decreased in the MB (58.:3~. 
P<0.001), brain stem (65,5%, P<0,005) and hypothalamus (7603%, P<0.001). 
DA concentrations are elevated significantly in the brain stem (155407%, 
P<0.005). 5HT levels decrease significantly in the MB (58.3%, P<0.05) r'nd 
hypothalamus (79,5%, P<0.005). Significant circadian variations in 11 of 12 
umine patterns examined were obtained after DB pretreatment, 
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c. Diphenhydramine(Figures 42-43, Table 16) 
DPH (50mg/kg, IP) was administered one hour prior to PB. At 
0600 hours, DPH increases MB 5HT concentrations over controls (39.2%, P<0.025) 
but hypothalamic NE is reduced significantly (25.6%, P<0,001). At 1200 
hours, there is a significant elevation of CN 5HT (97,0%, P<0.02). At 1800 
hours MB NE levels are reduced significantly (19.4%, P<0.01). 
Eight of twelve amine patterns vary significantly during the 24-hour 
period of measurement, The details of these variations can be seen in Fig.43 
Table 16 and Appendix B. 
5. Gamma-butyrolactone(Figures 44-45, Table 17) 
Amine concentrations in MB, CN, brain stem and hypothalamus were 
evaluated half-way through the previously-determined sleep period at 0600, 
1200, 1800 and 2400 hours (Table 17). The results over the 24-hour period 
for controls are plotted separately (Fig, 44) from GBL-treated (Fig. 45). 
The controls, receiving saline, of course did not sleep. 
There are significant changes in amine concentrations of GBL-treated 
animals, compared with controls, in the following cases: MB 5HT, 1200 hours 
(77,8% increase, P<0,001); CN DA, 1200 hours (41,3% increase, P<0.05); 
brain stem 5HT, 1200 hours (50% increase, P<0,05); MB 5HT, 1800 hours (64.7~ 
increase 9 P<.0.05), ~othalamic DA, 1800 hours (128.17: increase, P<0.02) 
and l!Ypothalamic NE, 2400 hours (20.4% decrease, P<0.05). 
Circadian fluctuations in the amine patterns were seen in 6 of 12 cases. 
The details of these variations can be seen in Fig. 45, Table 17 or Appndix B. 
Table 16: CNS concentrations of NE, DA and 5HT after DPH pretreatment 227 
with PB, on a 24-hour basis 
0600 1&QQ. 1800 2400 
-
-
MB NE 
c .76+.06 .64+.17 .98+.08 .65+.ll (4) (5) (2) (4) 
T .70+.05 .76+.20 .79+.05** .52+.04 (6) (3) (6) (3) 
Hpth NE 
c 2.22+.19 1.91+.38 1.96+.03 1.59+.46 (4) (5) (2) (4) 
T 1.65+.08** 1.63+.50 2.05+.16 
.99+.21 (5) (4) (5) (3) 
CNNE 
c .19+.03 .12+.05 .19+.03 
.10+.05 (3) (5) (2) (4) 
T .18+.02 .18~05 .20+.04 .16+.07 (i) (3 (6) (3) 
Stem NE 
c .93+.06 .88+.16 1.10+.14 
.81+.13 (4) (5) (2) (4) 
T .89+.10 
.73+.16 .99+.09 
.74+.06 (6) (4) (6) (3) 
MB DA 
c .11+ .02 .21+.06 • ll+.002 
.06+.001 (3) (4) (2) (3) T .13+.007 .20+.06 
.15+.04 
.06+.003 (6) (3) (6) (3) 
Hpth DA 
c (.25~ .221)07 .22+.0l .14+.05 (1 (3 (2) (4) 
T .18+.03 
.26+.02 
.26+.10 (.03) (3) (2) (5) (1) 
CN DA 
c 7.01+.21 10.48+.58 7.58+.10 7 .06+1.57 (4) (5) (2) (4) T 7.49+.53 13.33+2.03 6.63+1.59 7 0 99+ .26 (5) (3) (6) (3) 
Stem DA 
c .07+.003 
.07+.003 
.05+.0l 
.05+.02 (2) (3) (2) (3) T • 08+.02 
.07+.0l 
.06+.02 
.03+.003 (4) (3) (6) (3) 
Table 16 (continued) 228 
0600 1200 1800 2400 
-
MB 5HT 
c .44+.05 .52+.19 .75+~07 ~66+~10 (4) (5) (2) (3) 
T .61+.09* ,.57+ 0 12 .75+.12 • 63+.14 (3) (3) (6) (3) 
Hpth 5HT 
c .35+.0l • 76+.05 .31+~007 0 49+ 0 12 (3) (3) (2) (3) 
T 0 42+ 0 06 .91+.15 .55+.14 .45~03 (3) (3) (6) (3 
CN 5HT 
c .22+.06 .32+~06 .34+.08 (.34) (4) (2) (2) ( 1) 
T 0 15+ 0 02 .62+o01* .44+.06 (ol8) (4) (2) (6) (1) 
Stem 5HT 
c .45+.03 .63+.15 .49+~05 .60+.06 (3) (4) (2) (4) 
T .44+.23 .64+.15 .45+.09 .51+.17 (3) (4) (6) (3) 
Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in 
the four areas indicated in Table 9, for animals receiving DPH pretreat-
ment and PB (50mgjkg, IP). Animals were sacrificed midway through the 
previously~etermined sleeping time. Values are means ~ standard deviation, 
with the number of animals used in parentheses. Significant differences 
from control are noted by * (P< 0.05) or ** (P <0.01). 
C = Control; T = Treated 
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Table 17: CNS concentrations of NE, DA and 5HT after GBL, on a 231 24-hour basis 
0600 1200 1800 2400 
MBNE 
c .80+.01 .90+.08 .83+.04 .87+.09 (?) (4) (4) (4) 
T .88+.05 .91+.08 .85+.09 .88+.07 (4) (5) (5) (5) 
Hpth NE 
c 2.39+.37 2.79+.49 2.74+.40 3.23+.16 (4) (4) (4) (4) 
T 2.33+.05 2.12+.51 2.43+.25 2.57+.47* (3) (5) (5) (5) 
CN NE 
c .18+.02 .20+.02 .21+.02 .17+.05 (4) (4) (4) (4) 
T .17+.007 .22+.04 .19+.05 .23+.08 (4) (4) (5) (4) 
Stem NE 
c 1.03+.13 1.05+.06 .95+.08 l.21+.009 (4) (4) (4) (3) 
T 1.08+.13 1.21+.15 1.02+.09 1.14+.14 (4) (5) (4) (5) 
MB DA 
c .18+.03 .18+.05 .20+. 05 .21+.04 (3) (4) (4) (4) 
T .25+.05 .21+. 05 .26+.06 
.26+.06 (4) (5) (5) (4) 
Hpth DA 
c .34+.05 .61+.13 .,44+.12 
.44+.03 (4) (3) (4) (3) 
T .33+.13 .46+.06 1.00+.32* 
.44+.15 (4) (4) (4) (4) 
CN DA 
c 6.46+.90 6.17+.66 7.75+1.36 5. 72+1. 61 (4) (4) (4) (4) 
T 7. 72+lo00 8.72+1.66* 9.40+1.04 8.33+2.22 (4) (4) (5) (4) 
Stem DA 
c .20+.04 .05+.0l 
.n+.01 .06+e03 (4) (4) (4) (3) 
T .16+.06 .05+.007 
.14+.03 .10+.03 en (4) (4) (4) 
Table 17 (continued) 
0600 1200 1800 2400 
MB 5HT 
c .67+.10 .35+.05 .31+.14 1.09+.23 (3) (3) (4) (4) 
T .54+.30 .62+.07** .52+.07** 1.42+.44 
(4) (5) (5) (4) 
Hpth 5HT 
c .78+.28 .71+.14 .74+.36 1.20+.22 (3) (4) (3) (3) 
T .86+.07 .82+.14 .81+.18 1.32+.45 
(4) (5) (5) (5) 
CN 5HT 
c .36+.06 .37+.06 .48+.13 .34+.16 
(2) (3) (4) (3) 
T .28+.08 .40+.03 .67+.31 .38+.07 (4) (3) (5) (3) 
Stem 5HT 
c .53+.13 .54+.06 .53+.13 .60+.08 (4) (3) (4) (4) 
T .47+.04 .81+.15* .62+.03 .73+.10 (3) (4) (4) (4) 
Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in 
the four areas indicated in Table 9, for animals receiving GBL (350mg/kg, 
IP). Animals were sacrificed midway through the previously-<letermined 
sleeping time. Values are means :!:. standard deviation, with the number 
of animals used in parentheses. Significant differences from control are 
noted by * (P<0.05) or ** (P<0.01). 
C = Control; T = Treated 
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E. The Effect on Rectal Temperature of Pentobarbital Alone and in Combination 
with Drug Pretreatments 
1. Untreated animals 
Rectal temperatures were measured in groups of eight 7ats at 0600, 
1200, 1800 and 2400 hours (Table 18 ) o The 24-hour pattern for rectal temper-
ature peaks at 2400 hours (38.44 ± Oo38°C.) and is minimal between 1200-1800 
hours (36.90 ± 0 0 54 - 36.88 ± 0.68°C 0 ) (Fig. 4~. The trough values differ 
significantly from the peak value (each at P<0.001). The peak also differs 
significantly from the value at 0600 hours (P < 0.05). The 0600 hours value 
differs significantly from those at 1200 hours (P<0.005) and 1800 hours 
(P < 0.01). 
2. Treated animals 
Rectal temperatures were measured in vehicle-treated control and drug-
treated animals during the detenninations of sleep duration after PB. The 
patterns for the mean rectal temperatures of controls and treated animals are 
plotted at ten-minute intervals for each of the four experimental times 
during the 24-hour period (Figs. 47-5~. These plots of the temperature means 
demonstrate the hypothermia produced by PB (controls) and the influence of 
drug pretreatment on this patterno Values are tabulated in Table 19-22. 
Of all the pretreatment groups examined, the major temperature effects 
are produced only by TP (hypothermia), 5Hl'P (hypothennia) and DOPA-pargyline 
(resistance to hypothermia). 
At 0600 hours, rectal temperatures in TP-treated animals are 1.86 to 
3.81°C. lower than controls, and remain lower after the temperature begins to 
return to normal in controls. The pattern for the TP-treated animals differs 
Tablel8:Tbe 24-bour pattern of rectal temperature in untreated rats 
Rectal temperature 
( oc. ) 
0600 
37.9+0.6 (8) 
1200 1800 
36.9+0.5 36.9+0.7 
<sT (8) 
2400 
38 0 4+0 0 4 A B c E F+ 
ts) 
Table indicates rectal temperature ( 0 c.) measured at six-hour intervals. Values are means 
+ standard deviation, with the number of animals used in parentheses. 
+ For explanation of letter designations see Table 1. 
!\:) 
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Figure 41: Rectal temperature in CONTROLS and drug pretreated groups, with 
pentobarbital -- 0600 hours. The Y-axis is temperature, in °c. 
and the X-axis is minutes after the onset of pentobarbital sleep. 
Table 19: The time-course of PB hypothermia in controls and 
treated rats, 0600 
23n 
DOPA-
TIME CO:r-.ITROL 
(min.) ~· ~ 
pCPA TP 5H~ HdlOO 
5 38.5+.5 37.7+1.4 37.9+.2 38.4+.4 34.7+.3* 
(7) (5) (5) (3) (3) 
15 37.5+.7 37 .3+1.3 37.5+.5 37.6+.2 34.2+.4* 37.2+.9 37.4+.3 
(ll) (5) (5) (3) (3) (4) (3) 
25 36,7+.6 36.9+1.2 36.7+.6 36.8+.3 34.0+.4* 36.5+.9 36.9+.2 36.7+.2 
(l6) (5) ( 6) (4) (3) (4) (3) ( 6) 
35 36.1+.7 36.6+1.2 36.2+.8 36.1+.2 33.5+.6* 35.8+1.0 36.3+.3 36.1+.2 
(16) (5) (6) (5) (3) (4) (4) (6) 
c!5 35.7+.7 36.3+1.3 35.9+.9 35.6+.2 33.1+.6* 35.4+1.0 35.9+.~l 35.6+.~i 
(l6) (5) (6) (6) (3) (4) (4) (6) 
55 35.3+.7 36.1+1.3 35.6+.9 35.3+.3 32.9+.6* 35.0+1.0 35.6+.4 35.2+.3 
(16) (5) . (6) (6) (3) (4) (3) (6) 
65 35.0+.7 35.8+1.5 35.4+1.0 35.2+.5 32.7+.6*34.8+1.l 35.5+,2 34.0+.3 
(15) (5) (6) (6) (3) (4) (2) (6) 
75 34.7+.8 35.6+1.6 35.2+1.l 35.0+.6 32.5+.5* 34.7+1.2 34.5+.4 
(13) (5) (6) (6) (3) (4) (6) 
85 34.5+.9 35.5+1.6 35.2+1.3 34.9+.8 32.4+.5* 34.6+1.2 
(l3) (5) (5) (6) (3) (4) 
95 34.2+.8 35.3+1.7 35.l+l.5 35.2+.7* 32.3+.5* 34.7+1.2 3·1. 2+. 5 (1o) (5) (5) (6) (3) (4) ( 6) 
105 34. 2+1. 0 35.1+1.7 34.9+1.3 35.5+.9* 32.4+.6* 34.3+.8 33.8+.7 
(9) (5) (5) (6) (3) (3) ( 3) 
115 35. O+l. 8 35.9+.8 32.5+.8 
(5) (6) (3) 
125 34. 7+1. 7 36.4+1. l 32.6+.9 
(5) (5) (3) 
135 34.5+1. 7 36.5+1.4 32.7+1.0 
(5) (3) (3) 
145 34. 4+1. 6 32.9+1.l (5) (3) 
==== 
185 34.l+l.2 
(5) 
240 
significantly from the control pattern at all time points (5-105 minutes, 
P ( 0.001 - 0.005). The curves for the other treatments do not differ signif-
icantly from control, except for the pcPA values at 95-105 minutes, which are 
significantly elevated above controls (P < 0.025). 
At 1200 hours, the fall in rectal temperature of DOPA-pargyline-treated 
animals proceeds at a slower rate than for controls. The DOPA-pargyline pattern 
is elevated significantly from the control pattern during 25 to 95 minutes 
(P< 0.01 - 0.001), ranging from 1.53 to 2.85°c. The rectal temperature in 
5HTP-treated animals is significantly lower than the controls during 5-95 
minutes (P<0.001), ranging from 1.62 to 3.22°c. The temperature effects of 
the other treatments at this time are not significantly different from control, 
except for the following: M25 lower than control during 75-85 minutes (0.92 
and 0.37°c., respectively, each P < 0.025) and pcPA higher than control at 65 
minutes ( 0.88°C., P < 0. 05). 
At l&QQ hours, the rectal temperature in DOPA-pargyline-treated animals 
is also above control values. They are significantly greater than the controls 
during 15-85 minutes (P (0.05 - <0.001), ranging between 0.88 to 2.01°c. TP-
treated animals have a significant lowering of temperature compared with 
controls during 5 to 95 minutes (P<0.001), ranging between 2.17 to 3.75°c. In 
5HTP-treated animals the rectal temperature is significantly lower than the 
control temperature for 15 to 25 minutes and at 65 minutes (P<0.05), with 
differences ranging from 1~04 to l.12oc. 
At giQQ. hours, the rectal temperatures of DOPA-pargyline-treated 
animals are significantly elevated above controls during 15 to 95 minutes 
(1.60-3.00, P<0.001). The 5H'IP pattern is significantly lower than the control 
241 
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Figure 48: Rectal temperatures in CONTROLS and drug pretreated groups, with 
pentobarbital -- 1200 hours, Figure legends are the same as 
Figure 46. 
Table 20: The time-course of PB hypothermia in control and 242 
treated rats, 1200 
DOPA-
TI~£E CONTROL ~· AMPT pCPA 5HTP M HdlOO (min.) 
5 37,7+.3 35.3+.3** 37.9+.l 
(3) (4) (4) 
15 37.3+.5 38.0+.9 37.6+.2 34.6+.2**36.5+.5 37.1+.3 (8) (4) (3) (4) (2) (5) 
25 36.5+.6 37.7+.8**36.8+.2 36.5+.3 34.0+.2** 35.8+.4 36.3+.3 
(ll) (4) (5) (3) (4) (4) (5) 
35 35.2+.6 37.5+.6**36.2+.2 36.1+.3 33.5+.2** 35.3 +.2 35.7+.3 
(l3) (4) (5) (4) (4) (4) (5) 
45 34.8+.6 37.3+.5**35.6+.2 35.7+.4 33.1+.2** 34.6+.4 35,l+.4 
(13) (4) (5) (4) (4) (6) (5) 
55 34.4+.6 37.2+.5**35.2+.2 35.5+.4 32.8+.2** 34.2+.4 34. 7+.4 (fa) (4) (5) (4) (4) (6) (5) 
65 34.3+.7 37.1+.6**35.0+.2 35.2+.4 32.6+.2** 34.l+.3 34.3+.5 
(9) (4) (5) (4) (4) (5) (5) 
75 34.7+.5 36.9+.6**34.7+.3 35.0+.3 32.3+.2** 33.8+.3* 
(6) (4) (5) (4) (4) nn 
85 34.8+.6 36.7+.5**34.5+.4 35.1+.3 32.2+.2** 33,4+.l* 
(6) (4) (5) (4) (4) (2) 
95 35.1+.6 36.6+.5**34.5+,4 32.2+.2** 33.4+.l* 
(6) (4) (5) (4) (2) 
105 35.4+.9 36.5+.5 34.5+.7 32.2+.3 33.4+.2 
(4) (4) (5) (4) (2) 
115 35. 6+. 9 36.5+,5 32.3+.2 
(2) (4) (3) 
125 36.4+,4 32.4+.2 
(4) f3) 
==== 
215 34.9+.8 
(4) 
225 35.l+.6 
(3) 
235 35.1+.6 
(3) 
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Figure 49: Rectal temperature in CONTROLS and drug pretreated groups, with 
pentobarbital -- 1800 hours. Figure legends are the same as 
Figure 46. 
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Table 21: The time-course of PB hypothermia in control and treated rats, 1800 
DOPA-
TIME CONTROL parg. AMPT pcPA 'IT 5HTP M 
(min.) 
5 37.9+.5 38.8+.3 38.0+.6 38.1+.3 34.2+.2 
(8) (5) (3) (5) (3) 
15 37.4+.8 38.2+J 37.2+.8 37.6+.3 33.7+.2 36.2+.l 
(10) (5) (3) (6) (3) (3) 
** * 25 36.5+.8 37.8+.3 36.6+1.0 36~8+.3 33.3+.3 35.6+,.l 35.8+.2 
(12) (5) (3) (5) (3) (4J (3) 
** 35 35.9+.8 37.7+.5 36.1+1.0 36.2+.3 33.1+.2 35.0+.3 35.3+.2 
(13) (5) (3) (5) (3) (4) (5J 
** 45 35.4+,8 37.3+.4 35.4+1.l 35.7+.4 32.9+.2 34.6+.3 34.9+.2 
(14) (5) (3) (5J (3) (4) (5} 
55 35.0+.9 37.0+.'t* 35.4+1'.0 35.2+.4 32.8+.2 34.3+.3 34.6+.3 
(14) (5) (3) (5) (3) (4) (5) 
** 65 34.9+.9 36.7+.4 35.3+.9 34.9+.5 32.6+.3 33.9+.2 34.3+.4 
(13) (4) (3J (5) (3) (4J (5} 
34.9+1.l c ** 75 36.5+.4 35.2+.6 34.8+.6 32.5+.3 33.7+.2 34.1+.3 
(12) (4) (3) (5) (3) (4) (4) 
* 85 34.7+1.4 36.4+.3 35.2+.3 34.6+.6 32.4+~3 33.7+.2 33.8+.3 
(9J (4) (3) (5J (3J (4J (2J 
95 34.4+1.6 36.1+.3 35.1+.2 34.6+.8 32.3+.3 
(4) (4) (3) (5) (3) 
105 35.9+.3 35.4+.4 34.8+1.0 32.2+.3 
(4) (3) (5J (3} 
115 35.7+~4 35.2+1.2 32.1+.3 
(4) (5) (3) 
125 35.6+.4 35.5+1.5 32.1+.3 (4) (5) (3) 
135 35.4+.4 35.9+1.6 32.1+.3 
(4) (5) (3)-
145 35.2+.4 36.l+l.5 32.1+.3 
-----
(4) (5) (3) 
205 34.7+.4 
(4) 
r 
I 
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2400 
38 
37 
36 
CONTROL 
35 
pCPA 
~-----AMPT 
34 
Figure 50: Rectal temperature in CONTROLS and drug pretreated groups, with 
pentobarbital -- 2400 hours. Figure legends are the same as 
Figure 46, 
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Table 22: The time-course of PB hypothermia in control and treated rats, 2400 
DOPA-
TIME CONTRDL 
.E!!&• AMPT pCPA fil!'.!E. M (min.) 
5 39.2+.0l 
(2) 
** 15 37.7+.3 39.3+.8 37.7+.7 37.7+.l 37.3+.4 
(4) (4) (5) (2) (2) 
** ** 25 37. l+. l 39.l+.7 36.7+.5 36.7+.9 36.0+.5 36.8+.4 
(10) (5) (7) (5) (4) (3) 
** ** 35 36.5+.2 38.9+.7 36.2+.6 36.0+l.O 35.4+.3 36.3+.4 
(11) (5J (8) (5) (4) (4) 
** 
** 45 36.0+.3 38.7+.8 35.7+.4 35.5+1.2 35.0+.3 35.8+.5 
(ll) (5) (8) (5J (4) (6) 
** * 
** 
55 35.7+.4 38.5+.8 35.3+.3 35.2+1.3 34.7+.4 35.4+.5 
(11) (5) (8) (5) (4) (6) 
** * 65 35.3+.5 38.3+.7 34.9+.3 35.0+l.,3 34.5+.4 35.3+.5 
(8) (5) (8) (5) (4) (4) 
** 75 35.l+.6 38.1+.7 34.6+.3 34.7+.3 34.1+.3 35.0+.5 
(8) (5) (8) (5J (4) (2) 
85 35.4+.6 38.0+.7 34.3+.4 34.6+1.3 (6) (5) (8) (5J 
95 35.5+1. l 38.0+.6 34.2+.4 34.5+1.4 
(4) (5) (8) (4) 
105 37.9+.6 34.2+.6 
(5) (8) 
115 37.9+.6 34.2+.7 
(5) (8) 
125 37.8+.5 34.2+.8 
(5J (8J 
135 37.7+.6 34.2+.8 
(5) (7} 
-----
195 36.5+1.l 
(5J 
205 36.2+1. 0 
(5) 
p 
pattern during 25 to 75 minutes (P < 0.02 - 0.001) with differences ranging 
from 0.88 to l.08°C. The AMPT pattern is reduced significantly below that 
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of control for 55 to 65 minutes after PB, with differences of 0.43 and 0.47°C., 
respecti vely(P < 0.05). 
DB (15mg/kg, IP) in rats produces a significant fall in rectal temper-
ature, 24 hours after its administration. The subsequent administration of 
PB causes a more profound and significant decrease in rectal temperature. In 
male mice, the rectal temperature 24 hours after DB is less depressed than in 
the rats. After PB, the fall in rectal temperature is double that of saline 
or methyl cellulose controls. 
DPH (50mg/kg, IP) in mice, produces a marked fall in rectal temperature, 
from 38.1 .:!:. 0.9 to 34.3 ±. 0.7°C. After PB temperatureedecreases further to 
30 0 5 .:!:. 0.9, as compared to 35.7 .:!:. 2.4°c. for saline or methyl cellulose 
controls. 
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V. GENERAL DISCUSSION 
A. Introduction 
Normal sleep is a complex process, and drug-induced sleep further 
conplicates the process. It is evident that a variety of drug treatments 
and/or conditions (environmental, physiological, pathological, etc.) can 
inf nence the state of sleep considerably as has been illustrated by experi-
ments described in the thesis and elsewhere. Sleep induced by drugs has not 
hcen studied to any great extent from the standpoint of circadian alteration, 
i.e., time-linked drug effects, or with a consideration of the internal 
m:licu of the organism as it influences drug affect. This is an important 
consideration because of the periodicity basic to sleep-wakefulness phenomena. 
Since biological systems and organisms are in a dynamic state, studies of 
their functions ought to include these time-linked aspects. 
For these reasons an examination of alterations in the duration of 
drug-induced sleep has been made on a 24-hour basis. Concomitantly brain 
amine levels in specific CNS areas, body temperature changes, as well as 
their interrelationships have been studied. 
A basic question of this study revolves around the possible modes by 
which sleep induced by hypnotics might be affected. Several possibilities 
will be enumerated and subsequently examined as they might apply to data 
derived from specific drug treatments. 
The following are to be considered: 
1) amine background upon which the hypnotic acts 
2) the influence of temperature on metabolism and hypnosis 
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3) actions on metabolizing enzymes (of amines and the hypnotic) 
4) the binding of barbiturate and amines and their bioavailability 
B. Drugs affecting the NE and DA system 
1. DOPA-pargyline 
DOPA-pargyline pretreatment significantly prolongs PB-sleep at 
eacn Lime tested (Table 3 ). The curve over the 24 hour period is essentially 
flat indicating that at this dosage, sleep duration has reached a ceiling 
rP.sponse. Amine measurements made half-way through the sleep period in such 
animals indicate significant increases in DA concentrations in all brain parts, 
at almost every experimental time point (15/16 values). NE levels increased 
.c;ignificantly in only 4 of 16 values, viz, the CN at 0600, 1800 and 2400 
hcct0; brain~ at 0600 hours. 5HT levels are decreased in the MB at 1800 
.-ti1d 2!+00 hours. Of these amine changes, the increased DA concentration seems 
'.- cu~·relate hest with the prolongation of sleep (15/16 instances). In the 
CN at 1200 hours there is no significant change in DA concentration at a time 
when sleep duration is increased over controls. 
These results are in opposition to the reports of excitatory effects 
for DOPA or DA, administered intraventricularly, intracisternally and 
iontophoretically (Spooner and Winters, 1965). The changes in brain NE and 
SHT concentrations coincide only infrequently with the prolongation of PB-
sleep in this treatment group. In the face of a PB challenge the usual 
excitatory effect of DOPA or DA is inoperative and other mechanisms must be 
,. 
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considered. Lesions of the DA-containing areas in the mesencephalic ventral 
tegmentum (in the substantia nigra) produce behaviorally-comatose animals, 
but with a relatively normal EEG sleep-wake cycle (Jones~ al., 1969). On 
the other hand, Connor (1970) demonstrated that direct iontophoretic appli-
cation of DA to CN neurons produced spike rate depression. Lammers and 
;.·::tr'. Rossum (1968) reported bizarre stereotypic behavior in rats after the 
ad,,inistration of DOPA in combination with a peripheral decarboxylase inhi-
c).c r.or. When animals were isolated, they remained in a catatonic state. The 
behavior, which was maximal after one hour, lasted over an eight-hour period. 
Ihc prolongation of PB sleep in DOPA-pargyline rats might be a reflection of 
catatonia superimposed on depression. Ansel and Markham (1970) noted 
r:1:uwsiness in two of four normal patients given L-DOPA chronically, although 
t•iey did not appear sedated. Messiha et al. (1970) found that DA urinary 
~xcretion was elevated in both depressed and manic patients, and returned to 
uormal only in the latter case after lithium therapy. In the treatment of 
Parkinson patients, depression has been reported (Cherington, 1970; Damasio 
~al., 1970). These studies suggest that under some conditions DOPA and/or 
DA can exert depressant effects. 
Blum~ al. (1972a)demonstrated that DOPA enhanced ethanol-induced 
sleep, which seems to corroborate the present study. These investigators 
suggested that the enhanced sleep might be due to the naturally-occurring, 
alcohol-like metabolite of DA, 3,4-dihydroxyphenylethanol (DOPET), whir.h 
augments sleep. A similar argument could be invoked for the results obtained 
in the present study. To establish this it would be necessary to demonstrate 
this compound's formation in vivo, and correlate its presence with sleep. 
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Although there are no significant differences between sleep periods 
at the experimental times, the amine levels of DOPA-pargyline treated animals 
do exhih:it significant diurnal fluctuations (Fig 29 ) . These amine 
changes include MB, brain ~' and hypothalamic DA and hypothalamic SHT, 
::ill of which peak significantly at 1800 hours. CN SHT, brain stem SHT and 
Mfl NF levels exhibit significant peaks at 1200 hours. CN and hypothalamic 
N"E values are minimal at 0600 hours and maximal at 1800-2400 hours. These 
results indicate that the influence of pretreatment on amine levels in CNS 
varies with the tissue and time of the day. This could be of clinical im-
portance in the selection of the proper time of day,for example, for Parkin-
sonian patients to ingest L-DOPA, for maximum therapeutic efficacy. 
Rectal temperature in DOPA-treated animals decreases at a signifi-
cant1 y slower rate than in the controls, indicating that this treatment pro-
.· c.~': a n.:s is tance to the normal hypothermia induced by PB. Myers and Yaksh 
(1968) repcrted that in the rat, intraventricular NE and DA (DOPA after ,t 
latency) cause hyperthermia. At every experimental point, except 0600 hours, 
the pattern is elevated above controls, and continues to decrease, even when 
animals recover from sleep. A fall in body temperature might significantly 
decrease hepatic PB metabolism and thereby prolong its action, but the tem-
perature effect found favors a less depressed metabolic rate than in controls. 
It seems unlikely therefore that the body temperature changes play an im-
portant role in these effects. 
Another possible basis for DOPA-pargyline effects on sleep might be 
attributed to the binding of PB (Lasser et al., 1963; Pagnini et al., 1971) 
and CAs to plasma proteins. Danon and Sapira (1972) reported that labelled 
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cAs (including NE, DOPA and DA) are bound to human serum albumin, in vitro. 
These gel filtration studies demonstrated that the fraction of NE bound 
ru.nges from 20% at high protein concentrations to 90% at concentrations of 
3 x l0-811. Goldbaum and Smith (1954) reported that 37/o of PB is bound in 
vitro to bovine serum albumin. Pagnini et al. (1971) found that a number of 
d~nus which are bound to serum albumin in a manner similar to PB, enhance the 
di~ration of PB narcosis in mice. Increasing the concentrations of these drugs 
in vitro results in a further reduction of PB bound to serum albumin. The 
drugs were without effect on liver metabolism of PB. In mice treated with 
one of these drugs (sulfaethylthiazole), brain levels of PB were signifi-
c,rntly higher than in animals receiving PB alone. These findings suggest that 
t 1H' large dose of DOPA or the DA formed from it (and/or possibly their meta-
bclites), might be bound to plasma proteins, thereby displacing PB from sites 
•,:Y-1id otherwise bind to. With more free PB available to act upon the CNS 
~tructures, hypnosis would be prolonged. 
It is not likely that the prolonged hypnotic sleep is due to inhibi-
tion of the metabolizing enzyme. Nair (personal corrnnunication) indicated that 
the half-life of the enzyme oxidizing PB is about 15 hours. Since DOPA-
pargyline are administered 60 and 30 minutes, respectively, prior to PB, 
there is relatively little time for them to alter enzyme activity. 
2. Alpha-methyl-£-tyrosine 
AMPT pretreatment significantly prolongs PB-sleep at 1200 and 
2400 hours (Table 3, Figs. 11-12), and significantly decreases NE and DA 
levels from controls (Table 10, Fig. 31). However 5HT levels are 
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unchanged in 10/14 values, increase in 3/14 and decrease in 1/14 values. 
Brain stem SHT and DA, CN SHT and MB SHT levels exhibit diurnal patterns 
with peaks at 1200 hours and troughs at 2400 hours, in the dark. Hypotha-
lamic DA also peaks significantly in the light (1800 hours) and troughs in 
the dark (0600 hours). CN NE and DA, and MB DA have maxima in the dark phase. 
These results demonstrate that even when CNS CAs are depleted, the reduced 
amine concentrations vary with the time of day. 
Amine reductions from control were as follows: MB NE, 43.6% - 58.9%; 
brain stem NE, 45.8 - 51.6% and hypothalamic NE, 52.1 - 62.6%. CN NE de-
creases significantly only at 0600 hours (61.3%) and 1800 hours (43.9%). 
The percentage depletion from controls for NE in all tissues examined ranges 
between 43.6 - 62.2% in 14/16 instances (Table 10). The percentage de-
pletion from control for CN DA (70.0 - 78.5%, 4/4 values) and hypothalamic 
DA (74.7 - 86.3%, 2/4 values) is somewhat higher than for NE. The extent of 
depletion of NE in the tissues over the 24 hour period studied is relatively 
constant. AMPT is a tyrosine hydroxylase inhibitor, exerting its amine-
depleting effects by blocking CA synthesis. The degree of depletion of NE 
and DA is indicative of different rates of turnover (Iversen and Glowinski, 
1966). Udenfriend and Zaltzman-Nirenberg (1963) reported that in the guinea 
pig brain the half-time of DA was 2 hours while that of NE was 4 hours. The 
greater depletion of DA could also be due to its greater release. 
Rech et al. (1968) reported that AMPT induces behavioral depression 
in rats, related to the CA depletion. Weitzman et al. (1969) found that AMPT 
decreases REM sleep, with a compensatory increase in NREM sleep. Hartman 
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~al. (1971) reported that in the rat oral AMPT increased PS, while IP AMPT 
(75 mg/kg) disturbed sleep and decreased PS. Torda (1968) found no obvious 
EEG changes 3 hours after AMPT (80 mg/kg, IP), but did after 18 hours (3 doses 
6 hours apart). SWS increased and PS and wakefulness decreased. King and 
Jewett (1971) described that AMPT in cats enhanced REM sleep, at a time when 
NE levels are significantly reduced. Sjoerdsma et al. (1965) found that AMPT 
produced sedation in humans. Jouvet (1972b) indicated that the effects of 
AMPT on PS were variable, but in all species behavioral and EEG waking were 
decreased, which could le counteracted by DOPA administration. These studies 
indicate that after AMPT administration waking is reduced. Such depression 
might be expected to enhance PB-sleep. This is demonstrated in the present 
study at 2400 as well as 1200 hours. The latter result occurs during the 
normal sleep period of rodents, when hypnotically-induced sleep reaches a 
maximum. The second, more prominent peak at 2400 hours, comes at a time when 
the rats are nonnally awake and active. There are several amine differences 
at 2400 hours compared to 1200 hours that might contribute to the augmented 
sleep. These differences include: significantly-reduced MB and hypothalamic 
DA at 2400 hours. MB SIIT and brain~ DA are elevated and hypothalamic 5IIT 
is reduced compared to controls at 1200 hours, but not at 2400 hours. Since 
the MB includes the anterior portion of the SIIT-containing raphe system, 
which numerous lesion and pharmacological experiments (cf. Jouvet, 1972b) 
indicate is vital for sleep, facilitation of PB-sleep might be attributed to 
the augmented MB 5IIT levels. This effect would have to be balanced somewhat 
by the decreased hypothalamic 5IIT which would tend to counter sleep (vide 
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infra regarding reduced SHT and depression). There are no significant dif-
ferences for SHT from control at 1200, 1800 or 2400 hours for brain stem, 
which contains the posterior portion of the raphe system. 
An examination of the time-course of rectal temperatures in treated 
animals reveals a pattern that is in essence similar to that of the control. 
This would tend to eliminate temperature changes as a factor for the signi-
ficant increase in PB-sleep at 1200 hours. At 2400 hours, rectal temperature 
is significantly lower in AMPr-treated animals than controls (at 55 and 65 
minutes) 0.43 and 0.49°C. lower, respectively) but such small differences in 
body temperature are not likely to be effective in prolonging PB-sleep at 
2400 hours. 
The effects of AMPT on PB-binding to serum proteins or the PB-meta-
bolizing enzyme are probably minor. AMPT was administered 4 hours prior to 
PB) which probably is insufficient time to alter the PB-metabolizing enzyme 
system (Nair, personal conununication). Danon and Sapira (1972) reported that 
L-tyrosine is not boµnd to albumin, but AMPT was not studied. Notwithstanding 
its inhibitory effect, there is some indication that AMPT itself can be hy-
droxylated to alpha-methyl DOPA and subsequently form alpha-methyl DA and 
alpha-methyl NE (Maitre, 1965). Danon and Sapira (1972) did find that alpha-
methyl DOPA was bound to the same extent as DOPA. Moore~ al. (1967) 
reported a number of toxic effects after AMPr, but which do not appear until 
20-48 hours after administration. These effects include hypothermia (b.0°C. 
lower than controls)) lethargy, and weight loss. AMPT-treated animals have 
higher blood glucose levels within 2 hours after injection, which return to 
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normal 24 hours later. An interesting aspect of the AMPT-sleep pattern is 
its similarity to the bimodal circadian plasma glucose pattern obtained by 
Frideman and Walker (1969). They explained the nature of their pattern on 
the basis of a diurnal rhythm for the initial glucose peak and a feeding 
rhythm for the second peak. Lawson~ al. (1951) demonstrated that glucose 
was effective in restoring sleep to animals awakening from drug-induced sleep. 
Finally, one cannot help but think that the possibility exists for the dis-
placement of PB from plasma by several substances entering the plasma con-
comitantly with AMPT itself or its metabolites and dietary constituents. 
C. Drugs Affecting the 5IIT System 
1. p-Chlorophenylalanine 
pCPA treatment significantly prolongs PB-sleep above controls 
at all experimental time points. Furthermore, the 24-hour pattern of sleep 
duration is circadian, with a peak at 1200-1800 hours (Figs. 13-17 ). This 
compound produces a significant reduction of 5IIT levels at each point of 
measurement during the 24-hour period (16/16). Several concomitant reductions 
in DA levels occur during the light phase, viz., 29.1% decrease in MB DA 
(P < 0.05) at 1200 hours, 24.2% decrease in CN DA (P < 0.05) at 1200 hours 
and a 72.7% decrease in hypothalamic DA (P < 0.005) at 1800 hours. 
MB 5IIT exhibits a maximum at 2400 hours in the dark phase, with 
significant differences between this peak and 0600, 1200 and 1800 hours. 
Hypothalamic NE is minimal at 1800 hours, differing significantly from 0600, 
1200 and 2400 hours. CN NE and hypothalamic DA are also minimal at 1800 
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hours, differing significantly from the values at 0600 and 1200 hours. CN 
DA is maximal at 1800 hours, differing significantly from 0600 and 1200 hours 
levels. Hypothalamic 5HT exhibits a trough at 0600 hours (SHT concentrations 
reduced to zero) and a peak at 1200 hours, with significant differences between 
the trough and the other three time points and the peak and the 2400 value. 
CN SHT levels are minimal at 1200 hours and maximal at 2400 hours, during 
the dark phase. Brain stem DA is minimal at 0600 hours, while brain stem 
SHT is maximal at 1200 hours. 
The amine patterns after pCPA exhibit diurnal variations, which, in 
general are at their normal levels for CAs and reduced for SHT. The extent 
of depletion is great, i.e., in 12/16 measurements it is greater than 85%. 
MB SHT is depleted to the smallest extent (40.4%) at 2400 hours, when the 
prolongation of sleep by PB is least. The depletion of hypothalamic SHT at 
1200 hours (66.9%) or CN SHT at 1800 hours (74.5%) occurs when the augmenta-
tion of PB-sleep is maximal. In the pCPA-depleted state, brain stem and 
hypothalamic 5HT are at their peak levels, at 1200 hours, although these 
tissues are at 13.2% and 33.1% of their respective control levels. The fact 
that the sleep pattern, although shifted to an augmented level, still main-
tains a 24-hour variation, reflecting the normal pattern would suggest that 
the relative, rather than absolute 5HT values play a role in the modulation 
of sleep. Superimposed upon this effect is the general depressant activity 
of PB itself. The brain stem contains most of the 5HT-containing raphe 
system, which is important in normal sleep (cf. Jouvet, 1972b). The con-
comitant reduction in CN NE and hypothalamic NE and DA are factors that might 
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facilitate PB sleep. Many studies suggest that NE and DA are important for 
waking (cf. Marczynski, 1967; Marley and Stephenson, 1972; Jouvet, 1972b). 
In view of several reports of the insomnic effect of pCPA (Delorme 
et al., 1966a;Koella et al., 1968; Mouret~ al., 1968; Pujol~ al., 1971), 
one would not have expected the prolongation of sleep obtained in the present 
studies. In pCPA-induced sleep changes, both REM and SWS are decreased. 
Dement et al. (1972) reported in the cat, that the early effect of pCPA is 
an increase in REM sleep for the first 24-48 hours (no dosage is given). This 
is followed by a reduction in REM and SWS after the third day. The prolonged 
deprivation of REM and SWS over the three-day period in which pCPA was ad-
ministered could explain the enhanced effect of PB seen in these studies, as 
a rebound phenomenon. The circadian variation in the prolongation might then 
be a reflection of the variation of the CA present, as well as a change in 
relative, rather than absolute levels of SHT. 
Central depression can occur with reduced 5Hr levels. Shaw et al. 
(1967) and Pare et al. (1969) demonstrated that 5Hr levels were significantly 
lower in the brain stem of depressed subjects. Bourne et al. (1968) found 
that 5HIAA was also reduced in such cases. These findings, together with 
others (vide supra) seem to indicate that depression can occur whenever 5Hr 
levels deviate from a specific optimal range of values. 
Whether binding of pCPA to plasma proteins is involved in this aug-
mentation of PB-sleep is not certain, since it is not known if pCPA bin~s 
significantly to plasma proteins, although phenylalanine does not (Danon and 
Sapira, 1972). However, pCPA is fairly slowly cleared from the plasma. Koe 
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and Weissman (1966) reported that 3 days were required for a single dose of 
pCPA (316 mg/kg, IP), to fall to one-half its maximum plasma level. With such 
a slow clearance, the consecutive administration of pCPA would result in its 
accumulation in the plasma. 
pCPA affects the rectal temperature only slightly under the conditions 
of these experiments, compared to controls. Occasional changes, in the 
direction of hyperthermia compared to controls, occurred (at 0600 hours, at 
95-105 minutes, 1.11 and l.27°C.; and 1200 hours, at 65 minutes, 0.88°C). 
These changes would very likely mitigate against prolonged sleep. 
2. Tryptophan 
TP prolongs PB-sleep significantly over controls at each of the 
experimental times (Table 4 ), but the only significant difference between 
the TP groups is between the 1800 and 2400 hours values. TP significantly 
elevates 5HT at 0600 hours in the MB and hypothalamus and at 1800 hours in 
the hypothalamus. Amine concentrations decrease in the following areas: 
hypothalamic NE levels at 0600 hours; in the MB, brain~ and l!Ypothalamic 
DA and CN NE at 1200 hours; in Ma.NE at 1800 hours; and hypothalamic DA levels 
at 2400 hours. TP, a secondary precursor of 5HT, was given to elevate brain 
5HT, which it did in only 4/16 instances, perhaps because the time interval 
and dose schedule used was insufficient. The use of 5HTP to increase central 
SHT has been criticized because of the widespread distribution of the decar-
boxylating enzyme leads to formation of SHT in CNS areas in which it is not 
normally present (Moir and Eccleston, 1968). Exogenous TP follows the phy-
siological uptake pathways, which involve hydroxylation of TP at intra-
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neuronal sites and uptake into the CNS SHI stores. Exogenous SHIP is taken 
up by the brain. and decarboxylated in the cytoplasm, and subsequently and 
quite readily attacked by MAO. 
MB and hypothalamic SHI concentrations peak at 1800 hours and are 
greater than levels at 0600, 1200 and 2400 hours. Brain stem NE is maximal 
at 1800 hours and CN DA is maximal at 1800-2400 hours. The elevated SHI in 
the hypothalamus (1800 hours) and brain~ (2400 hours) and decreased brain 
stem and CN DA at 1200 hours might be expected to favor sedation. MB and 
brain stem DA and CN NE levels are minimal at 1200 hours. Reduced levels of 
NE and DA at 1200 hours might be expected to reduce their alerting effects 
and facilitate depression by PB. It should be pointed out that the results 
favoring sleep that were obtained at 1200-1800 hours occur during the period 
of normal sleep in these animals. 
Several clinical studies have reported that TP ingestion by humans 
has a facilitatory effect on sleep (Wyatt£! al., 1970b; Hartman et al., 197lb). 
Wyatt et al. (1970b) found increased total and NREM sleep and decreased REM 
sleep. Pretreatment with a decarboxylase inhibitor enhanced the sedative 
effect, while reducing the unpleasant side effects. However, these investi-
gators concluded that TP does not act through a SHI mechanism, since SHIP 
increases REM sleep, but TP did not. They further report that TP still has 
the same effects in pCPA-treated patients, in which the conversion of TP to 
SHI is inhibited. Hartman et al. (197lb)found that TP reduced sleep latency 
and slightly increased total sleep time, which was dose-dependent. They also 
reported that similar doses of L-histidine or L-tyrosine did not have these 
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effects. 
As seen in Figs. 47, 49 and Tables 19, 21, TP markedly lowers body 
temperature from control levels, from the onset of sleep, throughout the 
period of measurement. For example 5 minutes after the onset of sleep 
temperature fell 3.81°C. (from 38.48 in controls to 34.67°C.) at 0600 hours 
and 3.75°C. (from 37.92 in controls to 34.70°C.) at 1800 hours. As pointed 
out earlier, the reduction of body temperature results in prolongation of 
PB-sleep, by decreasing its rate of metabolism. These changes in body tem-
perature are of such magnitude that they might readily contribute to the en-
hancement of sleep. 
The binding of TP to serum albumin might also contribute to pro-
longation of PB-sleep. McManemy and Oncley (1958) and McManemy et al. (1961) 
reported in fasting humans and ~vitro, respectively, that 75% of plasma L-TP 
is bound to albumin. This binding is stereospecific and pH dependent, in-
volving the indole ring. However, tryptamine and 5HT are not bound signifi-
cantly. The large dose of TP utilized (500 mg/kg, IP) could raise plasma TP 
levels significantly to displace PB and enhance its actions. 
3. Melatonin 
Two doses of melatonin (M25 and M50) were used in the hypnotic 
study but only the lower dose was used for the brain amine determinations. 
The M25 dose prolongs PB-sleep significantly at 1200, 1800 and 2400 hours, 
with a peak at 1200 hours and a trough at 2400 hours. The M50 dose prolongs 
PB-sleep significantly at each experimental time, but shifted the peak to 
0600 hours and the trough to 1800 hours. M has behavioral and EEG hyper-
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synchronizing effects (Marczynski et al., 1964; Arutyunyan ~al., 1964; 
Hishikawa et al., 1969). Barchas ~al. (1967) demonstrated in mice that 
M (25 mg/kg, IP) prolonged HB sleeping time by 50%. Arutyunyan ~al. (1964) 
found that M prolonged chloral hydrate- and hexenal-induced sleep. The 
present study is the first report of a diurnal pattern for this enhanced 
hypnotic effect of M. The peak effect of the M25 dose occurs in the light 
phase) when rats normally sleep. 
The M25 dose had relatively little effect on brain amines. At 0600 
hours the effects of increasing 5lIT and decreasing DA in the ~ favor sleep, 
which is prolonged at this time. At 1200 hours, the decrease of brain stem 
5HT favors waking, while reduced hypothalamic DA favors sleep. Prolonged PB-
sleep is the effect at this time, indicating that the overall effect of these 
amine changes is a facilitation of sleep. The primary CN amine, DA, is 
reduced significantly at 1800 hours, when PB-sleep is prolonged. Since the 
CN is involved with motor activity, the reduced DA level might reflect the 
inactivity of animals at this time. At 2400 hours the amines changes are not 
significant and PB-sleep is less prolonged. These amine results are in the 
same direction as those obtained by Anton-Tay~ al. (1968), who, in the female 
rat, found elevations of MB 51IT,. 1 and 2 hours after a considerably lower dose 
of M, as well as increased hypothalamic 5I:IT at 1 hour and reduced cortical 
5I:IT at 20 and 60 minutes. There were no significant changes in NE in these 
areas. The sites of the prominent amines changes are the same as those ~vhich 
3 have been shown to selectively concentrate H-M (Noble~ al., 1967; Anton-Tay 
and Wurtman, 1969). 
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The M25 dose had no significant effects on body temperature effects 
of PB, except for a reduction at 75-85 minutes in the 1200 hours group 
(Table19-2~ Figs .47-50 ) . Barchas ~ al. (1967) found that M (25 mg/kg) had 
no effect on body temperature in rabbits, while Arytyunyan et al. (1967) 
reported that in mice, dose of M (50-100 mg/kg, SC) lower body temperature 
2-3°C. Hypothermia obtained with M in the present study is probably a factor 
in the prolongation of PB-sleep. 
The effect of the M50 dose paradoxically is reversed, with a maximum 
at 0600 hours in the dark and a minimum at 1800 hours, but PB-sleep is pro-
longed to the same extent as the M25 dose at 1200 and 1800 hours. The M50 
results are subject to several possible interpretations. Doubling the M dose 
does not result in a uniform enhancement of PB-sleep over the M25-treated 
groups. The increased prolongation at 0600 and 2400 hours with M50(motor 
·and metabolic) occurs in the dark phase, suggests that there might be a re-
lationship to the greater activity of the animals at these times. Doubling 
the M dose might produce brain monoamine changes favoring longer sleep. 
Because M is structurally similar to 5HT it might displace 5HT from its 
active site, and to a greater extent with the M50 than the M25 dose. 3H-M 
selectively concentrated in the MB and hypothalamus (Anton-Tay and Wurtman, 
1969). Greater effects on these areas, which normally contain significant 
amounts of 5HT, would favor the depressant actions of Mand 5HT. The extent 
of M-hypothermia might be greater for the M50, when the animals normal tem-
perature is high, resulting in a greater fall when combined with PB, to yield 
a slower rate of PB metabolism. Finally, with the M50 dose toxic effects 
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might be more prominent during the active period. 
4. 5HTP and 5HT-related Compounds 
5HTP significantly prolonged PB-sleeping time over controls at 
1200 and 2400 hours (Figs. 13-17 , Table 5 ) , although there is an increase 
at 0600 hours that is of borderline significance. This bimodal pattern is 
similar to that obtained with AMPT, in which there is prolongation during the 
normal sleep period (1200 hours) and at 2400 hours, when rats are active. In 
a limited study of the brain amines after 5HTP, at 1200 hours, SHI was elevated 
in MB, hypothalamus and to a lesser extent in the CN. There was a concomitent 
increase in MB, CN and brain~ DA, as well as CN NE. A metabolite of DA 
might be involved in the enhanced PB-sleep after SHTP (vide supra). Because 
SHI plays an important role in the production of sleep (Jouvet, 1972b) the 
increase in SHI produced in many brain areas by SHIP might be expected to pro-
long PB sleep throughout the 24 hour period. The question to be asked then is 
why was there no prolongation at 1800 hours? 
The SHTP temperature pattern at 1200 hours is significantly lower than 
control (between S-95 minutes, P < 0.001), with absolute differences ranging 
between 1.62 - 3.22°C. (Table 20 , Fig. 48 ). Significant decreases occur 
at 1800 hours at the lS, 2S and 6S minutes measurements (each, P < O.OS). 
There are also significant differences between SHIP-treated and control groups 
at 2400 hours, at 2S-55 minutes (each, P < 0.001) and at 6S-7S minutes (each, 
P < O.OS). The absolute reductions in body temperature are less than at 1200 
hours, ranging from 0.88 - l.08°C. There are no significant differences 
between temperatures for SHIP-treated and control groups at 0600 hours and 
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most of the measurements at 1800 hours. The prolongation of PB-sleep at 1200 
and 2400 hours could be explained in part, on the basis of reduced body tem-
peratures at these times. Barofsky and Feldstein (1970) found that 5HTP (50-
200 mg/kg, IP) produced hypothermia. They attributed this effect to the 
formation of 11 tryptophols" (tryptophol, 5-methoxytryptophol and 5-hydroxy-
tryptophol), which can lower body temperature in a dose-dependent manner. 
Pretreatment with a MAO inhibitor prevented the 5HTP-induced hypothermia, 
suggesting that the "tryptophol" metabolite, rather than 5HT, is the active 
hypothermic agent. Feldstein et al. (1970) and Taborsky (1971) reported that 
5-hydroxytryptophol and 5-methoxytryptophol induce sleep as well. 
The effects of several 5HT-related compounds were tested for their 
ability to prolong PB-sleep in mice. 5HIAA and 5-methoxy indoleacetic acid 
were without significant effect, while 5-methoxytryptamine and N-acetyl-5HT 
were active. Rectal temperatures were not determined, but it is probable 
that these compounds share some of the hypothermic properties of the trypto-
phols. These studies indicate that the activity of metabolites should be 
considered in any analysis of the effects of biogenic amines. 
D· Drugs Affecting the Histamine System 
l· Histidine 
Hd significantly prolonged PB-sleep over controls in the following 
instances: HdlOO dose at 0600, 1200 and 2400 hours; Hd500 dose at 1800 hours; 
and at the HdlOOO dose at the four experimental time points (Table 6 , Figs. 
18-22 ). PB-sleep is reduced significantly with the Hd500 dose at 2400 hours. 
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PB-sleep in the Rd-pretreated groups follows a circadian pattern, with peaks 
at 1200 hours (HdlOO) and at 1800 hours (HdSOO and HdlOOO), during the normal 
sleep period for rats. Monnier and Hatt (1969) reported that H activates the 
CNS reflexly when administered systemically and by a direct action on the 
reticulo-thalamic activating systems after intraventricular injection. In-
ferentially, Friedman and Walker (1969) suggested a waking effect of H as 
the result of finding that H concentrations in the CN are maximal during the 
normal waking period of rats. The results of the present study do not support 
such a role for H in PB-sleep, although H might be active in the sleep-wake-
fullness cycle of physiological sleep. 
Although brain H levels were not measured in the present study there 
is abundant evidence to show that Hd elevates H in the brain (Taylor and 
Snyder, 1972; Schwartz£.!. al., 1972). Taylor and Snyder (1972) found in the 
mouse, that H was significantly elevated in the hypothalamus, MB-thalamus-
hippocampus, cortex, striatum, medulla-pons and cerebellum, one hour after 
Hd (1000 mg/kg, IP). PB (60 mg/kg, IP) alone, one hour prior to determina-
tion, produced a significant elevation (26%) of whole mouse brain H. 
After HdSOO, DA in the brain stem decreases and hypothalamic DA 
increases at 0600 hours, while MB SHT is elevated. At 1200 hours, brain stem 
SHT is reduced. At 2400 hours there are elevations in MB DA and hypothalamic 
SHT. At 1800 hours, when the peak prolongation of PB-sleep occurs, with the 
HdSOO and HdlOOO doses, there are no significant changes in the levels of any 
of the amines studied, in any of the brain parts examined, suggesting that 
these amine changes are of minor importance in the prolongation of PB-sleep. 
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The changes that do occur at other times tend to balance out. Taylor and 
Snyder (1972) found no significant alterations in whole mouse brain NE, DA 
or acidic and neutral indoles, one hour after Hd (1000 mg/kg, IP) but did 
find a significant decrease (35%) in 5HT. 
There is no simple explanation forthcoming for the significant de-
crease in sleep at 2400 hours compared to control, produced with the Hd 500 
dose. 
There are no significant alterations in body temperature at 0600 and 
1200 hours of rats pretreated with HdlOO (Tables 19, 20, Figs. 47, 48). Un-
fortunately this aspect of the study is incomplete, but the formation if H 
from Hd, might be expected to produce hypothermia according to the findings 
of Packman et al. (1953). Shaw (1971) reported that in mice, H (intra-
ventricular, 1~10 ugm) or 125 mg/kg H (SC) produced hypothermia. Packman 
~al. (1953) obtained hypothermia in rats, with several doses of H (SC). 
The prolongation of PB-sleep by Hd appears to be unrelated to changes 
in levels of CNS monoamines studied. Displacement of PB binding to serum 
proteins is probably not involved because Hd does not bind to proteins to a 
significant extent (McManemy ~al., 1961). The effects might be due to a 
direct depressant effect of H, which prolong PB-sleep in a pattern following 
the normal sleep cycle of the rat. Phillis ~al. (1968) described depressant 
effects of iontophoretic H on cortical neurones, which could be antagonized 
by antihistamines. The greater depression at 0600 hours by the HdlOOO as 
compared to Hd500 dose could be explained by the higher levels of H produced. 
Although they found that iontophoretic methyl H had similar effects on 
cortical neurons as H, Taylorand Snyder (1972) showed no significant trans-
, 
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formation of 3H-methyl H from 3H-histamine formed from 3H-histidine in rat 
brain. This argues against H metabolites being responsible for some of these 
effects. The overall result of increasing Hin many brain areas by Hd pre-
treatment would probably favor depression, facilitating the action of PB. 
Several investigators have reported that the H levels in neonatal 
rat brain are five times higher than in adults (Pearce and Scharnberg, 1969; 
Ronnberg and Schwartz, 1969). Snyder (1972) found that telencephalon and 
diencephalon H exhibit a peak 5-10 days after birth, with a decline to adult 
levels by day 17. The increased H might be related to the maturing CNS, 
since high H levels occur at times of rapid neuronal growth. However, this 
elevated CNS H might also be related to the increased amount of time new-born 
animals sleep, if H has the depressant effects mentioned above. 
2. Decaborane 
DB significantly prolonged PB sleep. The pattern is relatively 
flat, indicating that a ceiling effect has been reached. DB was used to 
deplete brain H, but also affected levels of NE, DA and 5HT. NE concentrations 
are significantly depleted in almost all tissues and at all experimental times 
(14/16). The extent of depletion in the hypothalamus (76.3 - 78.7%) is 
greater than that in the MB (58.1 - 61.1%) or brain~ (54.8 - 65.6%). 
Merritt~ al. (1964) reported that rat brain NE was depleted 63%, 
24 hours after DB (15 mg/kg, IP). In this study 5HT is also depleted in 
9/16 cases. Both of these amines· are involved in central temperature regu-
lation (Bligh and Cottle, 1966; Myers and Yaksh, 1969). Their depletion 
might be expected to disrupt mechanisms involved in heat production and loss. 
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DB inhibits decarboxylase activity, in vivo and in vitro, but also 
increases the rate of release of amines (Merritt and Sulkowski, 1967). The 
decarboxylase inhibition accounts for the depletion of NE and 5HT. Medina 
et al. (1969) demonstrated that DB (15 mg/kg, IP) depleted whole rat brain 
H maximally 24 hours after injection, by inhibiting Hd decarboxylase. H was 
depleted about 60%, suggesting other, resistant pools of H exist. The de-
pletion of H, by DB, might be expected to increase circulating H signifi-
cantly, with a resultant H-induced vasodilatation which would further the 
heat loss (vide supra discussion of H-induced hypothemia; Packman et al., 
1953). 
The elevated DA in the MB at 0600 and 1800 hours and at 0600 hours 
in the hypothalamus might be expected to favor a waking effect. At 0600 and 
2400 hours DA is reduced in the brain stem. Brain stem 5HT concentrations 
are also reduced. The H-depleting effects of DB fit with the arousal actions 
of H described earlier, in that the decrease in the levels of an alerting sub-
stance would tend to facilitate sleep. Sleep after Hd is augmented, partly 
because high concentrations of H exert a depressant effect. Hd pretreatment 
has fewer effects on other brain monoamines, while DB produced many, which 
contribute to the overall prolongation of PB-sleep obtained. A more specific 
H-depletor might better reveal the exact involvement of H in sleep. NE-
depleting actions of DB favor sleep, as do the effects interfering with temp-
erature regulation. 
Since DB inhibits decarboxylating enzymes, it might also inhibit the 
liver oxidizing enzyme system, responsible for metabolizing PB. Administra-
tion of DB 24 hours prior to PB would allow sufficient time for enzyme inhi-
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bition to occur, which would result in a reduced PB metabolism and therefore 
a longer duration of sleep. 
3. Diphenhydramine 
DPH significantly prolonged PB-sleep at all times examined and 
did so in a circadian manner (Table 6, Figs. 18-21). The effect is minimal 
at 1800 hours, and maximal at 2400-0600 hours. DPH was used because in its 
clinical use it frequently produces sedation. The maximum effect on PB-sleep 
occurs during the dark phase,unlike in the PB pattern, in which the peak 
occurs at 1200 hours, during the sleep period of rats. Clearly, the pattern 
does not follow that of sedatives, which produces longer sleep duration 
during the normal sleep period of animals. 
DPH effects on amine levels are not striking (Table 16, Fig. 41). 
The increase of MB SHT at 0600 hours favors enhanced sleep because this amine 
has a significant function in the raphe system. The reduction in hypotha-
lamic NE also contributed to this effect. This period corresponds to a time 
of maximal enhancement of PB-sleep by DPH. The elevation of CN SHT at 1200 
hours is the only significant amine change at a time which also favors sleep. 
However, SHT is of secondary importance in the CN. At 1200 hours, DPH-sleep 
duration is prolonged to an intermediate extent. The lowering of MB NE at 
1800 hours would favor enhanced sleep, which does occur at 1800 hours, 
although at this time DPH prolongs PB-sleep to the least extent. There are 
no significant amine changes at 2400 hours, although the prolongation of PB-
sleep returns to its maximal level. 
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The effect of antihistamines (beyond antagonizing H) are numerous and 
depend on structural features of molecular types. Most antihistamines have 
a dual central action: the initial depression seen at therapeutic doses 
shifts to EEG activation and seizures, if the dose is increased sufficiently. 
Douglas (1970) states that there is not yet a clear-cut explanation of the 
diverse actions of antihistamines, but a partial explanation might involve 
their anticholinergic effects or direct antagonism of CNS H. 
Green and Erickson (1964) reported that DPH (SO mg/kg, oral, one hour 
prior to sacrifice) reduces whole rat brain H. DPH (lS mg/kg, SC, 2 hours 
prior to sacrifice) increases guinea pig brain stem and cerebellum H (Green 
and Erickson, 1967). In whole mouse brain, Taylor and Snyder (1972) found 
no change in H, 4 hours after DPH (20 mg/kg, IP). Boissier et al. (1970) 
reported that DPH (SO mg/kg, IP, one hour prior to sacrifice) did not alter 
H levels in whole rat brain or in several rat brain areas, including hypotha-
lamus, CN and thalamus. 
Winter (1948) demonstrated in mice, the prolongation of HB (100 mg/kg, 
IP) or PB (SO mg/kg, IP) sleep, by DPH and other antihistamines (10 mg/kg, 
IP). No explanation of mechanism involved was given, except for citing its 
clinical sedative side effects. The results of the present study clearly 
corroborate this observation, but extend it by demonstrating that this pro-
longation varies significantly with the time of day. 
There are several other factors which could influence the duration of 
PB-sleep after DPH. The antihistamine might prolong sleep by blocking the 
alerting activity of H in the CNS, reported by Monnier and Hatt (1969) or 
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Friedman and Walker (1969). DPH has anticholinergic effects (Douglas, 1970), 
~hich could antagonize central ACh, which, according to Friedman and Walker 
(1972) is maximal in the rat when these animals are in an alert state. Anta-
gonizing ACh at times when it is normally maximal (i.e., 2400-0600 hours) 
might account for the longer duration of PB-sleep, because of the association 
of ACh with states of central excitation. Packman et ~· (1953) reported that 
in mice, DPH produced significant ·and maximal depression of body temperature 
one hour after its administration. Such a hypothermia could facilitate the 
prolongation of PB-sleep. 
Antihistamines also affect neural transmission and neuromuscular 
function. Abdel-Aziz and Bakry (1973) reported that DPH blocked transmission 
in a rat phrenic nerve-diaphragm preparation and reduced the action of ACh on 
the frog rectus muscle. This blocking action might delay the recovery of the 
righting reflex in PB-treated animals. A local anesthetic effect for anti-
histamines was also reported by Douglas (1970). 
The basis of the circadian differences in PB-sleep with DPH might be 
due to its monoamine changes, as well as the multiple effects just described, 
interpreted according to the continuum in the development of catalepsy by 
sedative drugs elaborated by Winters et al. (1967; 1972). Faingold and Berry 
(1972) demonstrated that IV infusion of DPH in cats (3.0 mg/kg/minute) in-
itially produced synchronized cortical activity, followed by an abrupt change 
to a desynchronized pattern approximately 5 minutes prior to the cortical 
seizure. The dose required to produce a seizure was 37 mg/kg. The dose 
utilized in the present study (SO mg/kg) is greater than that required for 
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seizure in the cat, although in the cat administration was IV and differences 
in species sensitivity must be considered. The use of PB in this study could 
obscure the later desynchronizing phase. 
E. Gamma-butyrolactone 
GBL (350 mg/kg, IP) produced a maximum duration of sleep at 1800 hours 
and a minimum at 0600 hours (Table 17, Fig. 44, 45), a pattern similar to that 
for PB-treated animals, in which the peak duration of sleep occurs during the 
normal sleep phase for rats. Significant increases over control for 5HT 
levels occur in the MB at 1200 and 1800 hours and in the brain stem at 1200 
hours. These areas contain the raphe system. Significant elevations in CN 
DA at 1200 hours and hypothalamic DA at 1800 hours, and CN DA at 1800 and 
2400 hours (with borderline significance: P about 0.05) favor waking although 
the possibility of structurally-related depressant amines cannot be discounted. 
A balance between these effects must exist, since the GBL pattern follows both 
normal and PB-sleep in a facilitory manner. 
Winters !:.!:_ !!._. (1967; 1972) have criticized designating the effects of 
GBL (or GHB) as "sleep". They found that GHB produced the following pro-
gression of effects: hypersynchrony, spiking with polyphasic bursts (7-15 
Hz) and periods of electrical silence and hypersynchronous high frequency 
generalized seizures. They claim that this is a "catatonic" state, or a 
"generalized non-convulsive epilepsy or seizure". They cite several other 
drugs used for anesthesia, which follow this GHB continuum, including ether, 
alpha-chlorolose and phencyclidine. The present study demonstrates a diurnal 
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pattern for GEL-induced sleep which is similar to that of PB. At this dose 
the hypersynchronizing effects described by Winters and coworkers might 
predominate and induce sleep, while facilitating normal sleep. If this is 
not the case, and the results of GBL administration is to produce catatonia, 
the present data would indicate that such a catatonia follows a circadian 
pattern. 
Roth and Suhr (1970) found that GBL (3 x 500 mg/kg, IP for three hours) 
significantly elevated whole rat brain DA and SHT, without any altering brain 
NE. (The results of the present study are similar although a considerably 
lower dose was used). They found that GBL (or GHB) specifically blocks DA 
release without affecting synthesis, but did not elucidate the mechanism of 
its CNS depressant action. They did find a good correlation between the 
sedative action and the increase in brain DA. Bustos~ al. (1972) indicated 
that the blockade of DA release is probably due to the reduced impulse flow 
in the nigro-neostriatal pathway, but did not elaborate on how this might 
affect sleep. In the present study brain DA levels increased only infre-
quently, therefore it cannot be directly related to the circadian pattern 
for the duration of GBL-induced sleep. Giarman and Schmidt (1963) reported 
that GBL increased ACh in whole mouse brain and rat MB and brain stem. 
Since microinjection of ACh into several areas of the RF results in be-
havioral and EEG sleep (Courville~ al., 1962; vide supra), this effect 
of GBL on brain ACh might be related to its depressant actions. 
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?. Anticholinesterases 
Physostigmine in mice increases PB-sleep significantly only at 2400 
hours (Table 7 , Fig. 23 ). The pattern is flat. Neostigmine significantly 
prolongs PB-sleep at 0600, 1200 and 2400 hours, while significance is border-
line at 1800 hours. The pattern has a peak at 0600 hours and a trough at 
2400 hours. Since neostigmine is a quaternary compound and does not cross 
the BBB, it must exert its effects peripherally by some indirect mechanism. 
Neostigmine inhibits cholinesterase, resulting in increased ACh at 
cholinergic sites. Its effects at the neuromuscular junction, spinal cord 
and ganglia are based on a combination of its cholinesterase inhibition and 
direct effects, which can result in muscle paralysis. Friedman and Walker 
(1972) demonstrated that rat MB and CN ACh levels were maximal at 2400 hours 
(and minimal for MB at 1200 hours and at 1800 hours for CN). They found that 
in mice, the neostigmine toxicity pattern, which was maximal at 0600 hours, 
and minimal at 1800 hours resembles the pattern of the duration of PB-sleep 
in mice after neostigmine. The LDSO of neostigmine ranged from 0.23 - 0.36 
mg/kg (IP) during the 24-hour period. The dose utilized in the present study 
(0.30 mg/kg, IP) is in the middle of this circadian LDSO range. The peak 
prolongation of PB-sleep at 0600 hours might be due to an interaction of PB 
with the toxic effects of neostigmine at various pharmacological sites. 
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VI. SUMMARY 
This study was undertaken in order toclarigy the influence of some 
rNS amines on the narcosis produced by a classic hypnotic agent, pento-
barbital and to a lesser extent, by another type of soporific agent, gamma-
butyrolactone (GBL). It was prompted by a number of earlier investigations, 
including those from our laboratory, which reported significant variations 
over a 24-hour period in the duration of drug-induced sleep, in the concen-
trations of biogenic amines in whole brain and portions of the brain. This 
study required a consideration of the normal circadian fluctuation of biogenic 
amines in various brain regions and the effects of pretreatment with various 
precursors, depletors, inhibitors of synthesis or metabolism, and other drugs 
related to biogenic amines, with respect to the duration of drug-induced sleep. 
An attempt to correlate alterations in brain amine levels in several brain 
areas with sleep duration seemed warranted. Since any drug or compound 
capable of changing body temperature presumably could alter the time-coursP 
of PB-sleep by influencing such activities as metabolism, an examination of 
temperature effects was also undertaken. 
The experimental animals (adult male rats and mice) were adapted under 
stable laboratory conditions to an automatically-timed light-dark cycle 
(0800-2000 hours light) for at least three weeks prior to use. The onset and 
duration of sleep, measured by the loss and recovery of the righting reflex, 
were determined every six hours ( at 0600, 1200, 1800 and 2400 boars), after 
IP doses of PB (50mg/kg) or GBL (350mg/kg). Pretreatment regimens were 
institlied at a sufficient time prior to the administration of the hypnotic 
so that the levels of the amine(s) under examination might be changed, Pre-
277 
treated and vehicle-injected control animals were used to determine alterations 
in sleeping timeo Similarly treated animals, sacrificed midway through the 
previously-determined sleep period were used for the spectrophotofluorometric 
determinations of biogenic amine levels in the midbrain, hypothalamus, caudate 
nucleus and brain stem. The duration of sleep in control rats after PB, 
50mg/kg, IP, ranged from a low of 101.3 + 8.9 minutes at 2400 hours during the 
dark phase of the illumination cycle, to 119.5 .±. 9. 7 minutes, at _1200 hours, 
during the light phase. Peak and trough values are significantly different 
(P < 0.01) and correlate inversely with rectal temperature, which peaks at 
2400 hours, when these nocturnal animals are most active and troughs at 1200 
hours, when they are quiescent. As a generalization, a majority of the treat-
ment regimens resulted in some prolongation of PB-sleep. The following types 
of modified PB sleeping patterns were obtained with the pretreatment regimens 
used: 
Type I: a normal diurnal or circadian pattern, in which the peak occurs 
during the usual sleeping period. In rats and mice this is during the light 
phase of the illumination cycle. 
Type II: a relatively flat pattern indicating that the system was 
responding maximally to a particular treatment. 
Type III: a relatively flat pattern in which one point departs signif-
icantly from the overall trendo 
Type IV: an inverted diurnal or circadian pattern, in which peak effects 
are observed during the dark phase of the illumination cycle. 
Type V: a bimodal or ultradian pattern in which a peak and trough occur 
in the light as well as in the dark phase of the illumination cycle. 
Treatments significantly prolonging PB-sleep in a Type I circadian 
fashion include pcPA (a 5HT depletor), histidine (a precursor of histamine) 
and melatonin (a naturally-occurring derivative of 5HT)o 
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pcPA administered in lOOmg/kg doses 72, 48 and 24 hours prior to PB 
significantly prolonged PB-sleep at every experimental time point (P< 0.001). 
The increases ranged from 19.5% at 0600 hours to 49.8% at l&QQ. hours. The 
peak duration at ~ hours differs significantly from the trough at ~ 
hours (P < 0.01). 
Histidine was administered IP one hour prior to PB at three different 
dose levels. At lOOmg/kg, histidine significantly prolonged sleep from 1506 
to 22.1% at 0600, 1200 and ~hours, but not at 1800 hours. At 500mg/kg, 
PB-sleep increased significantly at 1800 hours by 47 .6% (P < 0.001), but 
decreased significantly at 2400 hours by 13.4% (P<0.05). At lOOOmg/kg, PB-
sleep is significantly prolonged over the entire 24-hour period, from a low 
of 13.1% at 2400 hours to a high of 54.1% at 1800 hours. 
Melatonin, given concomitantly with PB potentiates sleep in a dose-depen-
dent manner. Sl~ep is significantly prolonged (from P < 0.05 to <..0.001) by 
50mgjkg at every time point and at every time point except ~hours with 
25mg/kg. Sleep is prolonged by 20.0 to 30o4% at the lower dose and by 29 0 5 
to 66.6% at the higher dose. There is a shift of the peak effect with 25mg/kg 
from 1200 hours to 0600 hours with 5 Gng/kg. The pattern with the M50 dose 
therefore must be categorized as a Type IV PB-sleep pattern. 
Highly significant potentiation of PB-sleep (P<0.001) was achieved 
after pretreatment with DOPA-pargyline (a precursor amine plus a MAO!) and 
decaborane (an inhibitor of histam,ine synthesis). These patterns were Type 
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II. DL-DOPA (500mg/kg, IP) and pargyline (6,0mg/kg, IP) administered one hour 
and 30 minutes, respectively, prior to PB, increased the duration of sleep 
from 103% at 0600 hours to 146.3% at 2400 hours. Decaborane (15,0mg/kg, IP) 
administered 24 hours before PB prolonged sleep at the subsequent 24-hour 
period from 69.1% at 1200 hours to 114.8% at 2400 hours. 
Type III PB-sleep patterns were obtained with tryptophan (a secondary 
precursor of 5HT) and 5HTP (the immediate precursor of 5HT). Tryptophan (500 
mg/kg, IP) administered one hour prior to PB, potentiated sleep significantly 
(P < 0.001) from 32.0% at 1200 hours to 59.1% at 2400 hours. Sleeping time was 
significantly lower at 2400 hours than at 1800 hours (P < 0.05). After 5HTP 
(lOOmg/kg, IP) administered one hour before PB, sleep was significantly pro-
longed (except for the measurement at 1800 hours) over control at 0600 
(P(0.05), 1200 (P(0.001), and 2400 (P<0.001) hours from 13.7 to 34.7%. The 
duration of sleep at 1800 hours was significantly lower than at 1200 hours 
(P( O. 01). 
A Type V bimodal sleep pattern was obtained after pretreatment with AMPT 
(200mg/kg, administered IP 4 hours before PB). The two significant peaks of 
19.8% and 75% above control occurred at 1200 (P<0.05) and 2400 (P<0.001) 
hours, respectively. The two troughs at 0600 and 1800 hours were not signif-
icantly different from controls. 
I>iphenhydramine (50mg/kg, administered one hour prior to PB) exhibited a 
Type IV pattern with the peak occurring in the dark phase of the illumination 
cycle. The significant increases in sleep (P< 0,001 at each time point) 
ranged from 62.7% at 1800 hours to 178.1% at 2400 hours. Peak and trough 
differed significantly from each other. 
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A tertiary anticholinesterase, physostigmine and a quaternary anticholin-
esterase, neostigmine were examined in mice for their effects on PB-sleep. 
Both were administered at a dose of 0~3mgjkg, IP, one hour prior to PB (50mg/ 
kg1 IP). The duration of sleep in control mice ranged from 26.3 ±. 18.3 min-
utes at 2400 hours to 41.7 ±. 26.0 minutes at 1800 hours. A diurnal rhythm 
was not obtained in these controls because of the variability of the data, al-
though there is the suggestion of a peak at !§QQ. hours. Phys•stigmine pro-
longed sleep at each time point but only at 2400 hours is an increase of 71.8% 
significant (P < 0.05). On the other hand, neostigmine prolongs sleep signif-
icantly at each time point {except at 1800 hours, where significance is border-
line) from 67 .6% (P < 0.01) at 1200 hours to 105.2% (P ( 0.001) at 0600 hours. 
- --
fhe effect on sleep of compounds structurally-related to 5HT were admin-
istered to mice at a dose of 20mg/kg, IP, one hour prior to PB at a single 
time point (1500 hours), favorable to eliciting a hypnotic effect. Signif-
icant prolongation of sleep occurred with 5-methoxytryptamine (74.6%;P<0.02) 
and N-acetyl-5HT ( 105.4% ;P < 0.025). 5HIM and 5-methoxyindole acetic acid 
were without signifieant effect. 
The duration of sleep produced in rats by 350mg/kg, IP, of gamma-butyro-
lactone varies with the time of day it is administered. It ranges from 68.2 
±. 9.3 minutes at 0600 hours to ll0.3 ±. 16.3 minutes at 1800 hours. The dif-
ference between peak and trough is statistically significant (P < 0.05). 
Pretreatment with histidine 100 and 500mg/kg produced augmented sleep only at 
,!&QQ_ hours, with the higher dose. The difference was significant at P < 0.05. 
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Pretreatment with DOPA-pargyline significantly elevated DA levels in 
various brain parts above control throughout the 24-hour period, in 15/16 
instances. On the other hand, NE levels were elevated in only 4/16 instances 
(in CN at 0600, 1800 and 2400 hours; in the brain stem at 0600 hours), while 
5HT decreased in 2/16 instances (in the brain stem at 1800 and 2400 hours). 
In 9 of 12 amine patterns a fluctuating pattern was obtained over the 24-hour 
period of measurement. The remaining 3 amine patterns, viz., MB-5HT, CN DA 
and brain stem NE, were unvarying. The fall in rectal temperature after PB 
is significantly reduced by DOPA-pargyline pretreatment. Prolongation of 
sleep with DOPA-pargyline correlates best with the increase in DA levels. 
The possibility that DA might displace PB bound to plasma proteins or that DA 
is converted to a metabolite exerting a hypnotic effect is considered in 
attempting to explain the augmentation of PB-sleep by this regimen. 
AMPT significantly reduced brain NE (13.6 to 62.2%) and DA (43.9 to 86.3%) 
levels in 14/16 and 8/16 instances, respectively, during the 24-hour period 
of examination. 5HT rose significantly in 3/14, fell in 1/14 and was 
unchanged in 10/14 instances. Sleep correlates best with the decreased 
le\els of NE and DA. Of 12 amine patterns, 5 are unvarying and 7 display 
diurnal rhythms, Temperature reductions after AMPT exhibit minimal differ-
ences from PB alone and do not appear to account for the increased duration of 
slPPp. Similarly, the effects of AMPT on the protein binding of PB are pro-
bably minor. 
pCPA significantly decreased 5HT levels in all tissues throughout the 24-
hour period (16/16 instances), from 40,4 to 97.0%, with only minor changes in 
CA levels. Body temperature reduction is probably of minor significance in 
the prolongation of PB-sleep. The effect of pCPA on the protein bindin~ of 
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PB is unknown, but the cumulative effect could be significant. The prolong-
ation Gf sleep correlates in this case with the widespread depletion of 5HTo 
8 of 12 amine patterns fluctuate during the 24-hour period. 
TP increased 5HT in 4/16 instances (40o5 to 69.2%), decreased NE in 3/16 
(15.7 to 48.5%) and decreased DA in 4/16 instances (29o3 to 81.0%), suggest-
ing that the amine changes were not of major importance in lengthening sleep. 
However, the significant increase in hypothalamic 5HT with a concomitant fall 
in MB NE at .!§Q.Q. hours might explain the peak effect in sleep seen at that 
time. Of 12 amine patterns, 10 show significant variation throughout the 24-
hour period. Two other factors undoubtedly contribute to TP-augmented PB-
sleep, viz., the probable displacement of bound PB because TP is significantly 
bound to plasma protein and the marked hypothermic effect TP produces. Within 
five minutes of the onset of PB sleep, rectal temperature was significantly 
lower than control by almost 4°C. This difference was maintained for more 
than two hours and was greater at 1800 than 0600 hours. 
The amine effects with M were studied only at the M25 dose. Only 5/48 
amine levels changed from control significantly (four decreases, MB DA (43.9%), 
CN DA (11.8%), brain stem 5HT (46.3%) and hypothalamic DA (76.1%); 1 increase, 
MB 5HT (76.3%)). Temperature effects of this dose are minor and displacement 
of protein bound PB is improbable. This suggests that the effect might be due 
to a direct depressant action. 
Although Hd500 significantly prolonged PB-sleep at 1800 hours, no sig-
nificant changes in the levels of the amines studied occurred in any of the 
brain parts examined, suggesting that neither NE, DA nor 5HT play a signif-
icant role in Hd-proiongation of PB-sleepo Only 6 of 48 amine levels changed 
significantly from control. Four increased and two decreased at times when 
2H3 
sleep was not significantly different from controls. Binding and PB dis-
placement does not seem to be involved in facilitated PB-sleep, since Hd does 
not bind to plasma to any extent. Two possibilitess to explain the effect 
observed include a direct depressant effect of the elevated histamine gener-
ated by Hd and/or histamine hypothermia. Temperature studies in the rat were 
limited to the HdlOO dose and were not striking. 7 of 12 amine patterns after 
Hd500 exhibited diurnal variation during the 24-hour period. 
DB, a histamine depletor, markedly reduces NE levels in 14/16 instances 
from 54.8 to 78.7%, an action favoring sleep. (Depletion of NE was consist-
ently greater in the hypothalamus than in MB and brain stem.) 5HT was lso 
depleted in 9/16 instances by 29.0 to 78.7%. On the other hand, DA increased 
in 7/16 cases. The latter two amine changes, it can be argued, favor waking. 
However, 5HT levels normally are inversely related to NE levels. When this 
relationship is altered sleeping time is extended. The rise in DA levels is 
probably not sufficient to overcome the loss of functional NE. Furthermore, 
the conversion of DA to a soporific metabolite cannot be discounted. Both NE 
and 5HT are involved in heat production and loss. The profound hypothermia 
produced by DB might reflect the reduced levels of these amines and their 
involvement in temperature regulation. Additionally, vasodilatation resulting 
from the mobilization of histamine by DB could contribute to heat loss and 
reduced metabolic activity. The degree of amine mobilization by DB suggests 
that it could raise the level of circulating amines and thus could interfere 
with PB binding. 11 of 12 amines exhibit significant diurnal variaiions after 
DB. 
The very significant prolonged Type IV PB-sleep patter after DPH does 
r 
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not appear to reflect brain amine changes to any extent. Only 2/16 5HT values, 
2/16 NE and no DA values were significantly different from controls. HoweYer, 
8 of 12 amine patterns display diurnal changes (These are detailed in Figs. 42-
43, Table 16 and Appendix B.) The DPH-augmented PB-sleep and its inverted diurn-
al pattern can be explained on the basis of some of the following diverse pharm-
acological and toxic actions of antihistamines: 1) antagonism of the CNS 
alerting effects of histamine, 2) hypothermia, especially during maximal met-
abolic activity, 3) local anesthetic, anticholinergic and neuromuscular-
blocking.actions, 4) time-related change in sensitivity to the toxic actions, 
which include, sedation and cortical seizure activity leading to catalepsy. 
There is no evidence available to suggest that DPH is bound to any extent by 
plasma proteins. 
The few significant amine changes after GBL (6/48) occur during the light 
phase, the normal sleeping time MB 5HT increases 77.8 and 64.0% respectinly, 
at 1200 and 1800 hours, while brain stem 5HT increased 50,0% at 1200 hours. 
-- -- --
CN DA at 1200 hours and hypothalamic DA at 1800 hours increased 41.3 and 128% 
respectively. The only decrease occurring is in hypothalamic NE (20.4% at 
2400 hours). These data in essence corroborate the findings of Roth and Suhr 
(1970) obtained in whole rat brain, with a considerably higher dose. They 
correlated sedative effects of GBL with the increased DA levels. The effect 
of 5HT might supersede any other amine, since the 5HT increases occur in the 
raphe system, where according to Jouvet (1972b) sleep centers are located. The 
possibility that what is termed "GBL-sleep" is really a state of catatonia has 
lwen suggested by WintPrs et !!.!_. (1972). If this is true, then this catatonia 
follows a circadian pattern. 
The question concerning the relationship of biogenic amine background 
to the hypnotic effect of PB can be answered in the following manner: 
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PB sleep is augmented by raising brain levels of DA or by reducing 5HT levels 
or by decreasing NE levels or by combination of these effects. The amine 
changes and sleep effects in general display a variety of diurnal or 
circadian patterns, when measured over periods of 24 hours. The probability 
that other amines must participate in these effects is inferred from data 
obtained with compounds that mobilize acetylcholine and histamine. Other 
factors influencing the duration of PB-sleep include: hypothermic effects of 
compounds, (a possible alteration of the protein binding of the hypnotic) and 
a direct depressant effect of the compounds themselves. GBL "sleep" 
follows the normal circadian sleep pattern of rats. Amine changes are not 
extPnsive, but when normal sleep is expected GBL increases DA, and 5HT 
levels and decreases NE levels. 
Appendix A: Drugs, Chemicals and Equipment 
1. Dru.gs 
N-acetyl-5-hydro:x:ytryptamine (Sigma) 
I 
L-alpha-methyl-E-tyrosine (Merck) 
DL-.E=,chlorophenylalanine (Sigma) 
Decaborane (Alpha Inorganics) 
Diphenhydram.ine HCl (Sigma) 
DL-DOPA (DL-394-dihydro:x:yphenylalanine; K & K) 
Gamma-butyrolactone (Eastman) 
L-histidine (Sigma) 
5-hydro:x:yindoleacetic acid (Sigma) 
Melatonin (Sigma) 
5-metho:x:yindoleacetic acid (Sigma) 
5-metho:x:ytryptam.ine 
Neostigm.ine methylsulfate (Roche) 
Pargyline (Abbott) 
Pentobarbital sodium (Abbott) 
L-tryptophan (Sigma) 
Physostigmine salicylate (Merck) 
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2. Chemicals 
Acetic acid (Baker) 
Alumina (Grade I, Woelm) 
Boric acid (Baker) 
Disodium. EDTA (Fisher) 
n-heptanol (Eastman, Sigma) 
Iodine (Baker) 
Perchloric acid (Baker) 
Potassium carbonate (Fisher) 
Potassium iodide (Fisher) 
Potassium phosphate, monobasic (Mallinkrodt) 
Sodium chloride (Fisher) 
Sodium phosphate, monobasic (Merck) 
Sodium phosphate, dibasic (Merck) 
Sodium sulfite (Baker) 
Ninhydrin (Pfanstiehl) 
Tricine (Calbiochem) 
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3. Equipment 
Aminco-Bowman Spectrophotof luorometer 
Beckman, Model 72 pH Meter, with electrode #39030 
Christian Becker, Model EA-1 Torsion Balance 
Eberbach, 2-speed shaker 
IEC centrifuge (Model K) 
Hythermco oven 
Precision Scientific beating bath (Model 83) 
Scientific Products Deluxe Mixer (vortex) 
Yellow Springs Telethermometer (with probes 401 and 403) 
Harvard decapitator 
Paragon 24-hour timer(Model 4000-0) 
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Appendix B: Analyses of Amine patterns 
1. Drugs affecting the NE and DA systems 
a. DOPA-parg;yline(Figures 28-29, Table 9) 
Analyses of the 12 24-hour amine patterns in DOPA-pargyline 
treated animals reveals that 9 are circadian. At 1200 hours, the M!!, NE peak 
is significantly different from the values obtained at 0600 (P < 0.02) and 
2400 hours (P < 0.025). MB DA maxima occur at 1800-2400 hours, while minima 
are at 0600-1200 hours. The concentration of MB DA at 11!.QQ hours differs 
significantly from that at 0600 and 1200 hours (each at a P < 0.001). The DA 
level at g!QQ. hours also differs significantly from that at 0600 (P < 0.02) 
and 1200 hours (P .( 0.01). CN NE concentrations exhibit a trough at 0600 
hours, which differs significantly from ~and 1800 hours levels (each at 
P<0.05). CN 5HT exhibits peak concentrations at 1200 hours, which differs 
significantly from ~hours (P <0.02) and 2400 hours (P < 0.05) values. 
5HT concentrations at ~and 11!.QQ hours also differ significantly (P< 0.05). 
Brain ~ DA levels peak at 11!.QQ hours, differing significantly from 0600 
and 1200 hours values, at .P< 0.01. DA levels at 0600 and g!QQ. hours also 
differ significantly (P<0.05). Brain stem 5HT levels reach a maximum at 
--· 
1200 hours, which differs significantly from the values at 1800 hours (P < 0 0 025) 
and 2400 hours (P< 0.005) •. Hypothalamic DA levels peak at 1800 hours, which 
is significantly different from the levels at 0600 (P < 0.001), ~ (P < 0.001) 
and 2400 hours (P < 0.02). There are also significant differences between the 
following points: 0600 vs. ~hours (P <0.005), 0600 vs. g!QQ. hours (P ( 
0.05). Hypothalamic 5HT levels exhibit a peak at 1800 hours and a trough at 
0600 hours, which differ significantly (P<0.05). The trou~h at 0600 hours 
also differs significantly from ~ and 2400 (both P < O. 01). 
b. Alpha-methyl-£-tyrosine (Table 10, Figs. 30, 31) 
In AMPT-treated animals, 9 of 12 amine patterns exhibit diurnal 
290 
fluctuations. MB DA exhibits a significant difference between levels at 1200 
and 2400 hours (P< 0.02; Fig. 31). The MB 5HT pattern has a peak at 1200 
hours, which differs significantly (P <o. 01), from the trough at 1800 hours. 
The peak also differs significantly from the values at 0600 hours (P<0.001) 
and 2400 hours (P < O. 02). The trough at 1800 hours also differs significantly 
from values at 0600 hours (P < 0. 01). CN NE levels at 0600 and 1200 hours 
differ significantly (P< 0.05). The values of CN 5HT exhibit a minimum at 
2400 hours, which differs significantly from those at 0600 (P < O. 02) and 
1200 hours (P < 0. 005). The maximum brain stem NE concentration at 0600 hours 
------
differs significantly from the values at 1800 and 2400 hours (both P< 0.0!5). 
~i~nifican~<' is bord<'rline at 1200 hours. Brain stem DA levels exhibit a 
--- ---
minimum at 2100 hours, that differs significantly from the values at 1200 
hours (P<0.02) and 1800 hours (P(0.01). The minimum brain stem 5HT concen-
--- ---
tration at 2400 hours differs significantly from that at 0690 hours (P < 0,001) 
and 1200 hours (P <0.01). Hypothalamic DA levels at 0600 and 1800 hours 
differ significantly (P<0.02). 
2. Drugs Affecting the Serotonin System 
a. £-Chlorophenylalanine (Table 11, Figs. 32,33) 
The aminP patterns of pCPA-treated animals exhibit circadian 
fluctuation i11 !) of 12 instances. MB 5HT levels in pCPA-treated animals 
2!11 
exhibit a maximum at 2400 hours, which differs significantly from the levels 
at .Q2QQ. hours (P < 0.005), 1200 hours (P < 0.005) and 1800 hours (P < 0.001). 
CN NE decreases to a minimum at 1:§.QQ hours, which differs significantly from 
the values obtained at 0600 hours (P < 0.05), 1200 hours (P < 0.005) and ~ 
hours (P < 0.025). CN DA exhibits a peak at 1800 hours, which differs signif-
icantly from the concent:rations at 0600 ho.urs (P< 0.025), 1200 hours (P< 0.001) 
and 2400 hours (P < 0.005). CN 5HT is maximal at ~hours, differing signif-
icantly from the value at 1200 hours (P < 0.001). The value at 1,gQQ hours 
differs significantly from that at 1800 hours (P< 0.01). 
Brain ~DA is minimal at .Q2QQ. hours, and differs significantly from 
the value at 1200' hours (P < 0.05). Brain ~NE is maximal at 2§.QQ hours, 
differing significantly from the values at !&QQ. hours (P about 0.05) and 1800 
hours (P < 0.01). Hypothalamic NE has a trough at 1800 hours, which differs 
significantly from the values at 2§.QQ hours (P < 0.05), !,g_QQ hours (P < 0.02) 
and 2400 hours (P < 0.005). The hypothalamic DA levels trough at 1800 hours 
and differ significantly from those at 0600 hours (P < 0.005) and 1200 hours 
(P < 0.01). The peak value of hypothalamic 5HT at ~hours, differs signif-
icantly from that at~ hours (P <0.,02) and ~hours (P < 0.05). The 5HT 
value at 0600 hours also differs significantly from that at 1800 hours (P < 
0.01) and 2400 hours (P< 0.001). 
b. Tryptophan(Figures 34-35, Table 12) 
TP (500mg/kg, IP) treated animals exhibited circadian flucfoations 
of 24-hour amine levels in 10 of 12 cases. The pattern of MB DA in treated 
animals exhibits a minimum concentration at 1200 hours, which differs signif-
icantly from the values at ~ and 2400 hours (both P < o. 01). MB 5HT has a 
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peak at !§QQ hours and trough at ~hours. These differ significantly (P< 
0.025). The peak at .!§.QQ hours also differs significantly from the values at 
1200 (P<0.02) and~ hours (P<0.01). CN NE exhibits a minimal concen-
tration at 1200 hours, which differs significantly from the value at 2400 
hours (P<0.01). CN DA concentration is minimal at .Q2.QQ.hours, and differs 
significantly from the peak level at 1800 hours (P < 0.001). CN 5HT levels 
describe a similar pattern with a trough at Q2QQ. hours, that differs signif-
icantly from the 2400 hours values (P < 0.05). The brain stem NE pattern is 
maximal at ~ hours, and differs significantly from the values at 1200 hours 
(P<0.02) and 2400 hours (P<0.05). The brain~ DA pattern has a trough 
at 1200 hours, which differs significantly from the concentrations at 0600, 
1800 and 2400 hours (all P <0.001). The minimum brain stem 5HT levels at 0600 
hours differs significantly from that at 1200 hours (P<0.01). Hypothalamic 
DA levels are minimal at giQQ. hours, and differ significantly from the value 
at 1200 hours (P<0.005). Hypothalamic 5HT exhibits peak levels at !§.QQ.hours 
and trough values at Q&QQ hours, which differ significantly from each other 
(P < O. 005). The peak value also differs significantly from that at 1200 and 
2400 hours (both P< 0.001}. 
c. Melatonin{Figures 36-37, Table 13) 
In M-treated animals, amine patterns fluctuated in a diurnal 
manner in 8 out of 12 instances. The pattern of ~DA has a minimam at Q2QQ_ 
hours, that differs significantly from the peak concentration at 1800 hours 
(P < 0.001). MB 5HT levels are maximal at g_QQ-~ hours. The value of 5HT 
at Q2QQ. hours differs significantly from that at 1200 (P < 0.05) and 1800 hours 
(P < O. 005) and the value at g!Q.Q. hours also differs significantly from 1200 
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and 1800 hours (each at P<0.01). CN NE is minimal at 1200 hours and is sig-
nificantly lower than the value at 1800 hours (P<0.005). CN 5HT concentra-
tion also exhibits a minimum at 1200 hours, which differs significantly from 
the levels at 0600 hours (P < 0.01), .!§QQ. hours (P < 0.02) and ~ hours 
(P < 0.05). 
Brain ~DA levels are maximal at 0600 hours, and significantly higher 
than the minimum level at 2400 hours (P < 0.01). The peak concentration of 
~ ~ 5HT at 1800 hours is significantly different from levels at 1200 
and 2400 hours (both P < 0.005). Hypothalamic DA levels exhibit a maximum at 
2400 hours and a minimum at .!_gQQ hours, which differ significantly from each 
other (P < 0.005). The trough value at .!_gQQ hours also differs significantly 
from the levels at .Q2QQ. hours (P < 0.001) and 1800 hours (P < 0.05). Hypothalamic 
5HT concentrations are maximal at .Q2QQ.-.!,g,QQ hours and minimal at t..!QQ_ hours. 
The trough differs significantly from .Q2QQ. (P < 0.01) and 1200 hours (P < 0.001). 
There is also a significant difference between the levels at 1200 and 1800 
hours (P < O. 005). 
3. Drugs Affecting the Histamine System 
a. L-Histidin~Figures 38-39, Table 14) 
Amine levels after Hd500 were altered in a cirdadian manner in 7 
of 12 instances. The 24-hour pattern of M!!_NE levels reaches a maximum at 
g.±QQ hours and differs significantly from the levels at .Q2QQ. hours (P< 0.05). 
~DA levels are minimal at .!§QQ. hours and maximal at 2400 hours, and differ 
significantly from each other (P< 0.001). The trough value at .!§QQ. hours is 
significantly lower than that at 1200 hours (P < 0.01), while the peak level at 
~ hours differs significantly from that at .!_gQQ hours (P < 0.025). CN NE 
concentration exhibits a peak at Q2Q.Q. hours, which is significantly greater 
than the values obtained at 1200 hours (P < 0.005), ~ (P < 0.001) and 2400 
hours (P<0.01). Brain stem DA and 5HT levels differ significantly between 
Q2.QQ_ and 2400 hours (P < 0.05). The difference in brain stem DA levels 
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between 0600 and 1200 hours is significant (P < 0.05). The difference in ~­
thalamic NE levels between 0600 and 2400 hours is also significant (P < O. 05). 
Hypothalamic DA levels are maximal at Q2Q.Q. hours and differ significantly from 
1200 hours (P< 0.005) and 1800 hours (P< 0.001). 
b. Decaborane(Figures 40-41, Table 15) 
DB-treated animals had brain amine patterns that showed diurnal 
fluctuations for 11 of 12 instances. MB NE levels exhibit a minimum at 2400 
hours, which differs significantly from levels at 0600 and ~ hours (both 
P< 0.01). MB DA is maximal at Q2Q.Q. hours, differing significantly from the 
values at 1200 hours (P < 0.005), !§QQ hours (P < 0.05) and 2400 hours (P< 0.01). 
MB 5HT concentration is maximal at 1200 hours, and differs significantly from 
that at 1800 and 240.0 hours (both p< 0.005). The 5HT value at 2400 hours also 
differs significantly from that at 1800 hours (P < 0.05). CN NE concentrations 
-
are minimal at g.±QQ hours and differs significantly from the value obtained 
at 1800 hours (P 0.05). The pattern of CN DA exhibits a minimum at 0600 
hours, which differs significantly from the values obtained at 1200, 1800 and 
~ hours (each at P < 0.001). CN 5HT levels are minimal at g!QQ. hours, and 
differ significantly from the level at ,!g.QQ hours. The 5HT values at ~ and 
1§.QQ hours differ significantly (P < 0.001). 
The ~~DA pattern has a minimum at ,!g.QQ hours, which differs 
significantly from the values at 0600 hours (P< 0.05), 1800 hours (P< 0.01) 
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and ?400 hours (P <0.001). Brain stem levels of 5HT are maximal at 1200 hours 
and differ significantly from the values obtained at~ hours (P<0.025), 
1800 hours (P < O. 05) and 2400 hours (P <.:, 0. 02). Hypothalamic NE levels reach 
a minimum at 2400 hours, differing significantly from that at 1200 hours 
(P\0.025) and 1800 hours (P<0.01). Hypothalamic DA concentrations are 
maximal at 0600 hours, differing significantly from the values at 1200, 1800 
and 2400 hours (each at P< 0.001). Hypothalamic 5HT is minimal at 2400 hours, 
differing significantly from the values at 0600 hours (P <\ 0.005) and 1200 
hours (P < 0. 02). The maximum at 0600 hours differs significantly from that 
at 1200 and 1800 hours (each at P<0.005). 
c. piphenhydramine (Table 16, Figs. 42, 43) 
DPH-treated animals had brain amines patterns that showed diurnal 
variations in 8 of 12 instances. The 24-hour pattern of MB NE has a minimum 
at ,?400 hours, which differs significantly from the values at 0600 hours (P <. 
' 
0.005) and 1800 hours (P < 0.001) (cf. Fig. 43). MB DA concentrations are also 
minimal at 2400 hours, and differs significantly from the levels at 0600 
(P < 0.001), 1200 (P< 0.02) and 1800 hours (P < 0.005). There is also a signif-
icant difference between MB DA levels at 0600 and 1200 hours (P < 0. 05). CN 
DA concentrations are maximal at 1200 hours, and differ significantly from 
0600 (P <0.001), 1800 (P<0.001) and 2400 hours (P<0.02). CN 5HT levels are 
minimal at 0600 hours, and differ significantly from 1200 and 1800 hours 
values (each at P <0.001). There is a significant difference between ~ 
~NE levels at 1800 and 2400 hours (P<0.005). Brain stem DA content is 
--- ---
minimal at 2100 hours, and differs significantly from that at 1200 (P < 0.01) 
and 1800 hours (P<\O.Of>). Hypothalamic:_ NE rpaches a minimum at 2400 hours, 
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which is significantly lower than the values at 0600 and 1800 hours (both Pz 
0.001). Hypothalamic 5HT levels peak at 1200 hours and differ significantly 
from values at Q2.Q.Q., 1800 and 2400 hours (each at P ( 0.01). 
4. Gamma-butyrolactone(Figures 44-45, Table 17) 
a. Saline controls 
The 24-hour patterns for the monoamine levels in the brains of 
controls exhibited a number of significant diurnal fluctuations. The pattern 
of MB 5H.T has a peak at 2400 hours and a trough at 1800 hours (Fig. 44 ). The 
- -
trough at 1800 hours does not differ significantly from the value at 1200 
hours. The peak value at 2400 hours differs significantly from the values at 
0600 (P < 0.05), 1200 (P < 0~005) and 1800 hours (P < 0.005). There are also 
significant differences between the concentrations at 0600 hours and that at 
1200 hours (P < 0.01) and 1800 hours (P < 0.02). Brain stem NE has a peak 
value at 2400 hours, which differs significantly from the values at 1200 hours 
(P < 0.01) and 1800 hours (P< 0.005). The pattern for brain stem DA is bimodal~ 
with peaks at 0600 and 1800 hours, which differ significantly from each other 
(P < 0.01). The primary peak at QQQQ_ hours is significantly greater than the 
value at 2400 hours (P < 0.01). The secondary peak at 1800 hours differs 
significantly from the DA concentrations at 1200 hours (P < 0.005) and g!Q.Q_ 
boll.rs (P< 0.005). The hypothalamic NE pattern has a peak value at 2400 hours, 
which differs significantly from that at Q2QQ. hours (P < 0.01), but not from the 
values at the other times. Hypothalamic DA exhibits a diurnal pattern, with a 
peak at 1200 hours and trough at Q2QQ. hours,wwhich differ significantly (P < 
0.02). The DA concentration at 2400 hours differs significantly from the val-
ues at Q2QQ. hours (P < 0.05) and ,!,g_QQ hours (P < 0.05). There is a significant 
2H7 
difference between the hypothalamic 5HT at 1200 and 2400 hours (P<0.02), but 
not the other values. 
b. GBL-treated(Figure 45, Table 17) 
The MB 5HT pattern for the GBL-treated animals exhibits a peak 
at ~ hours, which differs significantly from the values obtained at 0600 
hours (P< 0.02), !,g_QQ hours (P<0.005) and 1800 hours (P< 0.005)(Fig. 45 ). 
The value at ~ hours differs significantly from that at 1800 hours (P < 
0.005). The difference between the concentrations of CN NE at Q§.QQ and 1200 
hours is of borderline significance (O.l>P>0.05). The CN 5HT pattern 
exhibits circadian fluctuations, with a maximum at 1800 hours and a minimum 
at 0600 hours, which differ significantly (P< 0.05). There is borderline 
significance for the difference between the values at 0600 and 1200 hours 
( 0.1> P > 0.05). The brain stem DA pattern for GBL-treated animals is bimodal, 
with peaks at 0600 and 1800 hours. The minimum DA value at 1200 hours differs 
significantly from,concentrations at 0600 hours (P 0.02), ~hours (P< 
0.005) and g±QQ. hours (P< 0.05). The brain stem 5HT pattern is diurnal, with 
a peak at 1200 hours that differs significantly (P<0.02) from the trough at 
0600 hours. The trough also differs significantly from the values at 1800 
hours (P < 0.005) and giQ.Q_ hours (P < 0.01). Hypothalamic DA concentrations ex-
hibit a peak at 1800 hours that differs significantly from 0600 and 2400 hours 
values (each P<0.02). The peak hypothalamic 5HT concentration at 2400 hours 
differs significantly from the Talues at 1200 and 1800 hours (both P < 0 0 05). 
L. . 
298 
Appendix C: Additional amine studies 
1. Pentobarbital at the point of awakening 
The concentrations of NE, DA and 5HT in the MB, CN, brain stem and 
hypothalamus were determined at 0600, 1200 9 1800 and 2400 hours at the time 
of awakening from PB-sleep (50m.g/kg, IP; 'Table 231 Fig. 51 ) 0 MB DA varies 
significantly during the 24-hour period. The minimal concentration at 2400 
hours is significantly less than that at 0600 hours (P<0.05), 1200 hours 
(P.C 0.01) and 1800 hours (P< 0.025). CN NE concentrations, which are maximal 
at 2400 hours and minimal at ~ hours, differs significantly in the follow-
ing comparisons: .Q&Q.Q. vs 1800 hours (P < 0.05) and 1800 vs 2400 hours (P <. 
Os05). Brain stem NE concentrations are maximal at g!Q.Q_ hours, and differ 
significantly from the values at 0600 hours (P < Oo005), 1200 hours (P< 0.001) 
and 1800 hours (P < 0.001). The pattern of brain stem DA exhibits a clearcut 
diurnal pattern with a minimum at 1800 hours and a maximum at 0600 hours. 
The peak differs significantly from values obtained at 1200 hours (P < o. 05) 
and 1800 hours (P<0.005), but not from those at 2400 hourso The trough 
differs significantly from the concentration at~ hours (P<0.01). 
Brain ~ 5HT concentrations exhibit a maximum at 2400 hours, which 
differs significantly from those at 0600 hours (P< 0.001) and 1800 hours 
(P< 0 0 005). There is a significant difference between the 0600 and the 1800 
hours values (:p< 0.01). Hypothalamic NE has a minimal value at 1800 hours, 
which differs significantly from that at ~hours (P < 0.025) and 2400 
hours (P < 0.005). Hypothalamic DA is maximal at g!Q.Q. hours and differs 
significantly from the values at 0600 and 1800 hours (each P< o.05)o ~­
thalamic 5HT concentrations during the 24-hour period are not significantly 
different from each other. 
Table 23: CNS concentrations of NE, DA and 
from PB (50mg/kg, IP) 
5HT at the time of awakening 
0600 1200 1800 2400 
-
MB NE .85+.10 .87+.16 .78+.13 .87+.,10 (5) (5) (5) (6) 
Hpth NE 2.21+.22 2.32+.73 1.80+.28 2.61+.34 (5) (5) (6) (6) 
CN NE .29+.07 .26+.06 .16+.09 .,39+. 11 (5) (5) (5) (4) 
Stem NE .99+.10 .87+.10 .93+.06 1.33+.16 (5) (5) (6) (5) 
MBDA .24+.07 .28+.07 .25+.05 .17+.04 (5) (4) (4) (6) 
Hpth DA. .18+.07 .17+.08 .29+.07 (5) (6) (4) 
CN DA 6.48+.80 4.77+.74 4.72+1.42 5.14+1.67 (5) (5) (6) (6) 
Stem DA. .22+.07 .07+.02 .05+.02 .14+.05 (5) (2) (5) (4) 
MB 5HT • 71+.12 
.85+.15 .71+.30 (5) (5) (6) 
Hpth 5HT .34+.13 
.54+.25 .22+.04 (5) (5) (3) 
CN 5HT .32+.14 
.23+.08 (5) (5) 
Stem 5HT .28+.08 
.59+.17 1.15+.24 (4) (6) (4) 
Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT 
in the four areas indicated in Table 9, for animals receiving PB alone. 
Animals were sacrificed at the time of awakening from PB. Values are 
means ±.standard deviation, with the number of animals used in paren-
theses. 
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The effects of pentobarbi tal on the CNS concentrations of N<;, DA and !'>HT 
in rats, at the time of awakening. For complete explanation of notations 
of figure, see legend to Figure 28. 
2o Amine concentrations after 5Hl'P 
CNS concentrations of NE, DA and 5HT were determined in animals 
administered 5HTP (lOOmg/kg, IP) one hour before PB (50mg/kg, IP), at the 
time of awakening from PB-sleep. The determination was made at ~ hours, 
a time in which this pretreatment increased PB-sleep significantly (to 
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144.0 .:!:. 15.4 minutes, P <0.001). These results are summarized in the follow-
ing Table. 
MB CN Brain stem Hypothalamus 
.80+.01 .41+.12 .87+.02 1.91+.07 
(4) (4) (4) (4) 
NE 
DA .33+.20 14.70+.88 .22+.09 .66+.25 (3) (4) (3) (4) 
1.40+.20 .61+.16 .85+.20 1.46+.14 (4) (4) (4) (4) 
5HT 
Values represent means .:!:. standard deviation, with the number of 
animals used in parentheses. 
In comparison to similarly treated controls, 5HT is significantly 
elevated in all brain areas, except brain stem. Brain DA was elevated in 
all four areas, but there were no significant changes in NE levels. 
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